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ABSTRACT 
In ischemia, the decreased blood flow in the ventricle creates a 
pathophysiological condition which often lead to a progressive contractile failure 
in the heart. Currently available treatment options for heart failure, comprising 
pharmacological and surgical interventions, are less than satisfactory and often 
associated with various adverse effects. Since the levels of calcium are rarely 
changed in ischemic myocardium, evidence now suggests the reduction in 
contractility is due to the decrease in responsiveness of the myofilaments to 
available calcium. This reduced responsiveness is thought to be a consequence 
of desensitization of myofilaments to calcium, caused by alterations in the 
intracellular conditions such as pH and metabolite accumulation. 
Troponin C is a regulatory protein of the myofilament which binds to calcium to 
trigger the process of contraction. This protein exists in two isoforms, skeletal 
and cardiac, which are spatially and temporally regulated. Protein isoform 
substitution experiments in cardiac and skeletal muscle fibres have shown that 
the skeletal isoform of Troponin C is more resistant to adverse intracellular 
conditions such as changes in pH, than its cardiac isoform. Thus, sTnC is a good 
candidate for manipulation to alter the calcium sensitivity of myofilaments during 
ischemia. 
Work in this project builds the primary stage of a long-term project, for using 
gene transfer method to overexpress the skeletal isoform of Troponin C in 
cardiomyocytes. The long-term aim is to achieve complete or partial substitution 
of the native cardiac isoform and study the effects on contractile force produced, 
in normal and ischemic cardiomyocytes, both in vitro and in vivo. 
This project has involved designing, constructing and analyzing expression of 
adenoviral gene transfer vectors overexpressing the sTnC isoform. Several 
XXIII 
adenoviral vectors were generated with the wild type sTnC gene under the 
control of muscle-specific promoters. To facilitate analysis of protein expression 
and its subcellular localization, the sTnC protein was tagged with epitope tags 
and adenovirus generated, with this gene under the control of constitutive (CMV) 
and cardiac-specific (HCA) promoters. Epitope-tagged adenoviruses were 
expressed in vitro using mouse fibroblast (NIH3T3) cells and analyzed by 
western blot analysis, showing successful constitutive expression. Recombinant 
adenoviruses containing epitope-tagged-sTnC under the control of the human 
cardiac actin promoter showed cardiac-specific expression in cultured 
cardiomyocytes, in situ, using immunocytochemistry. The constitutively-
expressing sTnC adenoviral vector showed successful expression in 
cardiomyocytes in culture, using northern blot analysis. 
A range of adenoviral vectors have been successfully generated, and constitutive 
and tissue-specific expression has been established for some of these vectors. 
Successes attained in this project have established the initial requirements to 
achieve the long-term goal to alter calcium sensitivity of myofilaments, by 
overexpression of sTnC isoform in cardiomyocytes, both in vitro and in vivo. 
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Chapter 1 
1.1. Heart Failure 
Cardiac failure follows from an interaction of complex pathophysiological 
conditions, causing a progressive deterioration of pump function of the heart. 
The compromised contractility results in inadequate blood flow which fails to 
meet the body's essential metabolic needs (Hongo et a/., 1997). The failing 
myocardium shows several cellular and sub-cellular aberrations which may 
include abnormal levels of intracellular Ca ++ (Lee et a/., 1988; Morgan et a/., 
1990; Morgan et a/., 1992; Denvir et a/., 1995), alterations in cytoskeleton 
proteins (Ganote and Vander Heide, 1987), functional and quantitative 
decrease of ~-adrenergic receptors (Bristow et a/., 1982), myocyte 
hypertrophy (Hongo et a/., 1997), and even myocyte death (Davies et a/., 
1996). 
The most commonly accepted cause for ventricular contractile failure is partial 
or complete occlusion of the coronary artery (Hongo et a/., 1997). Such 
obstructions to the myocardial blood supply may lead to reversible or 
irreversible loss of myocyte function (Jennings and Reimer, 1991) or even 
complete myocyte death (Davies et a/., 1996) causing a condition called 
Myocardia//schemia (Lee and Allen, 1991; Anversa et a/., 1993; Davies et a/., 
1996). However, after a brief period of obstruction, and subsequent re-
establishment of blood supply to the tissue can result in reversal of the 
detrimental effects. This process is known as Reperfusion. Tissue damage or 
necrosis is also thought to occur as a consequence of the reperfusion process 
and as such is termed Reperfusion Injury (Engler et a/., 1983; Werns et a/., 
1986; Downey, 1990). 
1.1.1. Myocardial Ischemia 
Ischemic heart disease is a complex clinical syndrome, resulting from 
shortage of blood circulation in the myocardium (Anversa et a/., 1993). In 
general, coronary artery blockage is temporary, resulting in a deficiency of 
oxygen supply to the cardiac myocytes, hence making the intracellular 
environment hypoxic. This scarcity of blood flow leads to a reversible episode 
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of contractile dysfunction with no cell death, termed as Myocardial Stunning 
(Braunwald and Kloner, 1982; Katz, 1992). However, if the episode of 
coronary artery blockage is prolonged, myocardial tissue injury may be 
irreversible (Opie, 1996). Such injury generally comprises an entire loss of 
myocyte function or even death of myocytes, either scattered "diffusely" 
throughout the heart wall as found in Ischemic Cardiomyopathy, or distributed 
segmentally as observed with Myocardial Infarction (Anversa et al., 1993). 
Prolonged hypoxia is seen as the prinCipal component of irreversible ischemic 
injury, but the effects of hypoxia itself are not as devastating as the broader 
range of pathologies associated with ischemia (Katz, 1992). The most 
fundamental outcome of ischemia is the reduction in developed tension in 
ventricular muscle cells. This effect has far reaching consequences at the 
intra-organ level. Altered developed tension is the outcome of contributory 
factors which are of metabolic, mechanical and electrochemical nature (Allen 
and Orchard, 1987). 
The metabolic changes occurring at the onset of ischemia in the myocardium. 
fall into two broad categories; 1) the reduction in the O2 supply and substrate 
availability to the tissue and 2) the accumulation of the metabolic products 
(Jennings and Reimer, 1991; Braunwald and Sobel, 1992; Katz, 1992). 
Ischemia can occur in varying degrees of severity, ranging from slight 
reduction in blood flow (low-flow ischemia), to complete absence of perfusion 
(total ischemia where both substrate delivery to and extrusion of metabolic 
products from cells is greatly diminished (Jennings and Reimer, 1991). 
1.1.1.1. Energy Status of Cardiomyocytes in Ischemia 
With the onset of severe ischemia myocardial O2 becomes exhausted within 8 
to 10 seconds (Jennings and Reimer, 1991). ATP remains relatively constant 
for the first few minutes of ischemia (Allen and Orchard, 1987) while cellular 
creatine phosphate is depleted and aerobic glycolysis switches over to 
anaerobic glycolysis (Jennings and Reimer, 1991). Due to the unavailability of 
an exogenous glucose supply, the glycogen stores become the main 
substrate for glycolysis. However, aerobic glycolysis is transient and soon 
Introduction 3 
Chapter 1 
ceases due to lack of ATP (Jennings and Reimer, 1991), and NAD (Katz, 
1992). Lactate, an end-product of anaerobic glycolysis accumulates in the 
ischemic tissue in addition to certain glycolytic intermediates such as a-
glycerol phoshphate (Jennings and Reimer, 1991). Other metabolites that 
accumulate include protons (H+), inorganic phosphate (Pi) and potassium 
(Allen and Orchard, 1987; Jennings and Reimer, 1991). These metabolic 
changes are contributing factors in myocyte dysfunction and subsequent 
contractile failure (Jennings and Reimer, 1991). 
1.1.1.2. Metabolite Accumulation by Heart Cells in Ischemia 
The intracellular metabolism in ischemic myocytes generates several 
catabolic products which accumulate due to absence of wash-through by the 
blood supply. Many products such as protons (H+) are directly toxic and 
others may contribute to increasing the osmotic load of the myocytes 
(Jennings et al., 1986). The catabolic products of ATP produces several 
smaller molecules such as ADP and AMP where the latter is further degraded 
to adenosine (ADO) and Pi and then to Inosine (I NO). ADO and INO can 
diffuse from the myocytes to the extracellular space. The INO is further 
degraded to hypoxanthine and xanthine and are retained within the ischemic 
tissue (Jennings and Steenbergen, Jr. 1985), and contribute to free radical 
generation (Chambers et al., 1985). In addition, lactate is also being produced 
(Jennings et al., 1985; Jennings et al., 1986), adding to the increasing 
osmotic load of the myocytes. The myocytes attempt to adjust the increased 
osmotic load by exporting K+ to the extracellular fluid (Kleber, 1984; Jennings 
and Reimer, 1991); the passive leakage of K+ from cells is known to be a 
common response to osmotic swelling of myocytes and other cells (Pine et 
al., 1982). 
1.1.1.3. Intracellular Acidosis 
The hydrolysis of the high-energy phosphate compounds ATP and 
phosphocreatine generates large quantities of inorganic phosphate (Pi)' a 
weak acid which liberates protons (H+) (Katz, 1992). Lactate, another weak 
acid, will add to the H+ content in the ischemic myocytes. As a consequence, 
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protons accumulate during ischemia in the myoplasm and cause a decline in 
the pH. The accumulation of lactate is also considered to be a major 
contributor to the acidosis of myoplasm (Allen and Orchard, 1987). 
1.1.1.4. Ion Balance in Cardiomyocytes 
Ischemia disrupts ionic balance of the myocytes, possibly by perturbations of 
ion transport system in the sarcolemmal membrane (Tani, 1990). Calcium 
(Ca ++), Sodium (Na +), protons (H+) and potassium (K+) are the major ions with 
the levels of each being inter-dependent, for maintaining the ionic balance 
needed for normal cell functions. 
Disorders of ion channel regulation have far reaching consequences on the 
electrophysiology and contractile performance of the heart. An increase in the 
extracellular potassium [K+]o is seen at the onset of ischemia and hypoxia due 
to K--efflux from the myocytes with a concomitant fall in intracellular K+ 
(Kleber, 1984). This anomaly of K+ levels across the membrane leads to 
depolarization of the cell membrane (Carmeliet, 1978), with crucial 
consequences on slowing down conduction of action potential and production 
of cardiac rhythm disorders termed as Arrhythmias (Allen and Orchard, 1987). 
Calcium accumulation, on the other hand is seen as the main cause of 
irreversible myocardial injury or infarction. 
Alterations of intracellular sodium ([Na +]i) levels, indirectly effect levels 
intracellular calcium ([Ca ++]i), through the action of the Na-Ca exchange 
mechanism present in the plasma membrane. This exchanger is potentially 
reversible, with the direction of flow determined by the gradient of each ion 
and membrane potential (Eisner and Lederer, 1985). Under normal 
conditions, Na+ entry is accompanied by H+ or Ca++ efflux from the cell (see 
table 1.1). While the Na+ can be removed by the Na+/K+ ATPase, the Ca++ 
concentration within the cell will remain stable (Jennings and Reimer, 1991), 
but during Na pump inhibition (as in ischemia, usually due to low ATP), the 
Na + -Ca ++ exchanger may reverse, allowing Ca ++ entry in exchange for Na + 
efflux (Allen and Orchard, 1987). This behaviour of the Na+-Ca++ exchanger is 
specially important in ischemia, when intracellular acidosis causes the Na +-H+ 
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exchanger to expel excess H+ from the cell, in exchange for extracellular Na+, 
hence increasing the [Na+]j. Higher [Na+]j levels thus produced, lead to a 
passive exchange of the increased intracellular Na + for extracellular Ca ++ by 
the reversed Na + -Ca ++ exchanger, resulting in elevated [Ca ++1 (Neely and 
Grotyohann, 1984). 
Intracellular accumulation of calcium ions (Ca ++) is often implicated as the 
primary event in irreversible myocardial injury and cell necrosis (Tani, 1990). 
High levels of [Ca ++]i are toxic for myocytes and inhibit oxidative 
phosphorylation. Lipolytic and proteolytic enzymes also become activated in 
response to high Ca++ and damage the myocyte membrane (Jennings and 
Reimer, 1991; Lee and Allen, 1991). A rapid uptake of extracellular Ca ++ 
immediately after reperfusion has been observed (Lee and Allen, 1991), 
which may precipitate muscle damage by a variety of routes (Allen and 
Orchard, 1987). Ca ++ overload is not seen in myocardium that is not 
irreversibly injured (Jennings et a/., 1985), which implies a significant role of 
elevated cytosolic free Ca ++ in causing irreversible damage to the 
myocardium. 
Reperfusion of ischemic myocardium with oxygenated blood, results in the 
formation of highly reactive cytotoxic free radicals which are postulated to add 
to the injury of myocardium (Downey, 1990). These oxygen-derived free 
radicals are produced by activated neutrophils that infiltrate the ischemic 
reperfused myocardium (Lucchesi, 1990). The oxidants produced include 
superoxide anion (02-), hydrogen peroxide (H20 2) and hydroxyl anion (Kloner 
et a/., 1989). Sources of such radicals include Hypoxanthine released from 
the ischemic heart, which is oxidized by xanthine oxidase upon reperfusion, 
producing both superoxide and hydrogen peroxide (Chambers et a/., 1985). 
Free radicals have the ability to react with and damage membrane 
phospholipids, proteins and nucleic acids, which cause structural changes in 
myocytes leading to reversible or irreversible cell damage. 
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1.1.1.5. Calcium Homeostasis in Ischemic Cardiomyocytes 
Intracellular Ca++ homeostasis plays a central role in regulating excitation-
contraction coupling in the vertebrate heart. Systolic contraction of the heart 
depends upon the availability of free cytosolic Ca ++ to the myofilaments 
(Brixius et al., 1997), whereas diastolic relaxation requires the [Ca ++]i to return 
to the resting levels Resting state [Ca ++]i is approximately 10-7 M which is 
raised momentarily to 10-5 M in response to excitation, allowing Ca ++ 
interaction with myofilaments and triggering the contractile process (Allen and 
Lee, 1997). This transitory increase in [Ca ++]jJ which takes place in response 
to action potential, and is known as a calcium transient. 
Several studies have reported little or no difference in levels of Ca ++ -transients 
in control and failing hearts (Gwathmey et al., 1987; Gwathmey et al., 1990; 
Vahl et al., 1994). However, vacillations in Ca ++ homeostasis during ischemia, 
have wide ranging and sometimes detrimental effects on the contractile 
performance of myocardium Such abnormalities of [Ca ++]i handling, rather 
than decreased [Ca ++]jJ in acute and chronic heart failure, are suggested as 
the cause underlying systolic and diastolic dysfunction (Perreault et al., 1990; 
Liao et al., 1994). Moreover, measurements of [Ca ++]i in ischemia have 
clearly demonstrated that the fall in contractile force of the myocardium is not 
due to failure of Ca ++ transients, but due to reduced sensitivity of the 
myofilament proteins to respond to Ca ++ (Lee and Allen, 1991). Hypoxia, 
which is an essential component of ischemia is found to decrease the 
myofibrillar responsiveness to calcium in the myocardium (Hajjar and 
Gwathmey, 1990). 
1.1.2. Myocardial Remodelling 
Extended duration of ischemia can lead to myocyte cell death and formation 
of an infarct, which is a group of necrotic and non-contracting myocytes or 
regions of scar tissue. As myocytes are terminally differentiated non-dividing 
cells, the infarct cannot be repaired. Loss of a part of the myocardium, 
redistributes the load of contraction to the remaining viable myocardium 
(Anversa et al., 1993). The myocardium adapts to the increased workload by 
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an increase in cell volume and altered expression of specific genes (Komuro 
and Yazaki, 1993). The contractile proteins myosin heavy chain and alpha-
actins are selectively induced during myocardial hypertrophy. P-Myosin Heavy 
chain gene transcription is elevated while its alpha isoform RNA is 
downregulated, possibly as a means for efficient contraction. Skeletal a-actin, 
a developmentally regulated gene expressed during the fetal stage, is 
expressed again in hypertrophy in equal quantity to the cardiac a-actin 
isoform (Schwartz et al., 1986). Growth factors (Parker et al., 1992), 
hormones (Nadal-Ginard and Mahdavi, 1989), catecholamines (Bishopric et 
al., 1987; Bishopric and Kedes, 1991) are seen as the stimuli responsible for 
initiating hypertrophy. Mechanical stress, such as stretch (Komuro and 
Yazaki, 1993) or pressure overload are also postulated as possible inducers 
of hypertrophy. 
1.1.3. Drug Therapies for Failing Heart 
Heart failure remains a lethal condition with treatment options which are less 
than satisfactory. Pharmacological therapies aimed at supporting the pump 
function of the heart are expected to have greater impact on treatment of 
heart failure (Lee and Allen, 1997). Inotropic drugs are widely used which aim 
at improving the contractile function of the failing heart. Digitalis, a cardiac 
glycoside, has been in used for about two centuries and works by inhibiting 
the Na + -Ca ++ exchange, thereby increasing intracellular Ca ++ concentration 
(Webster et al., 1996). Though beneficial effects have been obtained, the 
side-effects produced by the drug are significant. fJ-adrenergic agents and 
phosphodiesterase (POE) inhibitors also act by indirectly increasing the 
[Ca ++]j. The p-agonists act by occupying the p-adrenergic receptor causing a 
rise in cyclic AMP via the action of coupled G protein and adenyl cyclase, 
whereas POE inhibitors reduce the activity of the cAMP breakdown. The 
cAMP causes the phosphorylation of Ca ++ -channel proteins of the 
sarcolemma, causing increase Ca ++ entry and increase sarcoplasmic 
reticulum loading. Thus both p-adrenergic agents and POE cause increase in 
force of contraction by elevating rCa ++]j. In addition, higher cAMP may affect 
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other proteins such as Troponin I and Phospholamban, and cause 
acceleration in the relaxation rate of myocytes (Zhang et al., 1995), which 
may contribute to overall efficiency of contractile function. 
Elevated rCa ++]i is known to cause a state of "Calcium overload', where 
increases in rCa ++]i beyond a certain level causes a decline in force (Allen et 
++ f al., 1985), and can also cause spontaneous release of Ca rom the 
sarcoplasmic reticulum, when its contents become excessive (LakaUa, 1992). 
The conventional positive inotropes which act by elevating rCa ++]i> are likely to 
cause reduced contractility, aftercontraction, and also trigger arrhythmias due 
to sudden elevation of rCa ++]i (Lee and Allen, 1997). An excess of arrhythmias 
is a serious problem associated with most positive inotropic agents used to 
date (Allen and Lee, 1997). In addition, elevated intracellular rCa ++] may result 
in unwanted consumption of energy, as Ca ++ recycling uses more energy to 
bring Ca ++ levels down, by SR-uptake and expulsion from the cell. The myosin 
ATPase activity is of course already increased, due to increased cross-bridge 
cycling, consuming the larger part of the ATP store (Gibbs, 1978; Ruegg and 
Morano, 1989). Hence, such a strategy seems clinically ineffective for 
treatment of diseased myocardium which is already deficient in energy (Allen 
and Lee, 1997; Lee and Allen, 1997). 
Pharmacological agents which can increase the calcium responsiveness of 
myofilaments, have recently come under focus, for use as positive inotropic 
drug for treatment of heart failure (Lee and Allen, 1997; Strauss et al., 1997). 
Calcium sensitizers are compounds that increase the force of contraction 
without increasing the rCa ++]i levels, by increasing the responsiveness of 
myofilaments to Ca ++ (Lee and Allen, 1991; Lee and Allen, 1997). These 
compounds can produce a positive inotropic effect, without provoking the 
dangerous side-effects, associated with drugs which elevate rCa ++]i' Currently, 
a number of Ca++-sensitizers are under investigation, and agents such as 
EMD 53998 have been found to increase calcium sensitivity by influencing the 
myosin-actin interaction (Lee and Allen, 1991; Haikala et al., 1995). Another 
drug, Pimobendan achieves increased efficiency of Ca++-binding by increases 
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the affinity of Troponin C for Ca++ (Lee et a/., 1989). In order to further 
elucidate the mode of action of such drugs, their interaction with the 
myofilament components is also under investigation. 
The search for an ideal therapy for progressive heart failure is being 
vigorously pursued. It has become evident from the currently available 
treatments that an ideal treatment should be able to restore the decreased 
contractile function, without elevating the [Ca ++]j. In addition, the therapeutic 
intervention should not impose excessive demands of energy on the ischemic 
myocardium, already short of energy reserves. 
1.1.4. Gene expression in Ischemia 
On reperfusion, the reversibly injured myocardium shows a period of 
contractile dysfunction termed as myocardial stunning (Braunwald and Kloner, 
1982). Myocardium, which has undergone brief episodes of reversible 
ischemia, is found to have the ability for tolerating a subsequent, more 
prolonged episode of ischemia (Murry et a/., 1990; Jennings and Reimer, 
1991). This phenomenon is called Ischemic Preconditioning (Murry et a/., 
1986). The mechanism of such a protective effect is speculative. Adenosine 
has been linked to preconditioning possibly by opening of A TP-sensitive K+ 
channel (Speechly-Oick et a/., 1995), or activation of protein kinase C 
(Ytrehus et a/., 1994). Investigations into such adaptive responses could offer 
new molecular targets for therapeutic modulation of heart failure. 
Ischemic stress in myocardium induces expression of genes such as the 
immediate early genes c-fos, c-jun, jun-B and Egr-1 (Brand et a/., 1992; 
Wechsler et a/., 1994). The products of these genes trans-activate other 
genes which underlie the repair process in a reversibly injured myocardium. 
Stress related genes, such as Heat-shock Protein (HSP) 27, 70 and 89 and 
heat-shock transcriptional factor 1 (HSF-1) are induced by repeated ischemia 
and reperfusion episodes (Wechsler et a/., 1994; Nishizawa et a/., 1996). 
Antioxidant genes such as Manganese-Superoxide dismutase (Mn-SOO) and 
peroxisomal Catalase genes are also induced in ischemia and the enzyme 
levels of these free radical-scavenging enzymes are raised with successive 
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ischemia and reperfusion episodes (Oas et al., 1993). ~-Adrenergic receptors 
play an important role in myocardium stimulation by catecholamines, leading 
to increased contractility acting via the receptor-adenylate cyclase system. 
There is an increase in the number of ~-adrenergic receptors in the plasma 
membrane, despite the release of large and desensitizing levels of 
endogenous catecholamines (Ihl-Vahl et al., 1995). 
Ischemia induces an intracellular environment with accumulated metabolic 
products, hypoxia, low glucose and altered redox status. All these factors 
contribute to the pathophysiology of the ischemic myocardium. Some of these 
components of ischemia are found to trigger transcriptional activation of 
genes which may play a role in aiding the failing myocardium to adapt to 
stressed conditions. Hypoxia is an essential component of ischemia and is 
known to up-regulate genes including transcription factors, metabolic 
enzymes and growth factors such as Erythropoietin (EPO). Expression of 
growth factor is stimulated in hypoxia. Cis-acting enhancer element in the 3' 
flanking DNA sequence of the EPO gene is found to bind a trans-acting 
hypoxia-inducible factor (HIF-1) (Semenza and Wang, 1992). Several 
hypoxia-inducible genes are known to contain HIF-1 binding sites including 
glycolytic enzymes (Semenza et al., 1994). HIF-1 appears to playa central 
role in the hypoxia signalling by activating hypoxia-responsive genes at the 
transcriptional level. 
1.1.5. Models of Heart Disease 
Even though a wealth of information exists about clinical aspects of ischemia, 
the molecular controls and processes and cellular responses are poorly 
understood. This is partly due to non-availability of an animal model of heart 
failure and also to the technical and ethical limitations of carrying out analyses 
on whole animals or humans (Webster et al., 1996). Furthermore, the 
ischemic injury depends upon the duration and degree in reduction of 
coronary flow and variable restoration of cardiac function is achieved on 
reperfusion (Jennings and Reimer, 1991). Ischemia, being a multifactorial 
process, lowers the possibility of finding an animal model to mimic the 
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pathophysiology of human ischemia. A number of in vivo. and in vitro. models 
of ischemia have been developed in the three categories of chronic, transient 
and permanent ischemia. 
1.1.5.1. Chronic Ischemia Model 
This model involves reduction of blood flow to the myocardium, yet enough for 
sustaining the cells and keeping them viable. Clinically, such a condition may 
arise by partial occlusion of a coronary artery by an atherosclerotic plaque or 
a blood clot. Insufficient perfusion of a region of myocardium, supplied by the 
clogged artery, causes a deficit in meeting the metabolic demands of a 
contracting heart. Chronic ischemia is marked by decreased contractility due 
to waste metabolite build-up, and energy depletion. 
Chronic myocardial infarction can be induced in rats by coronary artery 
ligation. It is a well-established model of chronic heart failure and compares to 
myocardial infarction in humans (Hongo et al., 1997). 
1.1.5.2. Reperfusion Model for Transient Ischemia 
Temporary interruption of coronary blood flow to the myocardium followed by 
reperfusion exposes the myocytes to two extreme conditions of stress. First, 
the myocardial tissue experiences hypoxia-related stress conditions during a 
period of no-flow and then oxidative stress on reperfusion. Ischemia with 
duration of less than 15 minutes generally does not result in myocyte death or 
necrosis (Jennings and Reimer, 1983). Restoration of blood flow induces 
formation of reactive oxygen intermediates, which damages the cell 
components directly. In addition, the cardiac function may not return to normal 
for hours and the contractile function remains severely compromised during 
the early stages the reperfusion. The transient models of ischemia are 
particularly helpful for identifying the molecular processes involved in the 
adaptive response to stress and preconditioning (Brand et al., 1992). 
Rat models for transient ischemia are produced by 15 to 60 minutes of 
coronary artery occlusion, followed by 7 days of perfusion. No cell death is 
observed after 15 minutes while 60 minutes occlusion produces myocardial 
necrosis (Prentice et al., 1996). These models have been used to assess 
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gene transfer by adenovirus (Leor et al., 1996) and retrovirus and direct DNA 
injection (Prentice et al., 1996). 
1.1.5.3. Permanent ischemia or Infarct Model 
This model simulates the cellular environment produced in the myocardium 
where a coronary artery branch supplying the region is occluded permanently. 
Such a level of occlusion approximates the clinical condition of myocardial 
infarction (Ytrehus and Downey, 1993). Due to the presence of collateral 
blood flow, different areas of the affected myocardium will be perfused to 
varying degrees. Tissues not accessible by the collateral flow become 
necrotic, while areas with low-flow become permanently ischemic. The 
necrotic, non-contracting myocytes affect the overall synchronised contractility 
of the myocardium (Ytrehus and Downey, 1993). The necrotic tissue responds 
differently to a signal to contract due to compromised impulse conduction, 
sometimes causing regions of the ventricles to contract independently of the 
normal conduction system. The uneven pattern of electrical excitability in the 
myocardium is known as arrhythmia (Allen and Orchard, 1987). 
A number of studies on the infarct model have led to the understanding of the 
phenomenon of myocardial remodelling, which is an adaptive mechanism for 
the diseased heart to overcome stress (Parker and Schneider, 1991). The 
main feature of remodelling is hypertrophy, whereby the terminally 
differentiated cells of the myocardium increase in size to adapt to increased 
workload (Parker, 1993). Infarct models have contributed to the understanding 
of changes in pattern of gene expression which occur during cardiac 
remodelling (Komuro and Yazaki, 1993). 
1.1.5.4. Cell Culture Model 
Isolated myocytes in culture have also provided valuable insight into the 
cellular response of cardiac myocytes to stress conditions. Established 
cardiac cell lines are not available, but primary neonatal and adult myocytes 
have been successfully isolated, and conditions for culture of these cells have 
now been optimized (Simpson and Savion, 1982; Bugaisky, 1988; Lokuta et 
al., 1994). Moreover, healthy primary cardiocytes are able to contract 
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spontaneously in culture, making them useful for contraction studies. 
Conditions such as p02' pH, glucose and metabolite levels can be monitored 
and altered to simulate an ischemic environment. Techniques such as patch 
clamp, and video edge detection analysis (Chen et al., 1996), can be carried 
out on single cells. Due to versatility of this model by providing unlimited 
control of the environmental variables, it can be used to mimic the chronic, 
transient and permanent ischemia models. 
Cell culture models have been widely used in studying stress responses 
(Webster and Bishopric, 1992; Janero et al., 1993; Shyu et al., 1995) 
,preconditioning (Webster et al., 1995), acidosis (Acosta and Li, 1980; Chen 
et al., 1996), Ca ++ -flux (Murphy et al., 1987) and other variables which occur 
in cardiocytes during ischemia. 
1.1.6. Ex vivo Models for Assessing Contractile Performance 
The main parameter of interest in ischemia and heart failure is contractility. 
Isolated papillary muscles, trabeculae and myocardial muscle fibres are 
extensively used for investigating force generation and shortening produced in 
cardiac muscle, under a given set of conditions. The isolated tissue is set up 
in an apparatus, integrating a force transducer, to measure force production 
with the muscle fibre immersed in a small bath containing buffers (Strauss et 
al., 1997). Full heart preparations are also used in some cases to study 
outcomes of inotropic intervention produced by drugs or diseased conditions 
of myocardium (Edes et al., 1995; Sia et al., 1997). 
1.1.6.1. Skinned Muscle Fibres 
A useful model in contractile force measurement is the demembranated or 
"skinned" preparation of cardiac muscle. Detergents, such as Triton X-100, 
are used to dissolve the membrane, leaving the contractile apparatus 
functionally intact. Selective detergents such as saponin are also used for 
partial permeabilization, when required. Skinned fibres are bathed in buffers 
which mimic the intracellular environment where conditions of pH, ATP, and ion 
concentrations can be varied as desired. These models have been used for 
studying sarcoplasmic reticulum and myofilament function (Palmer and Kentish, 
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1994; Denvir et a/., 1995; Fuchs and Wang, 1996), and effects of varying 
intracellular conditions (Solaro et a/., 1988; Brixius et a/., 1997) and drugs on 
contractility. Several calcium sensitizing compounds have been evaluated using 
the skinned fibre system (Edes et a/., 1995; Haikala et a/., 1995). 
Much of the work contributing to the understanding of muscle contraction has 
been carried out on skinned fibres. However, these preparations are unusable 
with drugs acting viamembrane receptors or in experiments involving membrane 
depolarization due to the non-existence of the membrane. 
1.1.6.2. Isolated Papillary Muscle and Trabeculae 
Ventricular papillary muscle and specialized fibres known as trabeculae are 
also used in contractility studies of the heart. These muscle fibres are isolated 
from diseased or normal myocardium and immersed in appropriate buffers. 
Parameters such as myofilament Ca ++ -sensitivity (Lab et a/., 1984; Akella et 
al., 1997), Ca ++ -flux (Lee and Allen, 1992), acidosis (Solaro et al., 1988) or the 
effect of drugs (Lee and Allen, 1991; Edes et al., 1995) are studied under 
varying intracellular conditions by altering buffer components, which can 
simulate conditions of ischemia and/or reperfusion (Lee and Allen, 1992). 
Analyses on trabeculae and papillary muscle include force measurements 
using a force transducer, and may involve electrical stimulation. Ca ++ flux 
studies are carried out by injecting the muscle with fluorescent indicators such 
as aequorin (Lee and Allen, 1992). 
1.1.7. Transgenic Models 
Various models for simulating hypertrophy and myocardial ischemia have 
been developed using transgenic technology, and characterized for 
phenotype. Transgenic mice overexpressing single genes involved in cardiac 
physiological and mechanical functions have also been developed. 
Transgenics expressing contractile proteins such as skeletal Troponin C 
(Metzger et al., 1993), ~-tropomyosin (Mariappan et al., 1995), and membrane 
associated proteins like A 1 adenosine receptor (Matherne et al., 1997) and 
Na + -Ca ++ exchanger (Adachi-Akahane et al., 1997), in heart have been 
developed and effects of these genes in normal and ischemic conditions 
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studied. In addition, "knock out" mice with a specific gene "silenced", such as 
for the SR regulatory protein phospholamban have been constructed (Grupp 
et a/., 1995) and outcome of absence or down-regulation of this protein 
studied. Cardiac physiology of such transgenic mice can be studied in vivo. 
using miniaturized techniques on whole hearts or in vitro. using single isolated 
cells. These studies allow dissection of interactions between various factors 
which may lead to heart disease, and provide the insight for development of 
novel therapeutic strategies (Christensen et al., 1997). 
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1.2. Ultrastructure and Physiology of Contractile Myocytes in the Heart 
The process of contraction in skeletal and cardiac muscle is carried out by 
muscle cells called myocytes. Myocytes are specialized cells with a 
sophisticated and powerful intracellular apparatus made up of several 
structural proteins. Under the light microscope, both types of muscle show 
striations or banded appearance which is a demonstration of the highly 
organized contractile protein machinery accommodated intracellularly. 
In heart, the contractile proteins form a major part of cardiomyocytes. The 
cardiac myocytes comprise only one-third in number of all cells present, but 
occupy 75% of the volume of myocardium. Ventricular myocytes are 
organized into groups called myofibers, held together by collagen connective 
tissue. The individual cardiomyocytes are roughly cylindrical in shape with the 
atrial myocytes being smaller than ventricular myocytes. The larger ventricular 
myocytes measure about 17-26 microns in diameter with length measuring 
between 60 to 140 microns. Both atrial and ventricular myocytes are branched 
and attached to adjacent cells in a end-to-end manner (see fig. 1.2.1). 
mitochondria 
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Fig 1.2.1: Illustration of a section of myocardium, based on electron microscopic studies. 
Organization of sarcomeres in the myocytes, and gap junctions between the latter 
are magnified to show details of the structure (see text). (J.R. Levick; An 
Introduction to Cardiovascular Physiology, 2nd ed., Butterworth-Heinemann, UK. 
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Each cardiomyocyte is bounded by a cell membrane called the sarcolemma 
constituting a bilipid layer and several ion channels. Myocytes comprise 
cylindrical structures called myofibrils which constitute the elementary 
contractile components (see fig. 1.2.2). Myofibrils are generally 1 micron in 
diameter, often spanning the whole length of the myocyte, made up of 
repeating structural units called the sarcomere. Sarcomeres are the basic 
functional unit of contractility comprising a hexagonally arranged lattice of 
interlocked thick and thin filaments (see figs 1.2.2 and 1.2.3). 
The sarcolemma of myocytes invaginates into the cell forming an extensive 
tubular network known as Transverse tubules (or T-tubules) , which is seen as 
an extension of extracellular space into the cell interior. The nucleus is often 
centrally located with some myocytes having more than one nuclei. 
Mitochondria are interspersed between the myofibrils and mainly located 
immediately beneath the sarcolemma, provide the ATP needed for contractile 
functions and maintenance of ion gradients. Of the other sub-cellular 
organelles, the Sarcoplasmic Reticulum (SR) stands out in importance for its 
role in Ca ++ handling during the contraction cycle (see section 1.1.1.5). 
The SR is a network of tubules and flattened vesicles spreading throughout 
the myocytes, interspersed among the myofibrils. Parts of the SR lie very 
close to the T -tubules where it expands into bulbous sacs, often lying along 
the inner surface of the sarcolemma or wrapped around the T-tubules. Such 
regions of the SR are called terminal cisternae, and contain the calcium 
release channels also referred to as Ryanodine receptors. The longitudinal or 
network SR is made up of branching tubules and performs the function of 
calcium uptake into the SR by an ATP-requiring Ca ++ pump, called 
Sarcoendoplasmic Reticulum Ca ++ -A TPase (SERCA). Calcium taken up by 
the latter is stored in the SR at high concentrations and released when 
required via the ryanodine receptors. 
1.2.1. Contractile Apparatus 
The principal role of cardiomyocytes lies in the contraction-relaxation cycle, 
which brings about the unified contraction of the ventricle muscles. 
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Contraction of myocytes is brought about by the shortening of its sarcomeres, 
the basic contractile unit. Major molecules involved in the process are the thin 
(actin) filaments and the thick (myosin) filaments of the sarcomere. 
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Fig 1.2.2: Illustration of organization of cardiac myofibers including subcellular structures in 
the cardiac myocytes, down to the level of sarcomeres. The movement of Ca++ in 
the excitation-contraction cycle, and the actin-myosin overlap during systole and 
diastole is also shown. Steps involved in calcium movement are numbered, and 
discussed in section 1.2.5.2. (modified from Opie, L.H.; Mechanics of Cardiac 
Contraction and Relaxation. In: Heart Disease: A Textbook of Cardiovascular 
Medicine, edited by Braunwald, E., :W.B. Saunders, USA, 1997). 
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1.2.1.1. The Sarcomere 
The sarcomere is a unit of the contractile apparatus, occurring as repeating 
units in a myofibril. The banded appearance of the myofibres is attributed to 
this typical modular organization of the sarcomeres (Alberts et al., 1983). 
Electron microscopy reveals that the sarcomere being demarcated by the 
Z-line or more appropriately the Z-disc, which is the anchor-site for actin (thin) 
filaments. The myosin (thick) filament, on the other hand, extends in either 
direction from the center of the sarcomere toward the Z-line, but not reaching 
it. The myosin and actin filaments overlap and the extent depends upon the 
contractile state of the myocyte. The myosin filament is however secured to 
the Z-line by a protein called Titin which itself is anchored to the Z-line. Titin, a 
slender myofibrillar protein, is the largest protein molecule yet described. It 
has two distinct segments; a non-extendible portion which interacts with 
myosin and an extendible region which can stretch as the sarcomere shortens 
(Opie, 1997). The thick and thin filaments are arranged in interlocking lattice 
within the sarcomere and bring about the contraction of muscle without the 
individual actin or myosin molecules changing in length. This is achieved by 
the two filaments sliding over each other, bringing the boundaries (Z-discs) of 
sarcomere closer. With several sarcomeres undergoing this process, the 
cardiomyocyte contracts. 
1.2.1.2. Thick filaments and Myosin 
The molecular structure of the myosin molecule is now well understood. It is 
composed of two heavy chains (myosin heavy chains or MHC) and two pairs 
of light chains (myosin light chains or MLC-1 and MLC-2). The main body 
(sometimes referred to as tails) of the myosin molecule consists of two MHC's 
intertwined with each other into a coil, with each MHC ending in a head at the 
amino terminal. (Fig. 1.2.3). Light chains are associated with each of the 
myosin head regions which also possess ATPase activity. MHC has two 
isoforms, a and ~, with the ~ isoform predominant in adult humans. Both 
isoforms have the same molecular weight, but differ in their ATPase activity. 
MLC-1, also known as essential MLC, appears to be involved in interaction 
with myosin, while MLC-2, known as the regulatory MLC, is a potential site for 
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phosphorylation, which is postulated to increase the affinity of myosin for 
actin. 
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Fig 1.2.3: Ultrastructure of sarcomere showing components of myosin thick filaments and of 
actin thin filaments, including actin, tropomyosin and the Troponin complex. 
(adapted from Alberts, B., Bray, D., Lewis, J" Raff, M., Keith, R., and Watson, 
J.D: Molecular Biology of the Cell, Garland Publishing Inc. Conneticut, USA. 
1983) 
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Spatially, myosin assembles a filament with the coiled tail oriented towards 
the center of the filament and a globular flexible head projecting to the side. 
The thick filament thus appears as possessing tiny side arms or oar-like 
"cross-bridges" extending about 13 nm to make contact with the thin 
filaments. The base of the head referred to as the "neck", is a region of the 
myosin which changes in configuration in the contractile cycle. The myosin 
heads have "nucleotide pockets" which bind ATP and its breakdown products, 
and is in close proximity of the myosin ATPase. 
1.2.1.3. Thin filaments 
The thin filaments are composed mainly of actin and in addition contain the 
regulatory apparatus for controlling the process of contraction. The thin 
filament regulatory proteins comprise Tropomyosin protein and the Troponin 
complex. 
The globular actin (G-actin) monomers aggregate to form the fibrillar actin or 
F-actin molecule. F-actin is intertwined in a helical pattern with the 
Tropomyosin, which is a linear molecule, lying in the F-actin groove and acting 
as a backbone for the actin helix. The Troponin complex consists of three 
proteins with different but interactive functions, positioned at a regular interval 
of 38.5nm along the twisting F-actin molecule (Fig. 1.2.3). Troponin T 
mediates attachment of the whole troponin complex to the tropomyosin and 
actin. Troponin I is the inhibitory protein which inhibits interaction between 
actin and myosin: Under conditions of low cytosolic Ca ++ , Troponin I positions 
tropomyosin on the thin filaments such that sites of actin-myosin interaction 
on the actin molecule are unavailable for cross-bridge formation. Troponin C 
is the calcium-binding protein which is in fact the regulatory "switch" protein in 
this complex: It binds calcium on its release in high amounts from the SR, 
changing in conformation and relieving the inhibition of myosin-actin 
interactions imposed by Tropomyosin and Troponin \. 
1.2.2. Nature of Actin-Myosin Interaction or Cross-bridges. 
Myosin heads interact with specific sites on the actin filament forming cross-
bridges which have been postulated to exist in either a strong or weak binding 
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state. In the resting condition, the cross-bridges are attached in a weak state. 
This weak state of binding is due to the masking of myosin interaction sites by 
tropomyosin as described in the previous section. On elevation of calcium 
levels in the cytosol, a series of events known as "excitation-contraction 
coupling" are initiated. Calcium interacts with Troponin C, disengaging the 
inhibitory effect of Troponin I and Tropomyosin, and establishes a strong 
binding state of the cross-bridges. This binding state persists until high Ca ++ 
levels are present, however, continuous presence of such a state is 
undesirable as no relaxation is possible. Therefore, it is proposed that ATP 
binding to the myosin head brings the cross-bridges into a weak binding state 
even at high calcium concentrations (Brenner, 1988). Hydrolysis of ATP to 
ADP and Pi reverses the state of strong binding. A conformational change in 
the myosin head also occurs at the myosin head which brings about the 
relative movement of the thick and thin filaments, described in fig. 1.2.4. 
1.2.3. Molecular Model of Muscle Contraction 
The molecular model of muscle contraction is based on A.F. Huxley's model 
and has been elaborated at the molecular level (Ruegg, 1990). This model is 
also called the sliding filament model, as the filaments are propelled past each 
other by repeated altering of cross-bridge binding states. 
Muscle contraction can be seen as a repetitive process where the myosin 
heads act as force generating, or "stroke" producing structures, by changing 
conformations in between states of ATP association, breakdown by 
myosin-ATPase and subsequent release from the head. The model has been 
described in fig. 1.2.4. 
Cross-bridge cycling is continuous process which should occur provided there 
is sufficient intracellular Ca ++ to bind to Troponin C. Thus, at a given moment, 
myosin heads may be at different states of flexion. Some will be flexed and 
some preparing to flex, with others extending, attached to or detached from 
actin. Numerous cross-bridge cycles spanning only a few milliseconds, move 
the thin filament towards the central region of the thick filaments, resulting in a 
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Fig 1.2.4: Schematic presentation of the cross-bridge cycle in myocytes according to A.F. 
Huxley's sliding filament model. The cyclic process involves strong and weak 
binding of the cross bridges in presence of high Ca++ concentrations. 
Conformational changes in the angle of myosin head bring about the "stroke" 
action, causing sliding of the myosin thick filaments relative to the actin thin 
filaments. Cross-bridge cycling proceed during the whole period of a calcium 
transient with several cross-bridges cycling simultaneously, causing shortening of 
the sarcomere. (modified from Lodish, H. et al., Molecular Cell Biology, W.H. 
Freeman & Co. USA). 
shortening of the sarcomere. The number of cross-bridges formed at a given 
time is important in force production by the myocytes. The sum total of a\l 
shortening sarcomeres leads to systole, the contraction phase of the cardiac 
cycle. At low [Ca ++]i abundance, the Troponin C is not occupied by Ca ++ and 
no cross-bridge cycling occurs and the diastole part of the cardiac cycle 
begins to set in. 
1.2.4. Ion Pumps of the Sarcolemma 
Ion channels of the sarcolemma have a critical role in maintaining the ionic 
balance and consequently the electrical status of a myocyte. Ions such as K+, 
+ d ++ Na an Ca can permeate, or are gated through these channels by 
exchange or by ATP dependent mechanisms. These channels maintain ion 
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concentration differences across the cell membrane producing electrical 
potential differences of up to -60mV to -90mV in resting myocytes. K+ 
intracellular concentrations are 35 times higher than the extracellular 
concentration with potassium having greater permeability than other ions. 
Outward diffusion of K+ ions, down its gradient, through K+-channels creates a 
separation of charge compared to the cell exterior. Ion channels maintain this 
resting potential and also bring the cell back to the resting potential after an 
action potential. The main ion pumps of the sarcolemma and their functions 
are shown in table 1.1. 
Table 1.2.1: Main Ion Channels of Myocyte Sarcolemma 
Ion Function Activated by ATP Inhibited overall effect on cell 
Channel required by 
Na+-K+ 3 Na+ out membrane Yes ouabain depolarization; 
ATPase potential sustaining K+ and Na + 
2 K+ in concentrations 
Na+-Ca++ 3 Na+ in membrane No responsible for 
exchanger potential expulsion of 3/4 of the 
Ca++ out cell calcium in resting 
Ca++ and Na+ cardiomyocytes; the 
reversible gradients direction of the 
exchanger reverses 
and Ca ++ are carried 
into the cells, albeit in 
smaller amounts, 
during action potential; 
sustains late Ca ++ 
plateau 
Na+-H+ 1 H+ out high No amiloride maintaining 
exchanger 1 Na+ in extracellular and its intracellular pH. 
reversible Na+ derivatives 
high 
intracellular H+ 
Levels of intracellular calcium are critical for efficient contractility of myocytes. 
In addition to the membrane bound ion channels of the sarcolemma, rCa ++]i 
levels in myocytes are regulated by two main channels present in the 
sarcoplasmic reticulum. Calcium ions are taken up to accumulate in the SR by 
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the calcium-pumping ATPase, also called SERCA. The stored Ca ++ is 
released in large amounts into the cytosolic space via a calcium release 
channel (also called the Ryanodine receptor) in an indirect response to 
electrical stimulus. 
1.2.5. Calcium Fluxes in Contraction-Relaxation Cycle 
Intracellular calcium level increase in myocytes and subsequent contraction, is 
associated with electrical stimulation of myocyte membrane or excitation, 
which occurs on arrival of an action potential. This phenomenon is called 
excitation-contraction coupling. In intact heart, the Ca ++ level rises in 10 to 20 
milliseconds (ms) and within 200 to 400 milliseconds, the calcium is removed 
from the cytoplasm (Allen and Kurihara, 1980), and maintained at the resting 
stage levels, until the next excitation. Thus high Ca ++ concentration in the 
cytoplasm is transient and amplitude of this pulse of Ca ++ is referred to as the 
calcium transient. Calcium transients are produced and maintained by a 
complex system tightly regulated by a range of membrane bound ion 
channels of the sarcolemma and the sarcoplasmic reticulum. Some of these 
ion gates are ATP-dependent or gradient-propelled while others may respond 
to an electrical stimulus and are known as electrogenic. 
1.2.5.1. Calcium Handling 
The cellular mechanisms involved in calcium ion fluxes during contraction and 
relaxation, and their association with wave of excitation are not fully clear. 
However, a working model based on Ca ++ release from the SR has been 
conceptualized (Fabiato, 1983; Nabauer et al., 1989). The model is based on 
observations that the SR releases relatively large amounts of Ca ++ in 
response to a much smaller amount entering the myocyte during each cardiac 
cycle. The model links entry of small amounts of extracellular Ca ++ into the 
cells, to the release of larger amounts of Ca ++ by the SR into the cytosol, and 
is known as, the theory of calcium-induced calcium release. The SR Ca++ 
release is known to raise the [Ca++]i up to ten-fold. Calcium levels return to 
normal at the termination of excitation, by uptake of excess cytosolic Ca ++ by 
the sarcoplasmic reticulum. 
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The theory of calcium-induced calcium release is now widely accepted after 
characterization of the ion channels of the sarcoplasmic reticulum (SR) 
involved in Ca ++ release (Opie, 1997). The myocytes have an elaborate 
system of Ca ++ handling gated by sarcolemmal ion channels which maintain 
the normaI10,OOO-fold trans-sarcolemmal gradient of Ca++. Within the cell, the 
sarcoplasmic reticulum serves as a store of Ca ++, which is released in 
response to an action potential. The SR is gated by SR-Ca ++ ATPase, 
(SERCA) which during resting stage, maintains the cytosolic Ca++ at resting 
levels, by pumping any extra Ca ++ back into the SR lumen. The total amount 
of Ca ++ stored in this organelle (termed the SR Ca ++ load), and the fraction of 
load released by Ca ++ entry, become important determinants of the amplitude 
of the Ca ++ -transient and subsequent contractions (8ackx ef a/., 1989; 
Mubagwa, 1995). Stored Ca ++ is released from the Ca ++ -release channels 
known as ryanodine receptors. 
1.2.5.2. Calcium Release from Sarcoplasmic Reticulum 
The calcium release channels of the SR is a part of a complex structure 
known as the ryanodine receptor. These channels lie in close anatomical 
proximity to the sarcolemmal Ca ++ channels located in the invaginated 
I ++ sarco emma structures, the T-tubules. Each of these sarcolemmal Ca 
channels can induce a number of SR calcium release channels. Calcium 
enters the myocyte when the voltage-sensitive calcium channel opens in 
response to depolarization of the T-tubule (fig. 1.2.2-(1) & (2)) (Fabiato, 1983). 
The calcium ions induce changes in molecular configuration of the ryanodine 
receptor, opening the SR-calcium release channels (fig. 1.2.2-(3)). Hence the 
stored SR calcium is discharged into the cytosol increasing the rCa ++]i up to 
10-fold (fig. 1.2.2-(4)). Free cytosolic Ca ++ causes activation of the 
myofilaments in the sarcomere (fig. 1.2.2-(5)). 
The rise in cytosolic Ca ++ stops with passing of the wave of excitation. There 
is no entry of Ca ++ into the myocyte or any Ca ++ release by the sarcoplasmic 
reticulum at this stage and Ca ++ concentration starts to fall to its resting level, 
initiating the relaxation of myocyte (fig. 1.2.2-(7)). The fall in cytosolic Ca ++ 
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level is brought about by uptake and re-storing of free cytosolic Ca ++ by the 
SR, and mainly by balancing of [Ca ++]i by the sarcolemmal ion channels such 
as the Na +-Ca ++ exchanger (fig. 1.2.2-(6))(Schwartz et a/' J 1992). 
1.2.5.3. Calcium Uptake and Storage into Sarcoplasmic Reticulum 
Calcium ions are taken up by the SR for storage by the SR calcium-pumping 
ATPase or SERCA. The cardiac isoform of this pump is known as SERCA-2a 
(Maclennan et al' J 1997). For each mole of ATP hydrolysed, two Ca++ ions 
are taken up to accumulate in the sarcoplasmic reticulum. SERCA is 
regulated by a protein called phospholamban, which when in 
un phosphorylated state, inhibits the pump. High cytosolic Ca ++ and ~­
adrenergic stimulation are known to phosphorylate phospholamban, activating 
the uptake of Ca ++ by SERCA. 
1.2.6. Myoplasmic Calcium Concentration and Force Generation 
The resting or non-contracting muscles are maintained at a Ca ++ level where 
no tension is generated in the myofibrils. During the excitation-contraction 
phase, the myoplasmic Ca ++ concentration increases and excess Ca ++ 
becomes available to bind the low affinity sites of Troponin C and triggers 
contraction in the myofibers. Hence, higher [Ca ++]i or efficient binding of Ca ++ 
to TnC is seen to influence force of contraction directly. Furthermore, there is 
an upper limit, above which Ca ++ concentration becomes so large that the 
Troponin C is saturated and unable to generate any additional force 
(discussed in section 1.2.6.1). However, force is known to increase beyond 
this Ca ++ threshold, possibly by better thin and thick filament interactions. 
A force-Ca ++ relationship can be presented as a curve plotted between force 
and myoplasmiccalcium concentration. This force-calcium relationship is able 
to reflect the nature of interactions taking place under normal physiological 
conditions or those resulting from intervention by inotropic agents (fig. 1.2.5). 
The resting [Ca ++] is 1-2 x 10-7 moillitre, lying just below the tail of the curve 
and activation of contraction beginning at approximately 5 x 10-7 molll and 
saturates between 10-5 molll and 10-4 molll of Ca ++, as demonstrated in 
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studies on skinned muscle fibres (Fabiato and Fabiato, 1978; Kentish, 1984; 
Pan and Solaro, 1987). 
A (i) (ii) (iii) (Iv) 
Intracellular 
calcium 
.J'----
~ f\ J~ JL JL 
Force ~ J',,- j( J~ 
B 
.... -~ /~-(iii)········1 
i / ".) 
~ 1/') I 
__ ._1 
Peak intracellular calcium 
Fig 1.2.5: Relation between [Ca++]; and force in intacrt heart muscle during inotropic 
intervention. A- intracellular calcium transients and the force produced in intact 
heart muscle at four levels of extracellular calcium. 8- shows a typical 
relationship curve between peak [Ca++]i and peak force. Points marked in roman 
numerals correspond to the muscle activation levels shown in A. Note that at the 
highest concentration of [Ca++];, the force developed begins to decline (adapted 
from Lee, JA and Allen, D.G.; Cardiovascular Research 36:10-20, 1997). 
In normal conditions, a twitch is induced well down the force-Ca ++ relation 
curve, i.e. much before the point where myofilaments are saturated with Ca++. 
An inotrope which acts by increasing contractile force by elevating the 
concentration of [Ca ++]j, will produce a curve similar to shown in fig.1.2.5-B. An 
agent able to produce a more efficient response to a given calcium 
concentration by increased occupancy of Troponin C (such as calcium 
sensitizers), manifests itself in the force-Ca++ curve as shown in fig. 1.2.7(b), 
showing a parallel leftward shift of the entire force-Ca ++ relationship curve. 
Similarly, an increase in force produced at the threshold where Ca ++ induced 
response saturates under normal conditions, is also known to occur. This is 
postulated to happen due to better actin-myosin or cross-bridge interactions 
and alters the force-Ca ++ relationship as shown in fig 1.2.6 (b). 
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An inotropic intervention brings about certain characteristic changes in the 
force-Ca ++ curve, as discussed above. Force-pCa relationship curves which 
help in determining the molecular mechanism or mechanisms responsible for 
bringing about this change in contractility. Such relationship curves are useful 
method of determining the mechanism of action for any positive or negative 
inotropic intervention. 
1.2.6.1. Altering Maximum Ca ++ -activated Force 
Force generation in muscle can be manipulated by changing the maximum 
Ca++-activated force. This concept aims at modifying the force produced per 
cross-bridge, the number of active (force-generating) cross-bridges under a 
given condition, or the number of cross-bridges employed to produce a 
"contractile 
Maximun Calcium-activated Force (ii) 
----------------
100" - - - - - - - - - - - -
FORCE (ox.) 
saturation 
O. d': V 
MVOPLASMIC CALCIUM CONCENTRATION 
Fig 1.2.6: Schematic presentation of effects of an inotropic intervention causing an ideal 
increase in maximun calcium-activated force in myocytes (b). An increase in the 
slope of the force-pCa curve (i), and an increase in the force produced at the 
highest level of intracellular calcium, presented by dotted lines (ii), is seen in (b) 
due to the effect of the inotrope, as compared to the normal force-pCa curve (a). 
Force generation threshold Ca++ and saturation Ca++ levels are same in both (a) 
and (b). (modified from Allen, D.G. & Lee, J.A.; 1997, Modulation of Cardiac 
Calcium Sensitivity: A New Approach to Increasing the Strength of the Heart: 
Oxford University Press, NY.) 
stroke". Such variables can be altered to produce greater force at a given 
Ca ++ concentration by increasing the overall proficiency of myosin head-actin 
cross-bridge formation and interaction. 
In conditions where the contractile force is altered purely by increasing the 
maximum Ca ++ -activated force, the force-Ca ++ relation curve is altered as 
shown in figure 1.2.6. It can be seen from the curve that the force is increased 
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beyond the maximum, at Ca++ concentration where the force response 
saturates under normal conditions. Thus a greater force of contraction is 
achieved at the same Ca ++ concentration due to increased efficiency of 
cross-bridge cycling in response to a calcium transient (fig.1.2.6-(ii)). The 
force generation [Ca++]i threshold remains unchanged, and the rate of 
increase in force, shown by the slope of the curve is fractionally increased. In 
addition, the force response is seen to saturated at the same rCa ++]i as in 
normal conditions (fig. 1.2.6). 
1.2.6.2. Calcium Sensitivity 
This phenomenon is based on the concept of altering force by altering Ca ++ 
occupancy of low-affinity Ca++-binding sites of Troponin C. At a given Ca++ 
concentration efficient Ca++-binding is a key factor in force generation, should 
be able to produce more force. 
The occupancy of the low-affinity Troponin C sites is determined by its Ca ++ 
affinity constant which is the ratio of the association and dissociation rate 
constants of calcium binding. Since the association constant is high and 
seems to be limited only to the availability of Ca ++, the dissociation rate may 
be retarded to increase the calcium occupancy of Troponin C. In effect, the 
Ca ++ stays bound to Troponin C for a longer period of time, maintaining the 
force of contraction. 
Prolongation of the Ca ++ -bound state should allow formation of more 
cross-bridges resulting in more force generation. The outcome of increased 
occupancy of Troponin C manifests itself in the force-Ca ++ curve as shown in 
fig 1.2.7-(b)., which shows a parallel leftward shift of the entire force-Ca++ 
relationship. More force is generated at a given myoplasmic rCa ++], resulting 
in the lowering of threshold rCa ++] for force generation, and also the rCa ++] 
where the force response saturates (fig. 1.2.7). Several pharmacological 
interventions 
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(ii) 
Fig 1.2.7: Schematic representation of the effects of "pure" change in calcium sensitivity of 
muscle fibres. A leftward shift of the force-pCa curve (b), is seen as an increase in 
calcium sensitivity, produced by an inotropic intervention. The arrow (i) indicates 
an increase in force produced in (b), compared to (a) at a given intracellular 
concentration of calcium. Also the maximum force (ii) is achieved at a lower 
calcium concentration in (a) when compared to (b). These two components form 
the phenomenon of calcium sensitivity. In addition, [Ca++]j concentration where 
contraction initiates (Ca++ thresho/cl) , is lowered, and [Ca++]j beyond which no 
further increase in force is generated (Ca++ saturation) is also decreased. 
(modified from Allen, D.G. & Lee, J.A.; 1997, Modulation of Cardiac Calcium 
Sensitivity: A New Approach to Increasing the Strength of the Heart: Oxford 
University Press, NY.) 
are known to result in such a parallel shift of force-Ca ++ relation and are 
referred as "calcium sensitizing" agents. The concept of increased Troponin C 
occupancy stands out as the most probable mechanism for calcium sensitivity 
alterations produced by these drugs. However, theoretically any inotropic 
intervention showing such a parallel shift of force-Ca ++ relation, without any 
effect on maximum force produced, can be classified as an inotropic 
intervention affecting calcium sensitivity. This effect may involve increased 
calcium occupancy of Troponin C or may be due to altered molecular 
interactions between the various units of the troponin complex and 
tropomyosin. 
In practice, it is difficult to categorize the response discretely as being due to 
modified calcium sensitivity or to maximum calcium-activated force unless a 
wide range of Ca ++ concentrations are studied. It should however be clear that 
there are two independent ways at which force can be altered at a certain 
Ca ++ concentration, which can be generally termed as myofilament calcium 
responsiveness. Some interventions for example Pimobendan alter force by 
increasing calcium sensitivity and calcium-activated force (Lee et a/' J 1989), 
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while caffeine sensitizes the myofilaments but reduces the maximum Ca ++ 
activated force (Wendt and Stephenson, 1983). These observations support 
the hypothesis of the two mechanism being independent and having the 
potential of being manipulated separately, provided an appropriate method is 
found. 
1.2.7. Endogenous Calcium Sensitizing Factors of the Heart 
A number of factors have been found to shift the Ca ++ -force relation curve 
indicating their direct or indirect influence on myofibrillar Ca ++ responsiveness. 
Change in pH, intracellular Mg ++ or Pi concentration, ATP levels, muscle 
length, troponin I/myosin light chain phosphorylation, and several drugs such 
as caffeine are known to alter force produced in response to a given rCa ++]i 
(Lee and Allen, 1997; Miller et al., 1997). 
Increased calcium sensitivity of myofilaments is known to be achieved by a 
number of native molecular mechanisms in the heart muscle. The Frank-
Starling mechanisms stated that calcium responsiveness in cardiac muscle is 
dependent upon the sarcomere length and is manifested in greater force of 
ventricular contraction produced with increased preload (Hibberd and Jewell, 
1982). On the other hand, increased Pi and H+ during hypoxia desensitizes 
the myofilaments. Protein Kinase C (PK-C) and PK-A have also been 
implicated in influencing calcium sensitivity by phosphorylating Troponin I 
(Tnl) and decreasing the sensitivity of the Ca ++ by stabilizing the actin/Tnl 
bound state. The phosphorylation of the light chain 2 of myosin (LC-2) of the 
thick filament is correlated with increased calcium sensitivity (Strauss et al., 
1997). These examples indicate the presence of a number of systems which 
can be modulated to increase sensitivity of the contractile apparatus to 
calcium. Thus therapeutic interventions can exploit these systems to 
ameliorate the compromised contractility in a failing heart. 
1.2.8. Pharmacological Agents for Altering Mechanisms of Inotropy 
Current pharmacological approaches for treatment of myocardial dysfunction 
mainly use inotropic agents to stimulate myocardial contractility, having a 
varied but limited success (Webster et al., 1996). Many of these agents aim at 
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elevating the intracellular Ca ++ during contraction, thereby increasing the 
amount of free cytosolic Ca ++, for the Troponin C to bind (Allen and Lee, 
1997). Among the inotropic agents currently in use, are cardiac glycosides, ~­
adrenergic agents and phosphodiesterase (POE) inhibitors (Lee and Allen, 
1997). 
Cardiac glycosides, such as digitalis, block the Na + pump, increasing the 
[Na +]i which exchanges the high Na + with Ca ++ from the extracellular space, 
via the Na + -Ca ++ exchanger. ~-adrenergic agonists occupy the ~-receptor 
causing an increased level of cyclic AMP through the action of G-protein and 
adenyl cyclase. POE inhibitors also elevate cyclic AMP levels, and they act by 
reducing the rate of cAMP breakdown. Higher cAMP levels cause 
phosphorylation of some intracellular proteins, such as Ca ++ channels of the 
myoplasmic membrane, increasing Ca ++ -entry, and hence higher 
accumulation of Ca ++, in the sarcoplasmic reticulum (Lee and Allen, 1997). 
However, these positive inotropic agents have a limited clinical value (Lee and 
Allen, 1991). The sarcoplasmic reticulum has a high risk of overloading if the 
Ca ++ content is increased beyond a certain level. This may cause 
spontaneous Ca ++ release resulting in arrhythmias(Alien and Lee, 1997). 
Arrhythmia is a common and serious problem with many positive inotropic 
drugs used to treat ischemic cardiac muscle, where the [Ca ++] may already be 
at higher levels. 
1.2.8.1. Calcium Sensitizing Drugs 
Alternative inotropic drugs are being investigated which can increase force of 
contraction by mechanisms other than elevation of intracellular Ca ++. 
Increasing the sensitivity of the myofilaments towards calcium is one option 
whereby higher force can be achieved at a given Ca ++ concentration. 
Theoretically, increased Ca ++-sensitivity can be brought about in at least four 
different ways (Lee and Allen, 1997); 
i). Increasing affinity of Troponin C for Ca ++. 
ii). Increasing the effectiveness of cross-bridge formation 
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iii). Increasing the rate of cross-bridge attachment or decreasing the 
cross-bridge detachment rate. 
iv). Enhancing the myofilament cooperativity by altered feedback between 
attached cross-bridges and Troponin C affinity for Ca++. 
A newer group of inotropic agents called "Calcium Sensitizers" are in the 
process of development, which aim to increase the response of myofilaments 
to Ca ++ and stimulate cardiac contractility in the failing heart (Lee and Allen, 
1991; Edes et a/., 1995). These drugs have attracted interest as they are able 
to avoid the toxicity problems associated with Ca ++ overload produced by 
agents presently used for treatment of contractile failure of the heart (Lee and 
Allen, 1997). Calcium sensitizers such as EMD 53998 (E. Merck-Darmstadt) 
have been observed to increase the sensitivity of intact ventricular muscle 
(Lee and Allen, 1991). Drugs have been designed to bind myofilament 
components such as cardiac Troponin C (Levosimendan, Orion 
Pharmaceuticals Inc.) which are found to increase force in skinned fiber 
bundles (Edes et a/., 1995). Several Ca++-sensitizers have been found to have 
a phosphodiesterase inhibiting activity and may act indirectly, or have dual 
activity of PDE inhibition and Ca ++ -sensitization. The molecular mechanisms 
involved are being investigated and agents with a more clear-cut positive 
inotropic effect of increasing myofibrillar sensitivity are being pursued (Lee 
and Allen, 1997). 
1.2.9. Molecular Targets of Therapeutic Interest 
Several cellular abnormalities of heart muscle are associated with contractile 
dysfunction. Proteins involved in these mechanisms are under investigation 
with a view to development of better therapeutic interventions. Most therapies 
are aimed at making the proteins perform better under conditions of stress 
and to sustain contractility, without having any adverse effect on the 
compromised myocardium. Several natural compensatory mechanisms 
triggered by the diseased myocardium, have added to the range of possible 
targets, which can be of therapeutic value, and may be manipulated to cure 
the diseased myocardium. 
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Most therapeutic strategies for improving ventricular systolic function have 
been based on inotropic agents which produce greater contractile force by 
raising the cytosolic Ca ++. Calcium is likely to already be raised in diseased 
muscle (Lee and Allen, 1993) and can result in adverse effects. Agents such 
as ~-blockers and phosphodiesterase inhibitors have been found to induce 
fatal arrhythmias and sudden cardiac death (Lubbe et al., 1992). With the 
discovery of the phenomenon of calcium sensitization, and with the success 
obtained with pharmacological calcium sensitizing drugs, the treatment of 
compromised contractile force without elevating the cytosolic Ca ++ has 
become possible. Phosphorylation proteins such as protein kinase C (PK-C) 
and PK-A, thick filament myosin light chain 2 and Troponin T/Troponin I 
interactions, have been implicated in altering calcium sensitivity and can be 
targeted for modulation of the latter (Strauss et al., 1997). 
Troponin C is the foremost regulatory protein of the contractile system 
responding to inotropic stimulus of elevated calcium. Thus, this molecule was 
chosen for this study, as a target for therapeutic intervention for modulating 
calcium sensitivity of the contractile apparatus. 
1.2.9.1. Trapanin C 
Troponin C (TnC) is a calcium-binding, 18 kilodalton (kD), acidic protein 
component of the regulatory Troponin complex. The protein exists in two 
similar but functionally distinct isoforms in the vertebrate species, namely the 
slow and fast TnC (Moss et al., 1986). The fast TnC isoform is the exclusive 
isoform in adult fast-twitch skeletal muscle whereas slow TnC is expressed 
both in slow-twitch and cardiac muscle (Wilkinson, 1980; Gahlmann et al., 
1988). The fast isoform is thus referred to as skeletal Troponin C (sTnC), and 
the slow isoform is known commonly as the cardiac Troponin C (eTnC). 
The crystal structure of Troponin C has revealed a dumbbell-shaped protein 
with two globular domains connected by a long central helix (Farah and 
Reinach, 1995), with the globular domains containing Ca++-binding sites (see 
fig 1.2.8). The two isoforms of Troponin C have different binding affinities for 
Introduction 36 
Chapter 1 
calcium. The carboxyl-terminal half of both isoforms have two high-affinity 
Ca ++-binding sites, shown as sites III and IV in fig. 1.2.8. 
Troponin C 
160 am ino acids 
N-terminal 
Regulatory 
Domain 
Fig 1.2.8: Structure of Troponin C protein. The protein has an Amino-end regulatory domain 
including the two low-affinity Ca++- binding sites. The high-affinity sites at the 
carboxyl-end are occupied by Mg++ under physiological conditions. (adapted from 
Parmacek, M.S. and Leiden, J.M.; Structure, Function, and Regulation of 
Troponin C. Circulation 84(3):991-1003, 1991). 
The skeletal Troponin C isoform has two additional low-affinity Ca++-binding 
sites at the amino-terminal half of the skeletal Troponin C isoform, which are 
shown as sites I and II in fig. 1.2.8. The amino-terminal of the cardiac isoform 
has only one functional low-affinity Ca ++.-binding site while the other site is 
non-functional (Gahlmann and Kedes, 1990). The four TnC Ca++-binding sites 
are numbered I to IV according to their order in the primary protein structure. 
Sites I and II of the NH2 domain bind only to Ca ++ with a low affinity (K=3 x 105 
M-1), while sites III and IV of the COOH-terminal domain bind Ca++ with high 
affinity (K=2 x 107 M-1) and a higher affinity (K=2 x 103 M-1) to Mg++ , and 
hence occupied by the latter under physiological conditions (Grabarek et al., 
1992; Farah and Reinach, 1995). Calcium-binding site I is non-functional in 
cardiac Troponin C isoform owing to some amino acid substitutions (Grabarek 
et al., 1992). 
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1.2.9.2. Troponin C Isoform Substitution Studies 
The functional difference between the cardiac and skeletal isoforms of 
Troponin C have been under investigation for some time. Selective extraction 
and reconstitution of protein subunits, in skinned or permeabilized muscle 
fibres has become an important tool for probing into the mechanism 
underlying the regulation of contractility (Babu et al., 1988; Gulati et al., 1989; 
Moss, 1992). This methodology has been used to exchange native protein 
with mutated or fluorophore-Iabeled proteins or myofibrillar proteins obtained 
in bacterial expression systems, for analyzing protein functions and 
interactions (Akella et al., 1997; Gulati et al., 1997). Most protein substitution 
studies have been done in skeletal muscle fibres but the technique is also 
workable in cardiac myocytes and myofibres. Myosin light chain 2 (MLC-2) 
and Troponin C have been reversibly extracted from cardiac fibres 
(Margossian, 1985; Gulati et al., 1989; Moss, 1992). In addition, transgenic 
mice have been developed which express the sTnC isoform in heart and have 
yielded substantial information on the role of the skeletal isoform in heart 
(Metzger et al., 1993). 
The role of two Troponin C isoforms in determining the force-calcium 
relationship was investigated by extracting most of the native isoform of 
skeletal muscle fibre and reconstituting with cardiac Troponin C. Results 
showed an influence of the isoform of TnC present in the thin filament, on the 
tension-pCa relationship. The results apparently depend strongly on the 
number of low-affinity Ca ++ -binding sites on TnC and their relative affinities for 
Ca ++ and also affect the degree cooperativity in the thin filaments (Moss et al., 
1986). Similarly, a reciprocal experiment was done to study the length-
dependent change in performance of myocardium, using skinned cardiac 
trabeculae, where the cardiac isoform of Troponin C was substituted for the 
skeletal isoform. The length-induced response was found to be greater in the 
presence of cardiac Troponin C than skeletal Troponin C indicating that cTnC 
may be the length sensor for the Frank-Starling mechanism (Babu et al., 
1988; Akella et al., 1997). Such protein substitution experiments have clearly 
provided evidence that the fact that isoform of Troponin C present in the 
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myofiber, influences the form of tension-pCa ++ relation (Moss, 1992). In 
another study, pH sensitivity of contraction was found to be significantly 
increased in skeletal muscle fibres, where the native sTnC was extracted and 
substituted with the cardiac isoform (Metzger and Moss, 1991). Studies on 
transgenic mice expressing sTnC isoform in heart, have also shown that the 
skeletal isoform of the protein is more resistant to pH changes (Metzger et al., 
1993). 
1.2.10. Experimental Hypothesis: Rationale for Targeting of Troponin C 
The project is designed to initiate an investigation into therapies involving 
gene transfer, which are aimed at sensitization of contractile filaments of a 
compromised myocardium, in the course of a disease such as myocardial 
ischemia and progressive heart failure. It is known that [Ca ++]i levels in 
ischemia are rarely altered, yet contractile response is reduced due to 
desensitization of myofilaments. This study forms the groundwork of a long-
term project designed to investigate ways of manipulating myofibrillar proteins 
which are directly susceptible to desensitization during ischemia. 
Troponin C is a key Ca ++ -binding reg ulatory protein of the myofilament. The 
skeletal isoform of this protein differs from the cardiac isoform in having an 
extra low-affinity binding site. Both isoforms have been characterized, cloned 
and sequenced (Gahlmann et al., 1988). It is suggested that partial or 
complete substitution of the cardiac (cTnC) isoform by skeletal (sTnC) isoform 
in card iomyocytes , will have a positive inotropic effect on myocardium, by way 
of increasing the calcium sensitivity of contractions. 
Troponin C was selected on the basis of results from Troponin C isoform-
substitution experiments, where native sTnC isoform was substituted for cTnC 
in skeletal muscle fibres (Moss et al., 1986) and a similar reciprocal 
experiment (Babu et al., 1988) discussed in the previous section. In addition 
to possible high affinity for calcium, the sTnC isoform was shown to be less 
sensitive to lower pH when tested in transgenic mice expressing the skeletal 
isoform in the heart (Metzger et al., 1993). This experiment clearly identified 
cTnC as an attractive target for therapies designed to treat myocardial 
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ischemia, where contractility is compromised due to several adverse 
intracellular conditions, such as acidosis. 
Pharmacological calcium sensitizing agents are under investigation and are 
known to have a positive inotropic effect by enhancing Ca ++ -sensitivity of 
myofilaments (Strauss et al., 1997). Some compounds are designed to 
interact with myofibrillar components, such as Levosimendan, which is 
designed to increase the Ca ++ -sensitivity of cardiac Troponin C by binding to 
N-terminal domain of the protein in a Ca ++-activated state (Edes et al., 1995; 
Haikala et al., 1995). In this project we use a gene transfer approach to 
overexpress sTnC in cardiomyocytes, using adenoviral transfer vectors. This 
gene transfer approach has been successful in achieving expression of the 
foetal isoform of Troponin I, its myofilament incorporation and subsequent 
enhanced contractile function in adult rat myocytes (Westfall et al., 1997). 
Therefore our gene transfer approach may also result in partial substitution of 
the native cTnC by the sTnC protein and provide useful data to address the 
phenomenon of reduced Ca ++ -sensitivity during ischemia. 
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1.3. Gene Transfer to the Myocardium 
A crucial component of any gene transfer protocol is the delivery system 
available for transferring the desired gene. This factor becomes more 
important when therapeutic genes are expected to be transferred directly to a 
patient in a routine clinical setting. The future of gene therapy is to be 
determined largely by the development of effective in vivo. gene transfer 
vectors which can safely and effectively deliver genes into the human body 
(French, 1997). 
The ideal gene transfer vector should have the ability to introduce foreign 
DNA into the cell, protect it from enzyme degradation while it travels through 
the cytoplasm to the nucleus, facilitate transport across the nuclear 
membrane and protect from nuclear endonucleases, eventually retaining it for 
a certain time period to express as required. Viruses are known to carry out 
these processes very efficiently and are being used widely for this purpose 
(Dunckley et al., 1992; Lynch et al., 1992; Stratford-Perricaudet et al., 1992). 
Non-viral systems such as cationic liposomes have been effectively used 
(Nabel et al., 1990) and new mixed systems of viral proteins and non-viral 
macromolecules (Aoki et al., 1997) are being developed. Naked DNA has also 
been expressed in muscle by direct injection of plasmid DNA (Wolff et al., 
1990; Acsadi et al., 1991; Kitsis et al., 1991). 
1.3.1. Non-Viral Gene Transfer Systems 
Liposome-based DNA transfer systems form the major part of non-viral 
methods of gene transfer. These methods have been improved by coupling 
liposomes with viral proteins and cell surface receptors to direct the DNA to 
specific tissues. Direct injection of DNA has also been successful in transfer 
and expression of genes to muscle cells in vivo. 
1.3.1.1. Direct DNA Injection 
A super-coiled plasmid can be considered as the most elementary gene 
transfer vector, as it can be delivered by direct injection and subsequently 
expressed. Eukaryotic and reporter genes under the transcriptional control of 
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eukaryotic promoters have been successfully injected and expressed in 
skeletal muscle (Wolff et a/' J 1990) and cardiac muscle (Acsadi et a/' J 1991). 
The direct DNA injection method has been successful in myogenic tissues. 
The relatively efficient uptake of DNA has been attributed to the presence of 
the transverse tubule (T-tubule) system which is a unique characteristic of the 
both skeletal and cardiac myocytes (Wolff et a/' J 1990; Kitsis et a/' J 1991). 
However, this process is very inefficient as only a small fraction of the injected 
DNA gains entry into the cell and even less DNA survives the journey to the 
nucleus, where it is expressed (French, 1997). Nevertheless, plasmid DNA 
can be obtained in milligram amounts by amplification in E.coli and using 
routine plasmid isolation procedures (Sambrook et a/' J 1989). Direct injection 
of DNA is being used widely in studying promoter function (Prentice et a/' J 
1997). This approach may have clinical applications in situations where 
expression of minute amounts of extremely potent growth factor is required. 
Isner et a/. have successfully used plasmid DNA encoding vascular 
endothelial growth factor (VEGF) to stimulate collateral vessel growth in 
patients with peripheral vascular disease (Isner et a/' J 1996). 
1.3.1.2. Cationic Liposomes 
Commercial formulations of cationic lipids and non-ionic detergents are 
commonly being used for transfecting plasmid DNA into cultured eukaryotic 
cells. Lipofectin® (Gibco BRL) was the first such reagent to be used for 
in vivo. gene transfer to vascular tissue (Nabel et a/' J 1990). Cationic 
liposomes are positively charged synthetic lipid vesicles which have the ability 
to complex with negatively charged DNA and penetrate the cells by 
membrane fusion (Feldman and Steg, 1997). DNA-liposome complexes 
contain an excess of liposomes and hence are positively charged which 
facilitates their fusion with cell membrane (Feigner et a/' J 1989). On entry into 
the cell, the complex is routed to the lysosomal pathway and DNA-liposome 
complex is degraded by the lysosomal enzymes, with only about 1 % of the 
DNA reaching the nucleus (Feldman and Steg, 1997). The foreign DNA 
remains extrachromosomal and the transgene expression is therefore 
transient. There is no size constraint for the transgene and the DNA-liposome 
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complexes are prepared readily by diluting the liposomes and DNA in 
standard buffers and mixing in correct ratios. 
Various cationic liposome preparations are available commercially. Improved 
formulations are being researched, and new preparations are occasionally 
reported to mediate more efficient in vitro. transfections. Transfection 
efficiencies are reported to be as high as 90% for in vitro. gene transfer but 
similar results have not been achieved in vivo. Nevertheless, efficiency of 
transfer is known to improve by optimization of the DNA to lipid ratio (Feigner 
et a/., 1994; Gao and Huang, 1995). Despite these deficiencies, cationic 
liposomes are being used extensively for in vivo. gene transfer and have been 
approved for use in gene therapy clinical trials (Nabel et al., 1993; Caplen et 
al., 1995). 
1.3.1.3. Conjugated Vectors 
Molecular conjugate vectors comprise a group which benefits from the natural 
cellular mechanism of internalization of macromolecules by receptor-mediated 
endocytosis (Michael and Curiel, 1994). The basic design for such vectors is 
attachment of plasmid DNA to macromolecule ligands which can be 
internalized by a certain cell type. The vector is made up of polycations, such 
as polylysine, which are chemically linked to a ligand. The polylysine-ligand 
molecule can form a complex with the negatively charged transgene DNA via 
electrostatic interactions, condensing the DNA into a compact macromolecule-
like structure with the ligand presented on the surface. The ligand DNA-
polylysine-ligand complex binds to a cell membrane receptor facilitating the 
internalization of the whole complex into the cell vesicle system. 
Conjugate vectors were first developed by Wu et al. for gene transfer to 
hepatocytes using asialoglycoprotein as ligand both in vitro. (Wu and Wu, 
1987) and in vivo. (Wu et al., 1991). Later transferrin-polylysine vectors were 
also employed for hematopoietic gene transfer in vitro. (Wagner et al., 1990; 
Zenke et al., 1990). These vectors have virtually no DNA size limitation, and 
enter via a normal physiological pathway and hence are non-toxic to the cells 
(Michael and Curiel, 1994). Theoretically, in vivo. gene delivery can be 
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directed to the appropriate cell type with a varied choice of ligand domains. 
However, delivery of molecular conjugates, to cells with the compatible cell 
surface receptors, has generally resulted in poor gene expression (Zenke et 
al., 1990; Zatloukal et al., 1992). Moreover, in vitro. expression results have 
been inconsistent, possibly due to the fact that although efficient uptake of 
DNA is achieved with these vectors, the vector does not possess a 
mechanism for protection of the internalized DNA (Michael and Curiel, 1994). 
1.3.1.3.i. : Conjugated Vectors Associated with Hemagglutinin Virus of Japan 
(HVJ) 
HVJ-liposome vectors incorporate liposomes, DNA and UV-inactivated HVJ 
particles. The HVJ virus has a capability of fusing with the cell membrane at 
neutral pH by virtue of activity of its fusion protein. This property of the virus is 
used to introduce DNA directly into the cytoplasm avoiding lysosomal 
degradation. The DNA is first trapped into liposomes and then fused to the 
UV-inactivated HVJ to form a "fusigenic viralliposome" containing DNA, which 
is 500nm in diameter (Dzau et al., 1996). HVJ-liposome can fuse with the 
plasma membrane within 30 minutes at 37°C which is a great advantage for 
in vivo. gene deliveries. 
HV J-liposomes have been used for in vivo. gene transfer in a number of 
cardiovascular disorders. Vascular proliferative disease such as restenosis 
have been successfully inhibited by transferring antisense (AS) 
oligodeoxynucleotides (ODN), specific for cell cycle regulatory genes, viaHVJ-
liposomes into balloon-injured rat carotid artery (Dzau et al., 1996). Recently, 
Aoki et al. (Aoki et al., 1997) established an efficient in vivo. reporter gene 
transfer into the myocardial infarction model in rats, using the HVJ-liposome. 
1.3.2. Viral Vectors 
Viruses have emerged as the obvious candidate for use as vectors for gene 
therapy because of their high efficiency of introducing and expressing their 
genetic material in a variety of host cells (Ali et al., 1994). A number of viruses 
have been modified for use in gene therapy protocols. Basic recombinant 
modifications include deletion of portions of the genome to accommodate the 
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gene of interest and ensure the virus is replication defective, so as to prevent 
proliferation in the host cells. 
1.3.2.1. Retroviruses 
Most retroviral vectors are based on the murine moloney leukemia virus 
(MoMuL V). Retroviruses have a glycoprotein envelope with a protein core and 
two copies of 8.8 kb genomic RNA molecules. Upon retroviral infection into 
host cell, the genomic RNA is reverse transcribed by the viral reverse 
transcriptase into a linear double-stranded DNA. The DNA enters the nucleus 
and is spliced into the host genome by viral integrase and exists as a provirus 
(Nicolas and Rubenstein, 1988). 
All gene therapy protocols use disabled retroviral gene transfer vectors where 
the viral gag, pol and env genes are replaced by the therapeutic gene of 
interest (Anderson, 1992). The recombinant retroviral vector is capable only of 
a single infectious cycle, as it lacks the indispensable viral genes. "Helper" 
producer cell lines are used to make and propagate these viruses, and are 
engineered by introducing the essential, (gag, pol and env) genes into 
immortal cell lines. The producer cell line provides all replication and 
assembly proteins of the virus, but have no packaging signal in the provirus, 
which cannot be packaged (Morgenstern and Land, 1990). 
For generating a retroviral vectors, a retroviral genome, with the essential 
genes replaced by a therapeutic gene, but retaining the encapsidation 
(packaging) and replication signals, is made. This engineered genome is 
introduced into helper cell lines, usually as a plasmid (Miller and Rosman, 
1989). Since the two retroviral genomes (provirus and plasmid) are 
complementary, infectious particles are produced by packaging of RNA 
transcribed from the engineered viral genome, carrying the therapeutic gene. 
Titres up to 108 colony forming units (cfu) of recombinant viruses can be 
obtained from these helper cell lines in culture (Morgan and Anderson, 1993). 
Since retroviruses have the capability of integration into the host genome, 
persistence gene expression of the transgene is expected. Foreign genes of 
up to 8 kb can be accommodated in these vector and there is no inflammatory 
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response from the host due to absence of any viral gene products. However, 
retroviruses can integrate only into host cells which are capable of replication. 
Also persistent gene expression may not be required for many genes of 
therapeutic benefit. Cardiocytes are terminally differentiated cells and thus 
retroviruses may not be useful for these as they infect dividing cells only 
(Miller et al., 1990). However, therapies involving other dividing cells of the 
heart tissue matrix may utilize retroviral vectors. For example, retrovirus may 
be able to express the master regulatory gene for muscle cell differentiation 
MyoD, in cardiac fibroblasts, converting them to myoblasts (French, 1997). 
1.3.2.2. Adena-associated Virus (AAV) 
The adeno-associated viruses (AAV) are small single-stranded DNA viruses. 
The virion is icosahedral with a diameter of 20-30 nm, is non-enveloped and 
contains a DNA genome of 4.68 kb (Berns and Linden, 1995). Wild-type AAV 
have the ability to integrate stably into chromosome 19q13 of the human cell 
genome (Feldman and Steg, 1997). The virus has a broad host range and is 
able to replicate in any cell line provided a helper virus, usually an adenovirus, 
is present. AAV integrates into the host genome with high efficiency in the 
absence of a helper virus and is known to remain latent for prolonged periods. 
Latently infected cells subsequently infected with helper virus, rescue the AAV 
from the site of integration and trigger the complex lytic cycle (Flotte and 
Carter, 1995). 
AAV genome includes two 145 nucleotide inverted terminal repeats (ITRs) 
which are the minimal essential cis-acting sequences necessary for 
replication, package and rescue. In addition to the ITRs, the genome consists 
of two open reading frames (ORF) encoding Cap (capsid) protein and the Rep 
(replication) proteins (Ali et al., 1994). Three promoters are present in the 
genome which are activated in a cascade-type mechanism, initiating with 
adenovirus E 1 A protein activating the AAV p5 promoter. 
AA V vectors used for gene transfer are constructed firstly by substituting the 
Cap and Rep genes by the foreign DNA, on a bacterial plasmid. This plasmid 
is then cotransfected with a helper plasmid which provides the Cap and Rep 
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functions in trans. Recombinant vector is produced upon infection of the 
cotransfected cells with adenovirus. The recombinant AAV particles are then 
separated from the helper virus physically by buoyant density centrifugation. 
AAV has several properties which has made it a vector of choice for some 
gene therapy applications. AAV are not associated with any disease and has 
a minimal number of viral antigens to induce host immune response (Berns 
and Linden, 1995). AAV vectors have been shown to transduce cells stably at 
high efficiency and they have the ability to infect non-dividing cells (Podsakoff 
et a/., 1994). AAV integration into the host chromosome has not been 
encountered after an in vivo. infection and not shown to occur naturally in 
humans (Flotte and Carter, 1995). 
The small size of the AAV genome allows a maximum foreign DNA insert size 
of 4.2 kb which appears to be the only definite limitation for this vector (Ali et 
a/., 1994). The packaging and purification of large quantities of AAV-based 
vectors is somewhat limited by technical factors (Flotte and Carter, 1995). In 
spite of the limited size insert accommodated in AAV vectors, a significant 
number of potentially therapeutic genes have been cloned into AAV vectors 
and used to infect cells in vivo. These vectors have been evaluated in 
preclinical models for cystic fibrosis (Flotte et a/., 1993) and Parkinson's 
disease (Kaplitt et a/., 1994). 
1.3.2.3. Adenoviruses 
Adenovirus-mediated gene transfer is being used widely to introduce 
potentially therapeutic genes into the myocardium and coronary vasculature, 
to treat cardiovascular disorders (Dzau et a/., 1993). Certain characteristics of 
this virus make it an excellent candidate for gene transfer to the heart cells. 
Adenoviruses are not associated with any severe disease and of 
approximately 50 serotypes identified to date, only a third are known to cause 
disease. Adenoviruses can infect the respiratory tract, eye and 
gastrointestinal tract, but in most cases the infection in asymptomatic and 
subclinical (Ali et a/., 1994; Yeh and Perricaudet, 1997). Moreover, the virus 
can be grown to high titres and can infect slow-replicating and nonreplicating, 
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terminally differentiated cells, such as neurons and cardiac myocytes. The 
adenovirus genome generally does not integrate into the host cells and exists 
episomally, therefore vectors based on these viruses provide transient 
expression of the transferred foreign gene (Ali et a/., 1994). 
1.3.2.3.i. Adenovirus Biology 
Adenoviruses are intermediate sized DNA viruses with a genome comprising 
a linear double-stranded DNA molecule of approximately 36,000 base pair. 
The genome is traditionally divided into 100 map units (mu) with 1 mu 
representing 360 base pairs (Ginsberg, 1984; Horwitz, 1990; 8erkner, 1992). 
The virion particles lack an envelope and are 65-90 nm in diameter, with a 
spiked isocahedral morphology. The viral capsid is made up of protein units 
called capsomers and encloses the DNA genome at its core. The hexons, 
pentons and fibre are the major capsomers with the hexons being the major 
part of a viral capsid. Fibres are slender stalks with a globular head, attached 
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Fig 1.3.1 : Structure of adenovirus particle showing the major capsid proteins (8). DNA lies at 
the centre of the capsid, bound to protein, forming the core of the viral particle (A). 
to the penton, which are embedded in the main body of the capsid. Fiber and 
penton-base proteins are involved in the process of attachment of the virus 
particle to the host cell receptors and subsequent internalization. There are 
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252 capsomers with 240 hexons and 12 pentons positioned at apices of the 
isocahedron. Human adenoviruses have been classified serologically into 47 
serotypes (Ali et al., 1994). 
1.3.2.3.ii. Genome Organization 
A typical adenovirus genome comprises of a 35935 base pairs of double-
stranded DNA with Inverted Terminal Repeats (ITR) at either end of the linear 
genome. The genome encodes at least 30 mRNA species, organized into 
several early and late transcriptional regions (Ali et al., 1994). Generally, the 
transcriptional units are grouped into "early" and "late" expression units which 
transcribe mRNA before and after the viral DNA replication. 
The gene expression exhibits a cascade regulation (Berkner, 1992; Ali et al., 
1994; Spector and Samaniego, 1995). There are four early regions (E1-E4) 
and one major late region with five main coding regions (L 1-L5) (Berkner, 
1992; Ali et al., 1994; Graham and Prevec, 1997). The E 1 region is active 
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Fig 1.3.2 : Schematic presentation of the adenoviral genome showing the main transcriptional 
units encoding principal viral proteins, the inverted terminal repeats (ITRs) and the 
packaging signal ('1"). Arrows indicate promoters and the direction of transcription. 
Main function of some proteins are also shown. 
upon entry of the genome into the host cell nucleus, encoding proteins which 
activate the other early region genes. These gene transcripts in turn produce 
proteins which initiate DNA replication and cooperate to transcribe the late 
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genes from the Major Late Promoter (MLP) (Jones and Shenk, 1979; Bridge 
and Pettersson, 1996). E2 region encodes viral DNA replication proteins such 
as the DNA-binding protein and DNA polymerase (Horwitz, 1990; Berkner, 
1992; Yeh and Perricaudet, 1997) while E3, which is dispensable in vitro, is 
involved in evasion of the infected host cell from immune response (Wold and 
Gooding, 1991; Berkner, 1992). E4 region shuts down the host gene 
expression in favour of the virus gene expression (Ginsberg, 1984; Halbert et 
al., 1985; Horwitz, 1990) and also serves to upregulate transcription from E2 
and late regions (Ali et al., 1994), therefore effecting the early to late transition 
(Cutt et al., 1987). The major late region codes for most of the polypeptides 
which make up the capsid (Ginsberg, 1984; Zenke et al., 1990). 
1.3.2.3.iii. Life Cycle 
The adenoviral life cycle begins with receptor-mediated attachment of virus to 
the host cell membrane and subsequent internalization into endosomes. The 
virion then escapes to the cytoplasm by inducing endosomolysis and is 
transported to the nucleus where the DNA genome enters the nucleus 
through the nuclear pores and various transcription regions are expressed. 
On its way to the nucleus, the virion sheds its capsid proteins in a gradual 
manner at various steps and upon entry into the nucleus, most capsid 
proteins are already lost (Greber et al., 1993; Ali et al., 1994; Yeh and 
Perricaudet, 1997). The E1 region activates its own expression together with 
that of E2 and E3. After about 6- 8 hours, viral DNA replication ensues and 
then late proteins are expressed leading to assembly of 104_105 progeny 
virions within the infected cell nucleus. The whole host cell translational 
machinery is geared towards preferential processing of adenoviral transcripts 
and assembly of virion particles. 30 to 40 hours post infection, cell death by 
attrition rather than lysis occurs (Ali et al., 1994) releasing the progeny 
viruses. 
1.3.3. Adenoviral Gene Transfer Vectors 
The human adenovirus type 2 and 5 (Ad2, Ad5) have been the most studied 
in terms of genomic organization and gene expression pattern, with their 
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complete nucleotide sequences available (van Ormondt and Galibert, 1984; 
Berkner, 1992). Consequently, these serotypes are at the forefront of 
development of vectors for gene transfer (Ali et al., 1994). Most vectors 
encoding therapeutic genes been constructed using the Ad5 backbone. 
In this study, Ad5-based vectors were employed for gene transfer into the 
myocytes. Replication-defective human type 5 adenovirus (Ad5) have 
emerged as highly effective vector for delivery of various genes into several 
types of cells, in vitro. (Mestril et al., 1996; Hajjar et al., 1997; Westfall et al., 
1997), in vivo. (Barr et al., 1994; Leor et al., 1996; Muhlhauser et al., 1996; 
Rothmann et al., 1996; Franz et al., 1997). First generation recombinant 
adenoviruses have been manipulated to create capacity of up to 8.3 kb for 
accommodating the promoter-cDNA foreign DNA cassette in E1 and E3 
regions. In most of such recombinants, The E1 region only is substituted for 
the foreign DNA, while the dispensable E3 region is deleted to allow 
accommodation of larger inserts in the E1 region (Bett et al., 1994). These 
recombinants can be grown to high titres (Ali et al., 1994) in permissive cell 
lines, such as HEK 293, which are able to provide the missing E1 function in 
trans. Moreover, these viruses have been modified in a way that allows 
propagation in permissive cell lines only, performing the function of gene 
delivery to target cells not undergoing a replicative cycle in the latter. It is 
postulated that inverted terminal repeats (ITRs) and the packaging signal 
sequence (1jI), are the only cis-acting signals required for adenovirus 
replication and packaging. In theory therefore, all remaining viral DNA can be 
substituted with foreign DNA, however for propagation of such viruses, special 
cell lines providing all function in trans will be required (Ali et al., 1994; Yeh 
and Perricaudet, 1997). 
1.3.4. HEK 293 Permissive Cell Line 
For propagation of replication-defective (Er) recombinant adenoviruses, the 
functional gene products of the E1 are provided in trans by the permissive 
Human Embryonic Kidney (HEK) 293 cell line (Ali et al., 1994; Bett et al., 
1994), was obtained by transformation of HEK cells with sheared Ad5 DNA 
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(Graham et al., 1977). This cell line has the left-hand Ad5 genome sequences 
extending from nucleotides 1 to 4344, inserted in the pregnancy-specific ~-1-
glycoprotein 4 (PSG 4) gene (Louis et al., 1997). The 293 cell line expresses 
the E1 gene products, essential for virus growth and propagation, and 
therefore behaves as a permissive cell line for growth of Ad5 virus, providing 
the essentially required E 1 proteins in trans to adenoviruses defective in the 
E1 function. All first generation replication-defective recombinant 
adenoviruses are made with a foreign gene replacing the E1 region, which 
makes replication and propagation possible in 293 cells only. This is a 
preferred approach as it is a workable mode for biological containment of the 
recombinant virus. 
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1.4. Recombinant Adenovirus Construction 
Ad5 recombinants are made using a two component system comprising of 
the viral backbone DNA and an adenoviral plasmid shuttle vector carrying the 
Ad5 left-end genome fragment and the foreign gene. The two DNA molecules 
have the ability to undergo homologous recombination when cotransfected 
into 293 cells, and rescue the foreign gene into the viral genome. 
1.4.1. Viral Backbone DNA 
The adenovirus used in this study for making recombinants is an Ad5 mutant 
named d1309. It is a common adenovirus backbone used for constructing the 
"first-generation" replication-defective adenovirus for gene transfer (Graham 
and Prevec, 1997). The wild-type Ad5 has four Xbal sites at 4, 29, 79 and 85 
map units while its dl-309 mutant has a unique Xbal site which cuts in the E 1 
region at 4 map units (Graham et al., 1977), inactivating the E1 region. This 
feature of the mutant is utilized for generating recombinants by the procedure 
of homologous recombination (Graham and Prevec, 1997). In addition, the 
Ad5-d1309 genome has a deletion-substitution in the E3 region which extends 
from Ad5 bp 30005-30750 and is substituted with 642-bp of heterologous 
DNA that shows homology to salmon DNA (Bett et al., 1995). 
1.4.2. Design of Adenoviral Shuttle Vectors 
Adenoviral shuttle vectors are used for constructing Ad5 vectors with foreign 
gene inserts in the early (E1) region. Shuttle plasmids are designed to 
provide the essential left-end of an adenovirus type 5, but with the E1A 
region deleted to accommodate the foreign DNA insert .. The shuttle plasmid 
can undergo recombination with adenoviral genome, due to presence of a 2.4 
kb region of homology, in both DNAs. The recombined product is a 
replication-defective Ad5, with the E1 region being replaced by the foreign 
DNA cassette. Two types of adenoviral shuttle vectors were used to make 
recombinants; the Microbix shuttle vectors and the pLES53 based vector. 
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1.4.3. Conventional Method of Recombinant Construction 
The generally used procedure for Ad5 recombinant construction is based on 
the method of (Stow, 1981). In this method, the full Ad5-d1309 genome DNA 
is extracted from the virus, purified and digested with Xbal. This DNA is 
cotransfected into 293 cells along with a shuttle vector (see section 2.9.2) 
carrying the left-end of Ad5 genome, with foreign DNA insert. The 
replication-defective recombinant is generated by in vivo. homologous 
recombination (Berkner, 1992). The Xbal-cut viral DNA essentially forms the 
viral backbone, having all but the left-end of the genome. The pLES53-based 
shuttle plasmid provides the missing left-end of the virus genome, along with 
the foreign DNA which replaces the E1 region genes. The recombinant 
adenovirus is generated by recombination between regions of homology in 
the virus and shuttle vectors. 
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Fig 1.3.3: Strategy for rescue of foreign DNA into the Ad5 genome, by homologous 
recombination in 293 cells (modified from Graham, F.L. and Prevec, L.; Methods 
for Construction of Adenovirus Vectors. Molecular Biotechnology 3(3):207-220, 
1995.) 
1.4.3.1. Shuttle Vectors Based on pLES53 
The pLES53 adenoviral shuttle plasmid vector was obtained from Keith 
Leppard, University of Warwick, UK. This vector conformed to the basic 
design of an adenoviral shuttle vector as described in section 1.4.2. 
The shuttle plasmids have a pBR322 plasmid backbone with the ampicillin 
resistance selectable marker: It contains adenovirus type 5 (Ad-5) sequences 
from bp 1 (0 mu) to bp 5788 (16.0 mu), with a deletion of E1 sequences 
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(L~E1) extending from bp 544 to bp 3328 (1.0-9.8 mu). Thus a region 
spanning 2460 bp (from bp 3328 to 5788) is available for recombination with 
a homologous region in the adenovirus genome. Cloning sites in this vector 
are limited with only Xbal and 8g/l1 restriction enzyme sites at the E1 deletion 
site, for the cloning of the foreign gene. 
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Fig 1.3.4: Plasmid maps of promoterless pLES53 and its derivative pLECM which has a 
Human Cytomegalovirus Immediate Early (CMV-IE) 780 bp enhancer/promoter. 
The vector pLECM is a pLES53 derivative with Human Cytomegalovirus 
Immediate Early promoter (780 bp), following cloning sites, inserted at the E1 
deletion region. cDNAs can be inserted as an EcoRI/8g/il fragment for 
making a ubiquitously expressing expression vector. 
1.4.4. The "Large Plasmid" Method of Recombinant Construction 
(Graham et al.) 
The main system used in the study was developed by Frank Graham and 
colleagues which produces replication-defective adenoviruses with E1 region 
replacement (Graham and Prevec, 1995; Hitt et al., 1995; Graham and 
Prevec, 1997). It encompasses use of two bacterial plasmids, one a shuttle 
plasmid for carrying the foreign DNA and the other an adenoviral genome-
carrying plasmid with a bacterial pBR322 insert (McGrory et al., 1988; Bett et 
al., 1994). 
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1.4.4.1. Adenoviral Genome-carrying Plasmid pJM17 
The Ad5 genome plasmid pJM17 is based on the complete 35700 bp 
genome of Ad5-d1309 with a 4.4 kb insert of pBR322 DNA at the Xbal site in 
the E1 region (McGrory et a/' J 1988). This insert results in the plasmid DNA 
size exceeding the packaging constraints for the adenovirus (Bett et a/' J 
1993). Upon cotransfection with shuttle plasmid carrying the left-end 
sequences, the viral genome in pJM17 can recombine with homologous 
region in the shuttle vector, producing the recombinant adenovirus. The 
packaging constraint of pJM17 act as a selection, favouring the rescued 
viruses produced by recombination (Bett et a/' J 1994). This results in a very 
low background of nonrecombinant, parental-type infectious progeny 
(McGrory et a/' J 1988). The Ad5-d1309 backbone is able to accommodate up 
to 5.2 kb insert in the E1 region. 
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Fig 1.3.5: Plasmid map of adenovirallarge plasmid pJM17, carrying the complete Ad5-
dl309 genome showing HindIlI restriction sites. The pBR322 insert at XbaI site at 
3.7 mu is also shown with the Ampicillin resistance marker (APr) and the bacterial 
origin of replication (ORI). 
1.4.4.2. Microbix Shuttle Vectors 
The shuttle plasmids from Microbix Biosystems Inc. have a bacterial plasmid 
backbone with the ampicillin resistance selectable marker. On a pBR322 
backbone, the shuttle vector contains adenovirus type 5 (Ad-5) sequences 
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from bp 22 (0 mu) to bp 5790 (16.1 mu), with a deletion of E1 sequences 
(L~E1) extending from bp 342 to bp 3523 (1.0-9.8 mu): Thus a region 
spanning 2267 bp (from bp 3523 to 5790) is available to allow recombination 
with a homologous region in the adenovirus genome. A multiple cloning site 
(MCS) with several restriction enzyme sites is inserted in the deletion region, 
facilitating subcloning of the promoter-gene cassette into the shuttle vector. 
These shuttle vectors were constructed by Frank Graham et al. and obtained 
commercially from Microbix Biosystems Inc. Toronto, Canada, and used for 
the generation of constructs used in this study, with the ultimate aim of 
making an Ad-5 replication-defective recombinant virus. 
1.4.4.2.i. Basic Vectors 
The p~E1sp1A is a shuttle vector with the characteristics described in the 
previous section. In addition, it has a MCS with CIa I , 8amHI, Xhol, Xbal, 
EcoRV, EcoRI, Hindlll, SaIl and 8g/11 inserted at ~E1 in the clockwise 
orientation. The p~E 1 sp1 B shuttle vector is similar except for the orientation 
of the MCS between the CIa I and 8g/11 is reversed. 
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Fig 1.3.6: Plasmid maps of the basic p~E 1 sp 1 A adenoviral shuttle vector and its derivative 
p~E1sp1A polyA with the SV40-polyA sequence subcloned from pCA14. 
p~E1sp1A and p~E1sp1B vectors do not contain a polyadenylation signal, 3' 
to the cDNA insertion site. A 160 bp fragment of SV40 polyadenylation signal 
was cloned into the vector downstream of the MCS to produce plasmids 
p~E1 sp1A-polyA and p~E1 sp1 B-polyA (see section 3.1). 
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1.4.4.2.ii. Vectors with a Constitutive Promoter 
The pCA 13 and pCA 14 shuttle vectors have the characteristics of an 
adenoviral shuttle vector with an addition of a Human Cytomegalovirus, 
Immediate Early (HCMV-IE) promoter (-299 to +72), inserted 5' to the MCS. 
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If "~~"" 'Xba I l XhoJ 
// \ BamH I 
1(' pCA13 'I\SV40POLY 
i 6952 bp i \ Bg/ II 
\ /Ii \ 
'" ~' \ \, 1 ' \\ ,,; Sac I 
, N 
, . 
~':: ~, /;../ Ad 5 sequence 
"'\". ~. "~"~=c--,,"c . Sac I 
Fig 1.3.7: Plasmid map of pCA13 plasmid with the Human Cytomegalovirus Immediate Early 
(shorter) CMV-IE promoter used for making ubiquitously expressing adenovirus. 
At the 3' end of the MCS, the SV40 polyadenylation signal (SV40-polyA) 
sequence is present. pCA 13 has a multiple cloning site with cutting sites for 
Sal I Hindlll, EcoRI, EcoRV, Xbal, Xhol, BamHI restriction enzymes. The 
orientation of the cloning sites is reversed in pCA 14. 
1.4.4.3. Process of Recombinant Generation 
For rescuing of foreign genes into the viral genome, firstly, standard 
recombinant DNA manipulation techniques are used to clone the promoter-
cDNA cassette into the appropriate shuttle plasmid. The pJM17 plasmid and 
the shuttle plasmid are propagated in E.coli and extracted using the CsCI-
density gradient centrifugation (Sambrook et al., 1989) and cotransfected into 
293 cells, using the Calcium Phosphate transfection method. 
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Fig 1.3.8: Strategy for rescue of foreign DNA inserts into the E 1 region of Ad5 virus using 
pJM17. Ad5 recombinant virus are generated by overlap recombination between 
cotransfected bacterial plasmids carrying viral sequences. (modified from Hitt, M. 
et al., Techniques for Human Adenovirus Vector Construction and Characterization. 
In: Viral Techniques, edited by Adolph, K.W. Academic Press Inc., Orlando, Florida, 
USA:) 
A modified method based on the original protocol from Frank Graham 
(Graham and Van der Eb, 1973), was developed for post-transfection 
screening of the recombinants. This method used standard commercially 
available plaque overlay medium and low melting point agarose, in order to 
minimize the variables affecting 293 cells after cotransfection with the pJM17 
and shuttle plasmids. Recombinants are generated by homologous 
recombination of similar regions in pJM17 and the adenoviral shuttle plasmid, 
in the 293 cells (see fig. 1.3.8). 
1.4.5. Adenoviral Vectors for Gene Transfer to the Heart 
Adenoviral vectors have been successfully used for gene transfer into heart. 
Both in vitro. gene transfer to cultured cardiomyocytes (Mestril et al., 1996; 
Donahue et al., 1997; Westfall et al., 1997), and in vivo. transfers to hearts of 
mammals (Leor et al., 1996; Magovern et al., 1996; Rothmann et al., 1996), 
have shown efficient gene transfer and stable expression, using 
replication-defective adenovirus recombinants. 
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Adenoviral gene transfer and expression in vitro. using cultured neonatal or 
adult cardiocytes has been a useful tool for assessing recombinant vector 
transduction. In addition, adenoviruses expressing genes of myofilament 
protein Troponin I (Westfall et al., 1997), membrane proteins like SERCA and 
(Hajjar et al., 1997), ~2-adrenergic receptor (Drazner et al., 1997) and HSP-
70 protein induced during stress in the myocardium (Mestril et al., 1996) have 
been overexpressed in cardiac myocytes in culture and their effect studied. 
Adenovirus vectors expressing reporter genes have been used successfully 
to transduce rat (Guzman et al., 1993; Kass-Eisler et al., 1993; Muhlhauser et 
al., 1996) and porcine (FrenCh et al., 1994) myocardial cells, by direct 
injection into the myocardium. Direct administration of ~-galactosidase 
expressing adenovirus by intramuscular injection into porcine hearts in vivo. 
has shown transduction of myocytes in a well-localized area of the 
myocardium. The myocardial ~-gal activity peaked at 3-6 days after the 
injection, returning to control level within one month (Muhlhauser et al., 
1996). On the other hand, catheter-mediated infusion of replication-defective 
adenovirus into coronary arterial circulation of adult rabbit in vivo., has 
achieved efficient reporter gene transfer and expression, both in the coronary 
vasculature and in adjacent myocardium. Reporter gene activity was detected 
at 2 weeks post-infusion, while no activity was detectable at 1 month, in either 
myocardium or coronary vasculature (Barr et al., 1994). Adenoviral gene 
transfer and expression has also been assessed in infarcted rat myocardium 
model. The transducing efficiency of a ~-gal reporter gene-expressing 
adenovirus was lower in the infarcted, compared to normal hearts. 
Histological examination of transduced hearts at 7 days post-injection, 
showed ~-galactosidase gene expression limited to the viable myocytes at 
the border of the infarct. (Leor et al., 1996). 
Adenoviral vectors are shown to be the most efficient vector system for 
transgene expression in myocardium in vivo. (Rothmann et al., 1996). 
Improved vectors are now being developed to target the expression of 
therapeutic transgenes to ventricular myocardium by using cardiac muscle-
specific promoters (Rothmann et al., 1996; Franz et al., 1997). Generally, the 
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timing of gene expression in adult myocytes transduced in vivo. in animals, 
ranged from 3 days to 1 month (Jennings and Reimer, 1981; Kass-Eisler et 
a/., 1993; Barr et a/., 1994), in many cases, it may be ample for a transgene 
to express and show its therapeutic benefits on the myocardium. 
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2.1. Chemicals and Reagents 
The majority of chemicals and solvents were Analar grade, and obtained from 
British Drug House Ltd., Poole Dorset. Other more specialized and molecular 
biology reagents, except where stated otherwise, were obtained from Sigma 
Chemical Company Ltd. Poole, Dorset. Commonly used restriction enzymes 
were obtained from Promega and New England Biolabs, except where 
stated. T4 DNA ligase was obtained from Gibco-BRL., Paisley, UK Calf 
intestinal alkaline phosphatase was obtained from Boehringer Mannheim, 
GmbH, Germany. T4 polynucleotide kinase and other DNA modifying 
enzymes were from Promega. DNase II, RNase I, Lysozyme and 
Proteinase K enzymes were obtained from Sigma Chemical Company Ltd. 
Poole, Dorset. DNA size marker (1kb ladder) was obtained from Gibco-BRL, 
Paisely, UK and Protein size markers were from BioRAD Laboratories Ltd., 
Hercules, Ca, USA. The random priming kit used for radiolabeling DNA was 
obtained from Boehringer Mannheim, GmbH, Germany. RNAzol B for RNA 
extraction was obtained from Biogenesis Ltd. Bournemouth, UK. 
All radioisotopes, DNA sequencing kit, 33p labelled dideoxy-nucleotides and 
Hybond membranes were supplied by Amersham International pic., 
Buckinghamshire. Synthetic oligonucleotides were synthesized on an Applied 
Biosystems automated DNA synthesizer, or obtained from Gibco-BRL or 
Genosys Ltd. 
Plasmid with the adenovirus dl309 genome (pJM17) and compatible shuttle 
vector plasmid were obtained from Microbix Biosystems, Toronto, Canada. 
Other plasmid vectors for subcloning of DNA fragments were obtained from 
Promega unless otherwise stated. 
Agar, Tryptone and yeast extract for bacterial cultures and serum, media and 
supplements for eukaryotic cell culture were supplied by Gibco, Paisley, 
except where otherwise stated. The standard Phosphate Buffered Saline 
(PBS) used in tissue culture and immunostaining was without Ca ++ and Mg ++ 
and obtained from Sigma or Gibco. Another PBS of slightly different 
composition used for resuspending virus infected cell was obtained from 
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Gibco (referred to as PBS with Ga++ and Mg++). Plasticware for cell culture 
were supplied by Nunc Intermed, Denmark, Sterilin Ltd. Hounslow, Middlesex 
and Falcon Becton Dickinson Labware, New Jersey, USA. 
2.2. Preparation of Solutions, Glassware and Plasticware 
All solutions used in the isolation and manipulation of nucleic acids were 
prepared using molecular biology grade chemicals and distilled water and 
sterilized by autoclaving or by filtration through a 0.22/-LM filter. 
All solutions used for RNA extraction were made in distilled water treated to 
minimize degradation of RNA by contaminating RNase. Distilled water was 
treated with Diethylamine pyrocarbonate (DEPG), as a 0.1 % v/v solution and 
then autoclaved. Disposable rubber gloves were worn at all times during 
handling of RNA. RNA grade reagents, new, unopened packs of disposable 
microfuge tubes and pipette tips were used for autoclaving and these items 
were also handled wearing rubber gloves at all times. 
2.3. Plasmid DNA Purification 
Plasmid DNA was propagated in E.coli host and extracted when required for 
subcloning. Different methods of plasmid extraction were used for obtaining 
varying quality and amounts of plasmid DNA for transfections, use in 
subcloning, screening or long-term storage of plasmid DNA. 
2.3.1. Small-scale Isolation of Plasmid DNA (minipreps) 
Plasmid minipreps were done for screening recombinant plasm ids during 
subcloning of promoter-cDNA constructs or for obtaining plasmid DNA for 
long-term storage of subcloned DNA. 
2.3.1.1. Crude Alkaline Lysis Method 
This method was employed mainly for analysis of potential recombinant 
plasmids in DNA subcloning experiments. An individual bacterial colony was 
picked from an agar plate and inoculated into 5 ml of L-Broth (1 % Bacto-
tryptone, 0.5% yeast extract, 0.5% NaGI) supplemented with 100 /-Lg/ml 
ampicillin, in a 25 ml universal container. Subcultures were incubated at 37°G 
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overnight with orbital shaking at 180-200 rpm. One day later, 1.8 ml of the 
overnight culture was removed and transferred to a 2 ml Eppendorf tube for 
centrifugation (at 14000 rpm for 3 minutes in a microfuge). The bacterial 
pellet was resuspended very thoroughly in 100fli of cell resuspension solution 
(TGE; 25mM Tris-HCI, pH 8.0, 50mM glucose, 10mM EDTA, pH 8.0, by 
repeated pipetting. 200fli of alkaline-SDS (0.2M NaOH, 1 % sodium dodecyl 
sulphate) was then added to the tubes which were mixed by inverting several 
times. After 5 minutes of incubation on ice until the solution became clear and 
viscous, 150fll of neutralization solution (3M Potassium, 5M Acetate) was 
added, the solution was mixed by inversion until a white flocculant precipitate 
became visible. Tubes were incubated on ice for 5 minutes and then 
microfuged (14000 rpm for 5-7 minutes) to remove the white chromosomal 
DNA and cell debris. Approximately 430fll of clear supernatant was 
transferred to a fresh 1.5 ml Eppendorf tube while avoiding removal of any of 
the white precipitate. Cold 100% ethanol (900fll) was added, tube sealed and 
mixed by inversion and transferred to a - 70°C freezer for 30-45 min for 
precipitation of DNA. Tubes were then centrifuged at 14000 rpm for 15 
minutes and the DNA pellet washed in 70% ethanol, air-dried and 
resuspended in 50fll of TE pH 8.0 with 1 fll of RNase A (1 Omg/ml). The 
solution was incubated at room temperature for 10 minutes after which 
10-20fll of the DNA solution was employed for restriction analysis. 
2.3.1.2. Kits 
Commercially available kits were used for obtaining high quality plasmid DNA 
for sequencing and for long-term storage purposes. 
2.3.1.2.i. Qiagen Minipreps 
For obtaining microgram amounts of plasmid DNA of high purity, for using as 
vector or insert DNA for cloning, QIAprep Spin Plasmid kit was used. The 
DNA isolation protocol uses alkaline lysis of bacterial cells for releasing of 
plasmid DNA and adsorbing on to silica spin-columns followed by washing off 
the salts and finally elution of the plasmid DNA. The prescribed protocol 
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(QIAprep Plasmid Handbook 03/95) for the kit was followed except that the 
DNA was eluted in 50 III of TE pH 8.0. 
2.3.1.2.ii. Hybaid Minipreps 
Plasmid DNA for sequencing of new clones, was done using Hybaid 
RecoveryTM Plasmid Miniprep Kit. The kit protocol is based on alkaline lysis 
of the bacteria and binding of the released DNA to a silica gel matrix and 
entrapment in a spin-filter followed by washing and collection of plasmid 
DNA by elution. The kit protocol (version 5/96) was followed. 
2.3.2. Large-scale Isolation of Plasmid DNA 
Generally, larger quantity of plasmid DNA was required for transfections and 
for obtaining vector and insert DNA in subcloning procedures. Commercially 
available kits and CsCI preps were used to obtain milligram amounts of 
plasmid DNA. 
2.3.2.1. Plasmid Extraction for Caesium Chloride Preps 
Caesium Chloride-Ethidium Bromide (CsCI-EtBr) density gradient 
centrifugation was the method of choice of obtaining large amounts of 
plasmid DNA for transfection. For this purpose, 10 ml of overnight cultures 
were initiated from an inoculum (loop) of a glycerol stock or a single colony 
picked from a bacterial dish, as previously described. The following day 2 ml 
of the subculture was inoculated into L-broth (800 ml containing 100llg/ml of 
ampicillin), in a 2 litre bevelled conical flask. Incubation was carried out at 
37°C with orbital shaking at 180-200 rpm. For pBR322 based low copy 
number plasmids, a plasmid amplification step was employed. 
Chloramphenicol (170llg/ml final concentration) of was added after 6-8 hours 
of shaking (OD 600 = 0.6), after which the inCUbation was continued 
overnight. Cells were harvested by centrifugation (at 5000 rpm for 10 min, at 
4°C in a Beckman Model J2-21 centrifuge with a JA-14 rotor. The bacterial 
pellet was resuspended in 18 ml of TGE (25mM Tris-HCI, pH 8.0, 50mM 
Glucose, 10mM EDT A, pH 8.0), by repeated pipetting using a 10 ml pipette. 
2ml of lysozyme solution (50 mg/ml in TGE) was added and the solution 
mixed by swirling after which the tube was incubated for 20 minutes at room 
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temperature. 40 ml of alkaline-SDS (0.2M NaOH, 1 % sodium dodecyl 
sulphate), freshly prepared from stock solutions, was added and the solution 
mixed by inversion. The cell lysis reaction was incubated on ice for 10 
minutes and then neutralized by adding 20 ml neutralizing solution (3M 
Potassium, 5M Acetate). The tube was mixed well by inversion and incubated 
on ice for 10 minutes. 5 ml of sterile distilled water was added and tubes were 
centrifuged for 10 minutes at 7000 rpm as above. The clear supernatant was 
filtered through a sterile gauze into a fresh tube to remove cell debris. 0.6 
volumes of isopropanol was added to precipitate the DNA and the mixture 
was incubated at room temperature for 20 minutes. DNA was pelleted by 
centrifuging for 25 minutes (7000 rpm at 20-22°C in a Beckman J-20 
centrifuge). The supernantant was immediately discarded and the pellet 
gently washed with 70% ethanol. Tubes were centrifuged for 5 minutes at 
7000 rpm and the ethanol wash aspirated off completely and air-dried. The 
DNA pellet was dissolved in 3 ml of 0.1X SSC (15mM NaCI, 1.5 mM Na 
citrate, pH 7.0) 
2.3.2.1.i. CsCI·EtBr Density Gradient Centrifugation 
For DNA obtained from a 400-800 ml culture, the gradient was prepared as 
follows; 8 g of caesium chloride was weighed out in a universal container and 
dissolved in 3 ml of 0.1 X SSC. The solution was placed at 37°C in a 
waterbath to aid the dissolving process. DNA solution was added to the 
universal tube and the CsCI dissolved completely. 640111 of ethidium bromide 
(10 mg/ml in water) was added and mixed. Tubes were incubated on ice for 
20 minutes and then spun in alEC Centra-7R refrigerated centrifuge at 2500 
rpm at 4°C for 25 minutes The supernatant was then transferred to Beckman 
Quick-Seal tubes (Polyallomar #342412) using a short-form Pasteur pipette 
as a funnel. The remainder of the tube was filled with liquid paraffin and tubes 
were sealed and centrifuged in a Beckman Ti70 rotor at 49000 rpm for 16 
hours at 20°C in a Beckman L8 Ultracentrifuge. Plasmid DNA band was 
visualized using a long wavelength UV light source and the DNA band was 
drawn off using a 21 G hypodermic needle and syringe. Ethidium bromide 
was removed by successive extractions with TE-saturated butanol until the 
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organic supernatant became colorless. The DNA solution was dialysed 
against distilled water or TE for 12-48h at 4°C with 3-4 changes of buffer, 
using dialysis tubing. After dialysis, nucleic acids were analyzed on a 1 % 
agarose gel to check the integrity of DNA and the possible presence of any 
contaminating RNA. If RNA was found to be present, the DNA solution was 
treated with RNase (10llg/ml), and subjected to phenol-chloroform extraction 
and one chloroform extraction to remove any traces of phenol. DNA was 
precipitated using 1/10th volume of 3M Na-acetate pH 5.2 and 3 volumes cold 
100% ethanol. If no RNA was visible upon electrophoretic analysis, the DNA 
was ethanol precipitated as described and resuspended in a desired volume 
ofTE or 0.1X SSC. 
2.3.2.2. Wizard Maxipreps 
For large scale plasmid preparations where the quality of DNA obtained was 
not critical such as those employed for obtaining higher amount of vector or 
insert DNA required in subcloning of genes of interest, the Promega Wizard ™ 
Maxipreps DNA purification systems were used. The procedures for bacterial 
growth and DNA amplification (when required) were as described above. The 
procedure is based on alkaline lysis of bacterial cells and binding of DNA to 
resin and separation on a column followed by washing off excess salts and 
finally eluting the plasmid DNA. The alkaline lysis of bacteria and DNA 
isolation protocol outlined in Promega Technical Bulletin No. 139, revision 
10/94 was followed with minor modifications. The solutions provided in the kit 
were at times replaced with further solutions prepared according to the 
compositions supplied in the bulletin. DNA elution was carried out using an 
increased amount (2-2.5 ml) of preheated (70-80°C) TE buffer in 
circumstances where plasmid amplification was employed. 
2.4. DNA Manipulations for Subcloning 
Troponin C and other foreign cDNAs and promoters were subcloned into 
adenoviral shuttle plasmid vectors as a first step for making recombinant 
adenoviruses. In addition, molecular tagging of cDNA with epitope coding 
sequence was also carried out. 
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2.4.1. Plasmid Vectors Used for Subcloning 
The source of the skeletal Troponin C cDNA was plasmid LK419 obtained 
from Larry Kedes' Lab. at the University of Southern California, CA, USA 
(Gahlmann ef al., 1988). Plasmid pSP72 used as an intermediary vector in 
the cloning, was obtained from Promega Corporation, Madison, WI, USA. 
Adenoviral shuttle plasmid vectors pCA3, pCA4, pCA 13 and pCA 14, 
plasmids p~E1sp1A, p~E1sp1B and plasmids pFG140 and pJM17 were 
purchased from Microbix Biosystems Inc., Toronto, Ontario, Canada. 
Adenoviral shuttle vectors pLES53 and pLECM were provided by Dr. Keith 
Leppard, University of Warwick, UK. All plasmids required for subcloning 
purposes were extracted using Wizard Maxipreps while those required for 
transfections were purified by CsCI-EtBr density centrifugation. 
2.4.2. Oligonucleotides for peR, Sequencing and Epitope-tagging 
Oligonucleotides were obtained from Gibco-BRL or Genosys in lyophilized 
form, reconstituted with sterile distilled water. Stocks of oligonucleotides were 
made at concentrations of 200llM and maintained as frozen stocks at -20°C. 
Working solutions were made by diluting 1 :20 for PCR and 1: 1 00 for 
sequencing reactions, in fresh sterile distilled water. Oligonucleotides to be 
used for making epitope tag sequences were reuspended in TE to a final 
concentration of 21l911l1 unless otherwise stated. All primers were designed 
empirically or in some cases using GCG package or the Vector NTI software. 
Primer annealing temperature and other characteristics including possibility of 
hairpin loop formation were checked using the Primer Master Version 1.0 
public domain software. 
2.4.3. Agarose Gel Electrophoresis of DNA 
A 1 % (w/v) agarose solution was made up in 0.5X TBE buffer (0.0445M Tris 
base, 0.0445M Boric acid. 0.001M EDTA, pH 8.0) and heated in a microwave 
to boiling point to dissolve the agarose. The solution was cooled down to 40-
45°C and EtBr was added to a final concentration of 0.1 Ilg/ml and poured 
into a horizontal gel tray set with the appropriate gel comb. The gel was 
transferred to a electrophoresis gel tank with 0.5X TBE, the comb removed 
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ready to load the DNA samples. The DNA samples were mixed with one-sixth 
volume of 6X gel-loading buffer (50% glycerol, 1% bromophenol blue). Higher 
strength (1.2-2%) was used when smaller fragments «300 bp) needed to be 
resolved. Lower strength gels (0.5-0.8%) gel was used to resolve larger 
(>4000 bp) bands or for DNA fragments which required extracting from the 
gel for cloning purposes. 
2.4.4. Restriction Digests of DNA Fragments 
Restriction endonuclease digestion were carried out using a 1.5 to 2 times 
excess of the 1 Unit of enzyme per fl9 of DNA recommendation of the 
supplier. Fragments were separated by agarose gel electrophoresis and 
purified by electroelution or gel extraction as described in section 2.4.5. 
Micropure EZTM columns (Millipore Corp.) were used for removal of interfering 
enzymes from the DNA as per instruction of the manufacturer. Other 
manipulations done on the DNA are discussed later under the appropriate 
headings. 
2.4.5. Extraction of DNA Fragments from Agarose Gels 
DNA restriction fragments were isolated from agarose using the QIAprep Gel 
Extraction Kit. The prescribed protocol of QIAprep Plasmid Handbook 
revision 03/95 was followed for extracting DNA, with the exception of omitting 
the optional step #7 and eluting the DNA in TE. 1/10th of the eluted DNA 
fragment was run on a 1 % agarose gel to confirm and visually quantify the 
amount of DNA eluted. 
In case of low yield of some small sized DNA fragments, electroelution was 
employed as an alternative. The gel piece carrying the fragment was cut out 
and placed in prepared dialysis tubing with sterile TBE secured by dialysis 
clips. The tubing was then placed in a gel tank and electroelution carried out 
at 70-80V for 1-2 hours. After the eluted DNA was carefully collected from the 
tubing and extracted with phenol/chloroform once and then chloroform once 
and ethanol precipitated. DNA pellet was suspended in the appropriate 
volume to obtain the required concentration of DNA for use in ligations or 
other manipulations. 
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2.4.6. Preparation of Double-stranded DNA Oligonucleotides 
Double-stranded DNA oligos comprising the epitope tag coding sequence 
were made for incorporation into the sTnC cDNA. The appropriate oligos 
were synthesized, annealed and ligated into the sTnC cDNA to produce 
cDNA coding for skeletal Troponin C protein with a single copy of 
carboxyl-terminal epitope tag. 
2.4.6.1. Annealing of ss DNA Oligonucleotides 
Double stranded short DNA inserts were made for incorporating epitope tag 
sequences in the cDNA at the 3'-end. Single stranded oligonucleotides of the 
sense and the antisense DNA were synthesized with appropriate restriction 
sites and stop codon, annealed and then phosphorylated to obtain the double 
stranded epitope tag insert. The annealing reaction consisted of 20I-.d each of 
the sense and antisense oligonucleotides with 101-11 of 10X Klenow buffer in a 
total volume of 1001-11. The annealing reaction was heated to 95DC in a 
thermal cycler block for 5 minutes and then transferred to a waterbath which 
was preheated to 70D C. The waterbath was then switched of and the 
annealing mix allowed to cool over a 2 to 3 hour time period to allow 
annealing the oligonucleotides. The single stranded oligonucleotides and the 
annealed DNA was run on a 2.5% agarose gel to check for proper 
annealing: The annealed DNA band travelled slower than its two parent 
oligo n ucleotides. 
2.4.6.2. Phosphorylation of Annealed DNA 
51-11 of annealed DNA was used in the phosphorylation reaction with 51-11 of 
10X Kinase buffer, 2.51-11 of ATP (10mM) 21-11 of T4 Polynucleotide Kinase 
(Promega cat. no. M41 01) and 35.51-11 of distilled water. The reaction was 
incubated at 37 DC for 1 hour. 21-11 of 0.5M EDTA pH 8.0 was added at the end 
if incubation and the reaction heated at 75 DC for 10 minutes, and then 
transferred to ice. The phosphorylated DNA was preCipitated with 0.1 volume 
(5.51-11) of Na-acetate and 2001-11 of cold 100% ethanol and kept at -70DC for 
1 hour. The DNA was spun at 14000 rpm in a microfuge for 20 minutes, the 
pellet washed with 501-11 of 70% ethanol, dried and resuspended in 201-11 of TE 
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(final concentration of DNA being 100 Ilg/Ill). 1-31l1 of this DNA was used in 
ligation reactions. 
2.4.7. End-filling of Protruding and Recessed Termini of DNA 
Protruding or recessed end of DNA were filled in to produce blunt ends where 
required. DNA fragment was isolated from the gel as described in section 
2.4.5. and added to a reaction mix containing 1X Klenow buffer, 40llM of 
each dNTPs and 1 U of DNA Klenow polymerase (Boehringer Mannheim cat. 
no. 1008 404) per microgram of DNA, and incubated at 37°C for 3 hours. 
After the completion of reaction, the DNA was ethanol precipitated as 
described in section 2.5.2., and resuspended in a suitable volume. 
Alternatively, the enzyme and unused nucleotides were removed using 
Micropure EZTM for removing the polymerase and Microcon TM-30 for 
concentrating the DNA and removing the unused nucleotides as described in 
section 2.5.3. 
2.4.8. Dephosphorylation of DNA 
Vector DNA cut with an enzyme was prevented from religating back, 
favouring insert ligation, by dephosphorylation of restricted cohesive termini 
using Calf Intestinal Phosphatase (CIP; Boehringer Mannheim cat. no. 
713023). 1 Unit of CIP enzyme was added per 50 pmol of DNA 5'-recessed, 
3' recessed or blunt-ended DNA termini, to a vector restriction digest at the 
end of digest reaction and incubated at 3JDC for 1-1.5 hours. Buffer 
adjustments were made using the restriction enzyme buffer rather than CIP 
buffer, before adding the enzyme. After the completion of the 
dephosphorylation reaction, the CIP was inactivated by adding 1/10th volume 
of 200mM EGT A and heating at 65°C for 10 minutes. The enzyme was 
completely removed either by using Micropure EZTM columns or by 
phenol/chloroform extraction and ethanol precipitation as described in section 
2.5.2. 
2.4.9. Ligations 
DNA ligation reactions for splicing insert DNA into vectors were carried out 
using 20-50ng of vector DNA and 50-200ng of insert. 1:1, 1:2 and 1:5 DNA 
Materials and Methods 72 
Chapter 2 
molar ratios were used for the vector and insert DNA. Typically, 50ng of 
vector was mixed with twice molar amount (1:2 ratio) with 2111 of 5X ligase 
buffer, 1 III of ATP (10mM) and 1 III of T4 DNA ligase (Gibco-BRL cat. no. 
15224) in a 10111 reaction. For a protruding end ligation, the reaction was 
incubated at 4°C overnight and for blunt-end ligations, the incubation was at 
room temperature overnight. Control ligations were set up containing cut 
plasmid vector only (no foreign insert) plus ligase and used as background for 
vector DNA restriction quality. 
2.5. Additional Nucleic Acid Procedures 
The classical procedures for nucleic acid manipulation were employed for 
cleaning, concentrating and estimating DNA and RNA as described by 
Sambrook et al (Sambrook et al., 1989). Radiolabeled probing of nucleic 
acids was performed according to the protocols provided with Amersham 
Hybond-N+ membranes and modified wherever required. 
2.5.1. Organic Extraction of Nucleic Acid Solutions 
This method was used to remove cellular debris or contaminating proteins 
from crude DNA preparations. Equal amounts of Phenol washed in Tris buffer 
(Fisher Scientific, Loughborough, UK) was mixed with 24: 1 chloroform-
isoamyl alcohol and stored in a dark bottle at 4°C. The phases were allowed 
to separate. An equal volume of the lower organic phase of the phenol-
chloroform was added to the DNA solutions or crude DNA extracts and 
vortexed. The extraction mix was then centrifuged at 12000g in a microfuge 
at room temperature. The lower phenol phase was removed using a 
disposable fine pastette and an equal amount of chloroform-isoamyl alcohol 
was added, mixed by vortexing and centrifuged at 12000g in a microfuge for 
5-7 minutes. The upper aqueous phase was aspirated off carefully into a 
fresh Eppendorf tube and ethanol precipitated and resuspended in the 
desired volume of buffer or water. 
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2.5.2. Concentration of DNA Samples by Ethanol Precipitation 
Na-Acetate/Ethanol precipitation was used to concentrate dilute DNA 
solutions, or where the buffer of the DNA solution is required to be changed. 
To the DNA solution, 1/10th volume of 3M sodium acetate and 2.5 volumes of 
cold ethanol were added, mixed thoroughly, and frozen at -70DC for 1-2 
hours to precipitate the DNA. The DNA was pelleted by centrifugation at 
14000 rpm in biofuge and washed with 70% ethanol, spun, air-dried and then 
resuspended in water or TE. 
2.5.3. Concentration of Dilute DNA Samples 
Other than ethanol precipitation, DNA was also concentrated using 
Microcon-30 (for volumes up to 500j..d) or Centricon-30 (for volumes up to 2 
ml) columns (Millipore Corporation). DNA solutions were concentrated 
following the protocol described by the supplier. The total amount of DNA 
spun per column was kept below 400j.lg to prevent clogging of the filter 
membrane. 
2.5.4. Quantitation of Nucleic Acids 
DNA, RNA solutions and oliogonucleotide stocks were diluted 1: 1 00 to 1 :500 
in distilled water or preferably the buffer they were originally resuspended 
and the nucleic acid concentration and 260/280 ratio measured on the 
Pharmacia Biotech Ultrospec 2000 UV/VIS spectrophotometer, using the 
nucleic acid mode. The displayed results for concentration were multiplied by 
the dilution factor 
2.5.5. Preparation of Radiolabeled DNA Probes 
Radiolabeled single stranded DNA probes labelled with 32p were generated 
using the Random Primed DNA Labeling Kit (Boehringer Mannheim, cat. no. 
1004-760). 50 ng of DNA (from a 25 ng/ml solution) was denatured by 
heating to 100D C for 10 minutes and immediately placed on ice. 2j.l1 of 
denatured DNA was taken in an Eppendorf tube and placed on ice: 1 j.ll each 
of dATP, dTTP and dGTP and 2j.l1 of reaction buffer mix was added to the 
reaction followed by 5j.l1 of [a-32p]dCTP (50j.lCi) and 7j.l1 of distilled water. 
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Finally, 1 fll of Klenow enzyme added, mixed and incubated at 37°C for 30 
minutes to 1 hour in a waterbath covered with a lead pot. The reaction was 
stopped by heating. All non-incorporated dNTPs were removed using Nick® 
columns Sephadex® G-50 DNA-grade from Pharmacia Biotech (cat. no. 17-
0855-02) 
2.5.6. Hybridization of Radiolabeled Probe 
DNA and RNA transfers to Hybond-N+ membrane (see sections 2.12.2. and 
2.15.4.) were subjected to hybridization immediately after transfer or stored at 
4°C wrapped in Saran-Wrap. The membrane was prehybridized at 65°C for 1 
hour in prehybridization buffer (0.5X Denhardt's solution, 5X SSC, 0.5% SDS, 
20 flg/ml of heat denatured salmon sperm DNA) using a hybridization tube. 
The prehybrization solution was removed and replaced with hybridization 
solution (0.5X Denhardt's solution, 5X SSC, 0.5% SDS, 10% Dextran 
sulphate, 20 fl9/ml of heat denatured salmon sperm DNA) to which the 
denatured (single stranded) labelled probe had been added (not exceeding a 
20 ng/ml concentration limit). Hybridization was carried out overnight at 65°C 
in hybridizing oven. The following day, the membrane was washed twice with 
2X SSC/0.1 % SDS at 65°C for 10 minutes and 1 X SSC/0.1 % SDS at 65°C 
for 10 minutes if required due to filter being too hot. A high stringency final 
wash of 0.1 X SSC/0.1 % SDS at 65°C for 10 minutes was done only if the 
probe was 100% homologous. The membrane was removed from the 
hybridization bottle onto a 3MM paper for drying and then the filter wrapped 
in Saran-Wrap and exposed to autoradiography. 
2.6. DNA Transformation 
The modified plasmid vector DNA were transformed into E.coli host following 
ligation of foreign inserts into vectors, for obtaining amplified amounts of 
plasmid DNA. This plasmid DNA was then extracted for screening and 
selection of the proper plasmid vectors with the desired subcloned promoters, 
cDNA and other markers. 
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2.6.1. Preparation of Competent Cells 
A glycerol stock of E.coli DH5a cells of known single colony origin was used 
to inoculate 5 ml of L-broth supplemented with 20mM MgS04, 10mM NaCI, 
5mM KCI using a 100X solution of the salts and incubated at 37°C for 
overnight. The following day, 100 ml of L-broth supplemented with 1 ml of the 
100X solution of salts as before, in a sterile bevelled 250 ml conical flask was 
inoculated with 2 ml of overnight culture and incubated in an orbital shaker at 
3rC for 4-5 hours. When the optical density at 600nm reached 0.45, the 
cells were split in two 50 ml sterile Falcon tubes placed on ice for 15 
minutes. Cells were kept on ice and spun at 4°C from this step onwards. 
Cells were pelleted at 2500 rpm in IEC Centra-7R refrigerated centrifuge for 
15 minutes and the supernatant was discarded. The cell pellet was 
resuspended in 20 ml/tube TFB-1 (30mM potassium acetate, 100mM 
rubidium chloride, 10mM calcium chloride, 50mM manganese chloride and 
15% v/v glycerol, pH 5.8) gently and placed on ice for 15 minutes. Cells were 
again pelleted as before and resuspended in 4 ml/tube TFB-2 (10mM MOPS, 
75mM calcium chloride, 10mM rubidium chloride and 15% v/v glycerol, pH 
6.5) and placed on ice. The cells can now be used immediately or frozen. For 
freezing, the cells were aliquoted out into Eppendorf tubes which had been 
placed on ice, and snap-frozen in a ethanol-dry ice bath. Frozen aliquots 
were placed in the - 70°C freezer and taken out and thawed just before use. 
Thawed out cells were not refrozen, but discarded after use. 
2.6.2. Transformation of Bacterial Cells 
Frozen competent cells were placed on ice to thaw and an Eppendorf tube 
was placed on ice. 5fll of ligation mix or 100ng of plasmid DNA was 
transferred to the tube and 50fll of thawed competent cells pipetted into the 
tube, mixed gently and incubated on ice for 30 minutes. The cells were heat-
shocked for 90 seconds at 42°C without any shaking and placed back on ice 
for 5 minutes. 700fll of L-broth (without any antibiotic) was transferred to the 
tube and the cells incubated in orbital shaker for 45 minutes to allow 
expression of the ampicillin resistance gene. Cells were pelleted at 5000 rpm 
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for 2-3 minutes in a microfuge; all but 100fli of the supernatant was discarded 
and the cells resuspended and spread on a LB-agar plate with 100flg/ml of 
ampicillin. The plates were incubated at 3rC overnight. 
2.6.3. Screening of Putative Recombinants 
Single colonies were picked from the plates of ligation transformations and 
inoculated in 5 ml broth with 100 flg/ml of ampicillin and incubated at 37°C 
overnight. 2 ml of the culture was used for crude DNA minipreps. The DNA 
was digested with the appropriate enzymes to determine the successful 
ligation of the insert. In case of subcloning of PCR amplified fragment, after 
the confirmation of the presence of the insert, the inserted fragment was 
sequenced using the appropriate primers. 
2.7. Sequencing of Plasmid DNA 
All sequencing reactions were carried out using Thermo Sequenase 
radiolabeled terminator cycle sequencing kit (Amersham Life Science cat. no. 
US 79750) and Redivue ™ 33p labeled dideoxynucleotides (Amersham Life 
Sciences AH 9538). This method is based on PCR amplification of the DNA 
to be sequenced, using 32P-labelled dideoxynucleotide terminators and has 
the advantage of producing good results using low amount of template DNA. 
For each plasmid to be sequenced, 2fll of the termination master mix (dGTP) 
was dispensed in four thin walled PCR tubes (termination tubes) and labelled 
as G, A, T and C. 0.5fll of each of the four 33p labeled dideoxynucleotides 
(ddNTPs) was added to the respective tubes and kept on ice. 200-600fl9 of 
DNA was mixed with 2fll of reaction buffer, 2 pmol of primer made up to 
18.5fll with sterile distilled water: Lastly, 1.5fll (4U/fll) of Thermo Sequenase 
polymerase was added. 4.5fll of this reaction mix was added to each of the 
four termination tubes, mixed well and layered with mineral oil. Tubes were 
capped, placed in a thermal cycler and cycled 30 times with each cycle 
consisting of heating at 95°C for 30 seconds, 55°C for 30 seconds and 72°C 
for 1 minute. 4fll of stop solution was added to each termination mix tube. 
The samples were frozen at -20°C at this stage for running the next day. 
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Tubes were heated at 70°C for 2-5 minutes and placed on ice, immediately 
before the loading on a glycerol tolerant sequencing gel. 3-5/l1 of reaction 
was loaded in each well. 
2.7.1. Denaturing Polyacrylamide Gel Electrophoresis for Sequencing 
The gels was cast in the Biorad Sequi-Gen sequencing cell system. The 
glass plates were thoroughly cleaned with detergent and then wiped to 
dryness with 70% ethanol. The plates were assembled in the apparatus, 
separated by red 0.4 mm spacers. 6% polyacrylamide, 8M urea gel was 
made up using 10X TTE buffer (108g Tris base, 36g Taurine, 2g 
Na2EDTA.2H20 per litre, pH 8.0) to a final 1X TTE concentration, 30% 
Acrylamide/bis-acrylamide 19:1 solution (Biorad cat. no. 161-0154) and 
polymerized using 0.001 volume of ammonium persulphate and TEMED 
(N,N,N',N'-tetramethylethylenediamine) each. Gel was poured using a 50 ml 
syringe and allowed to set overnight. Electrophoresis conditions were usually 
constant 1800 Volts and the gel was pre-run for 1-1.5 hours to bring up the 
temperature to 45-50°C before the samples were loaded. The voltage was 
altered to keep the temperature of the gel between 50-55°C. At the end of the 
run, the plates were separated and the gel transferred to a Whatman 3MM 
paper, covered in Saran-wrap and dried in a Hybaid Gel-Vac gel-drier for 1 
hour. The gel was then exposed to Kodak Biomax MR film and the 
autoradiograph developed 16-24 hours later. 
2.8. Eukaryotic Cell Culture 
Animal cell culture was used routinely for maintaining and propagating 
established and primary cell lines required for generating adenoviruses and 
as gene expression systems. 
2.8.1. Growth and Maintenance of Cell Lines 
Generally cells were maintained in Minimal Essential Medium (MEM; Gibco-
BRL cat. no. 21090) or Dulbecco's Modified Eagle Medium (DMEM; Gibco-
BRL 41965), supplemented with 10% Foetal Bovine Serum (FBS or FCS; 
Gibco-BRL cat. no. 10108), 2mM Glutamine (using 100X (200mM) 
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Glutamine, Gibco-BRL cat. no. 25030) and 100 IU/ml of Penicillin and 
100Mg/ml of Streptomycin using 100X Penicillin/Streptomycin (10,000 IU 
Penicillin- 10,000 M9 Streptomycin, cat. no. 15140). The usual method for 
propagation of cells was as monolayers to logarithmic phase in a 175 cm2 
tissue culture flask. Cells were normally subcultured upon reaching 70-80% 
confluency. The cell monolayer was washed twice with 8 ml PBS and 
detached using 1 ml of Trypsin-EDTA (Gibco-BRL cat. no. 45300). The 
detached cell were diluted 10-20 fold in the appropriate medium and pelleted 
by centrifugation (IEC Centra-7R table top refrigerated centrifuge), at 1000 
rpm for 10 minutes The pellet was resuspended in 10 ml of appropriate 
medium and split in the required aliquots into fresh tissue culture vessels. 
Cells with special growth requirements such as HEK-293, and primary 
cardiocytes were treated differently. Milder methods of cell detachment and 
varied conditions of medium were employed for these cells which are 
discussed later. 
2.8.2. Freezing and Thawing of Cell Lines 
Most cell lines were frozen down for storage by first detaching the cells by 
trypsinizing. Detached cells were diluted 20 fold and pelleted as described 
above and resuspended in appropriate medium supplemented with 20% 
serum except where stated. An equal amount of medium with 20% DMSO 
was then added dropwise over a period of 3-5 minutes to avoid shock to the 
cells. The cells were then aliquoted into cryovials (1.8 ml) and frozen by 
cooling at the rate of 1 DC/min using a Nalgene Cryo 1 DC freezing container in 
a - 70DC freezer overnight after which they were transferred to the vapour 
phase of liquid nitrogen. 
293 cell were first detached from the culture vessels using citric saline as 
described above. Detached cells were diluted in 5 volumes of growth medium 
and the cells were pelleted by centrifugation (200g for 5 minutes). The 
supernatant was discarded and the pellet resuspended in 100% foetal bovine 
serum. 1/10th volume of sterile DMSO was added slowly to the serum/cell 
suspension and the mixture was aliquoted into sterile freezer vials. The vials 
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were placed in Nalgene Cryo 1°C freezing container for 1 hour at 4°C 
followed by 16-20 hours at -70°C. Vials were then moved to the vapour 
phase of liquid nitrogen, for long term storage. 
Frozen vials of all cell lines were thawed rapidly in a 37°C water bath. Vials 
were washed with 70% ethanol after which the cell suspension was 
transferred under aseptic conditions to a sterile tissue culture petri dish. 5-6 
ml of appropriate medium was added to the cells dropwise over 3-5 minutes 
while gently agitating the vessel. A further 10 ml of medium was added and 
cells were then incubated at 37°C in 5% CO2 overnight. The medium was 
changed the next day to remove the cryopreservative containing medium and 
cells were then allowed to grow as described above. 
2.8.3. Special Buffers and Solutions for Cell Culture 
DNase stock was prepared as 2 mg/ml Deoxyribonuclease II (Sigma Cat. 
No. D-B764) in 0.15M NaCI, filter sterilized and frozen down at -2()OC in 
aliquots. Trypsin (100 mg/ml solution in sterile water) was dissolved by 
stirring overnight at 4°C, filtered through a Whatman No 1 filter paper and 
filter sterilized using a bottle top filter. Trypsin stock was stored at -20OC in 
aliquots. 100X BrdU (30.74 mg 5-Bromo-2'-deoxyuridine, Sigma cat. no. 
B-5002) was dissolved in 10 ml of MEM, filter sterilized, aliquoted and frozen 
at -20°C: Once thawed, aliquots of BrdU stock were not refrozen. 
Calcium and Bicarbonate Free Hanks with HEPES (CBFHH) buffer was 
made from stock solution of its components. The stock components were: 
NaCI (200g/L), 40 ml to 136.9mM; KCI (40g/L) 10 ml to 5.36mM; MgS04 
.7H20 (20g/L) 10 ml to 0.B1mM; KH2P04 (6g/L) 10 ml to 0.44mM; 
Na2HP04.7H20 (9g/L), 10 ml to 0.34mM; HEPES pH 7.4 (47.66 giL), 100 ml 
to 20mM and Glucose (100g/L) 10 ml to 5.55mM: BOO ml of distilled water 
was added and the pH was adjusted to 7.5 with NaOH. 10 ml of Penicillin-
Streptomycin (1 OOX) was added and the volume raised to 1000 ml. The 
buffer was filter sterilized using a bottle top filter and stored at 4°C. 
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Citric Saline used for detaching 293 cells was made as 10X stock (1.350M 
KCI and 150mM sodium citrate), sterilized by autoclaving and stored at room 
temperature. Working concentration for citric saline was 1 X and was made 
using the stock when required and sterilized byautoclaving. 
2.8.4. Cell Lines 
Established human and rodent cell lines were used as in vitro. systems for 
analysing foreign gene expression and for making recombinant adenoviruses. 
The cell lines were maintained and propagated according to the cell culture 
protocols provided by the suppliers. In addition, primary cells such as 
cardiocytes were routinely isolated and cultured when required, using 
specially devised methods described later in this section. 
2.8.4.1. Human Embryonic Kidney 293 Cells 
Low passage cells (at passage 25), were obtained from Microbix Biosystems, 
Toronto, Canada. A frozen vial was thawed and plated on to a 100 mm tissue 
culture petri dish in Minimal Essential Medium (MEM) supplemented with 
10% foetal bovine serum, 2mM Glutamine and 100 IU/ml Penicillin/ 100 jJg/ml 
Streptomycin, and incubated at 37°C in 5% CO2, Cells were grown to 80-90% 
confluency and split 1 :3. A fraction of this batch was frozen down at the 
lowest (27-29) passage possible in order to provide stocks of low passage 
cells. 
Cells were maintained in logarithmic growth by subculturing every 3-4 days in 
175 cm2 tissue culture flasks (Nunc). Cells were split when at 80-90% 
confluency by aspirating off spent medium, and washing twice with 10 ml. 1 X 
citric saline (135mM KCI and 15mM sodium citrate). After the wash, 2ml citric 
saline was layered on the monolayer and incubated at 37°C for 5 min to 
detach the cells. Complete detachment of the cells was achieved by tapping 
the sides of the flask. 10-12 ml. of fresh medium was added to the dislodged 
cells and these were dispersed by pipetting. The suspended cells were split 
1:3 or 1:4 and aliquoted into fresh 175 cm2 tissue culture flasks. Media was 
added to a final volume of 18-22 ml. per flask and incubated as described 
above. 
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2.8.4.2. C2-C12 Myogenic Cell Line 
Cells were obtained from our lab liquid nitrogen stock. The cells were cultured 
in Dulbecco's Modified Eagles Medium with sodium pyruvate (Gibco cat. no. 
41965) supplemented with 20% foetal bovine serum, 1% chick embryo 
extract and 100U/ml Penicillin/100llg/ml Streptomycin. Cells were passaged 
every 2-3 days and generally split 1: 1 0 to 1 :20 as required, after detaching by 
trypsinization using Trypsin-EDTA. 
2.8.4.3. Cardiac Fibroblasts 
Cardiac fibroblasts were obtained as a by-product of the primary cardiocyte 
preparation, during the preplating step. These cells are maintained in MEM 
(5% FCS, 2mM Glutamine and 100llg/mi of Streptomycin and 100U/ml of 
Penicillin.) At 70-80% confluency, the cells were subcultured by detaching the 
cells using Trypsin-EDTA (Gibco-BRL) as described earlier. 
2.8.4.4. NIH-3l3 Mouse Fibroblasts 
NIH-3T3 Swiss mouse fibroblast cells were obtained as a frozen stock from 
the European Collection of Cell Culture (ECACC) at the Centre for Applied 
Microbiology & Research (CAMR), Salisbury, UK. Cells were thawed out and 
maintained in DMEM supplemented with 10% Calf serum, 2mM Glutamine 
and 100U/ml of Penicillin/100llg/ml Streptomycin. Upon reaching 70-80% 
confluency, the cells were subcultured by detaching the cells using Trypsin-
EDTA (Gibco-BRL) and diluting 1 :10 to 1 :20 as required. 
2.8.4.5. Primary Culture of Neonatal Cardiocytes 
Rat neonate cardiocyte culture procedure was modified from protocols 
devised by Paul Simpson (Simpson and Savion, 1982). Sprague-Dawley rats 
from day of birth to 4 days old, were used to obtain hearts for primary 
cardiocyte culture. 30 to 40 animals were sacrificed by Euthatal injection and 
hearts exposed and isolated using sterile curve forceps and scissors. Isolated 
hearts were transferred to a 1 OOmm tissue culture dish containing 10-12 ml of 
PBS. From this stage onwards, all manipulations were done under sterile 
conditions in a class II safety cabinet. 
All non-cardiac tissues were removed from the heart using fresh sterile 
surgical tools and the cleaned hearts were transferred to a 100 mm dish 
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containing 10 ml of CBFHH buffer. Hearts were cut in half and CBFHH buffer 
aspirated off. Hearts were rinsed twice with 10 ml of the buffer to remove 
blood. 4-5 ml of buffer was added and hearts were finely chopped into about 
2 mm size cubes using pointed scissors over 5-8 minutes. Heart tissues were 
transferred into a 50 ml falcon tube using a 10 ml pipette. Remaining tissue 
was transferred completely by rinsing the plate twice and transferring the 
mixture to the falcon tube. After the tissue segments have settled, the 
CBFHH supernatant is removed carefully. 
10 ml Trypsin solution was added to the cells and the tube shaken for 20 
minutes on an automatic shaker at room temperature. Tissue pieces were 
allowed to settle and supernatant transferred to a collecting tube with 2 ml of 
foetal bovine serum. Another 10 ml of trypsin solution was added to the 
tissue and shaken as before for 15 minutes The supernatant was transferred 
to the collecting tube. 9 ml of DNase solution was added to the tube and the 
tissues pipetted up and down several times to shear and degrade the DNA 
released from the cells. The trypsinization and DNase treatment steps were 
repeated until the pellet became white. 
Collecting tubes with cardiocytes were spun at 1000 rpm for 5 minutes. 
Supernatant was collected carefully and discarded. Cell pellets were pooled 
after addition of 2 ml of MEM per tube and gentle, thorough resuspension. 
Final cell volume was made up to 20 ml. 200IJI DNase stock was added after 
which cells were pipetted up and down several times until visible clumps were 
dispersed. Cells were then pelleted at 1000 rpm for 5 minutes. The 
supernatant was discarded and the cell pellet resuspended in 32 ml of MEM 
medium. 
Four 100mm tissue culture plates were taken and the lids removed in aseptic 
conditions under a flow hood. A sterile steel sieve was prewetted with MEM 
medium and 8 ml of cell suspension was poured through the sieve into each 
of the four plates. The plates were incubated at 3rC in a 5% CO2 for 45 
minutes. This pre-plating was done to eliminate the fibroblast content of the 
cell suspension. 
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After the pre-plating, plates were swirled to detach any partly attached 
cardiocytes and the cell suspension transferred to a 50 ml falcon tube. 2 ml of 
MEM was added to each of four plates which were tapped to dislodged 
incompletely detached cardiocytes and the cell suspension was then 
transferred to the falcon tube. 5 ml of MEM was pipetted through the four 
plates to completely detach the remaining non-adhering cardiocytes which 
were then transferred to the falcon tube. The final volume of the cardiocytes 
suspension was raised to 45 ml. In addition, the adherent cardiac fibroblasts 
were then grown by adding 10 ml of MEM medium and maintaining as 
described in section 2.8.4.3. 
Cardiac myocytes were centrifuged at 1000 rpm for 5 minutes and the pellet 
resuspended in 32 ml of MEM medium with 1 % BrdU. Cells were plated into 
60mm or 100mm tissue culture dishes and incubated at 37°C in 5% CO2, 
After 24 hours, cardiocytes were checked for contractions after 24 hours 
incubation and used either for transfections or viral infections. 
2.9. Transfection of DNA into Eukaryotic Cells 
Plasmid DNA was transfected into cells in culture for analysing gene 
expression and for making recombinant adenoviruses. Generally, caesium 
purified DNA was used for transfecting the cell lines, employing the CaP04 or 
the liposome transfection methods. 
2.9.1. CaP04 Transfection Method 
CaP04-DNA co precipitation method was used mainly for transfections in the 
production of recombinant adenoviruses. A modification of the method 
devised by Graham F.L. et a/ (Graham and Van der Eb, 1973) was used. 
250I-LI of 2X HBS (50mM HEPES, 274mM NaCI, 10mM KCI, 1.5mM 
Na2HP04, and 11 mM Glucose, pH 7.1) was taken in a 5 ml polystyrene tube 
and 0.002 volume of salmon sperm DNA (10 mg/ml) was added and the 
buffer-carrier DNA solution syringed through a 21 G hypodermic needle a few 
times to shear the carrier DNA. 5-10 I-Lg of plasmid DNA to be transfected, is 
made up in an Eppendorf tube to 2251-L1 with tissue culture grade distilled 
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water and 25J.t1 of 2.5M CaCI2 added dropwise with slow vortexing. The DNA-
CaCI2 mix was added dropwise to the HBS-carrier DNA in the tube and 
incubated for 5 minutes at room temperature or to the point of formation of a 
visible milky precipitate. The calcium phosphate-DNA precipitate was then 
added to the medium on a dish of appropriate cells and incubated for 6-18 
hours. After this incubation time the media was replaced with 5 ml of fresh 
medium and left for 36-48 hours to allow for expression of the desired gene. 
In case of production of recombinants, the media is removed after incubation 
and overlayed with soft agar consisting of BME Basal medium with 1.1 % 
agarose as described in section 2.10.2., allowed to solidify at room 
temperature and incubated at 3JOC in a 5% CO2 incubator. 
2.9.2. Liposome-mediated Transfection 
Cationic liposome-mediated transfection of DNA was used mainly to study 
transient expression of genes using plasmid DNA. Cells were grown to a 
confluency of 70-80% using the appropriate medium with a reduced serum 
supplement (2-5% FCS) in a 60 mm tissue culture dish. Spent medium was 
replaced with 5 ml of fresh low-serum medium, 3 to 12 hours before the 
transfection. The liposome, DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate) from Boehringer Mannheim (cat. no. 
1202375) was used for transfection. 5J.tg of plasmid DNA was diluted in HBS 
(HEPES Buffered Saline, 20mM HEPES, 150mM NaCI, pH 7.4) to a final 
concentration of 0.1 J.tg/J.tl, in a total volume of 50J.t1 using an Eppendorf tube. 
A separate polystyrene analyzer cup was used to dilute 30J.t1 of DOTAP to 
100J.t1 using HBS. The DNA solution was added to the diluted DOTAP and 
mixed carefully by gentle pipetting several times. The transfection mixture 
was incubated at room temperature for 10-15 minutes and then transferred to 
the cell and mixed thoroughly with medium by rocking the dish. The cells 
were incubated at 37°C in a 5% CO2 incubator with the DOTAP/DNA mix for 
4-16 hours and then replaced with fresh medium and incubated for another 
36-48 hours to allow for expression of transfected gene. 
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2.10. Construction of Recombinant Adenoviruses 
Recombinant adenoviruses were constructed using the method developed by 
Frank Graham et al (Graham and Prevec, 1995; Graham and Prevec, 1997) 
which utilizes the phenomenon of homologous recombination between the 
large adenoviral genome-carrying plasmid and smaller shuttle plasmid 
carrying the foreign gene of interest in 293 cells. 
2.10.1. Cotransfection of Adenoviral and Shuttle Plasm ids 
The adenoviral genome carrying plasmid pJM17 and the appropriate shuttle 
plasmid carrying the gene of interest were cotransfected into 293 cell lines 
using CaP04-mediated DNA transfection described in section 2.9.1. The 293 
cells were split 2 days before the transfection and grown to 60% confluency. 
The spent medium was replaced with fresh MEM with 5% FCS and 1 mM 
glutamine, 12 to 24 hours before the transfection. For the transfection, the 
larger pJM17 and the smaller shuttle plasmids (pCA13, pCA14 or p~E1sp1A 
or p~E1sp1B, carrying the appropriate cassette of promoter and cDNA) were 
mixed in quantities of 5fl9 + 5fl9, 5fl9 + 10fl9 and 10fl9 + 1 Ofl9. The DNA 
was coprecipitated and each of the three mixes transferred to the 60 mm dish 
of 293 cells at 70 to 80% confluency. The DNA-CaP04 precipitate was kept 
over the cells to settle for at least 6 hours, allowing uptake of DNA-CaP04 
precipitate, after which it was overlayed with soft agarose medium. 
2.10.2. Soft Agarose Overlay 
After the transfection, the cells were overlayed with BME with soft agarose 
and incubated at 37°C in 5% CO2 incubator. This overlay was prepared 
using equal volumes of 2X BME (Basal Medium (Eagle); cat. no. 21017), and 
melted and cooled 2.2% LMP agarose (2.2% w/v agarose type VII, Sigma 
cat. no. A-4108 in distilled water, autoclaved) supplemented with 5% CELLect 
GOLD foetal bovine serum (ICN cat. no. 2916849). The agarose was layered 
onto the transfected cells when cooled down to about 32-34°C gently and 
allowed to solidify at room temperature for 15-20 minutes. The dishes were 
observed daily for cell health. On day 3, post-cotransfection, the cells were 
overlayed with another 5 ml of BME/agarose overlay and incubated further. 
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Cells were observed daily for any signs of rounding up of cells or initiating 
plaques. On day 7 of transfection, cells were overlayed with 3 ml of 
MEM/agarose prepared by mixing equal amounts of 2X MEM (cat. no. 21935) 
and 2.2% LMP agarose, supplemented with 10% foetal bovine serum and 
100 IU/ml of Penicillin and 100llg/ml of Streptomycin. Incubation was 
continued in the same conditions as before, and the dishes screened daily for 
plaques. 
2.10.3. Plaque Selection and Recombinant-screening 
Plaques were marked and picked up as soon as they were visible by the 
naked eye. The agarose layer was stabbed with plugged short-form pasteur 
pipettes with bulb attached to suck in the agar plugs. The agar plugs were 
transferred to an Eppendorf tube with 500lli of Dulbecco's PBS (with Ca ++ 
and Mg ++ ) and rinsed thoroughly to mash and suspend the agarose. 150111 of 
this plaque suspension was used to infect 293 cells grown to 70-80% 
confluency in a 60 mm tissue culture dish. The dish was incubated at 3YOC in 
a 5% CO2 atmosphere for 45 minutes to 1 hour and then 3-4 ml of MEM was 
added to the dish and the incubation continued up to 7 days or until the 
appearance of a full cpe. Once the desired level of cpe was reached, the 
cells were harvested as described in section 2.11.1. and the cell lysate used 
for DNA minipreps as described in section 2.11.5. 4/5 th of the DNA isolated 
was digested with Hind II I restriction enzyme and the banding pattern 
produced compared with the Ad5-d1309 bands to check for potential 
recombinants. All recombinants were passed through at least two rounds of 
plaque purifications to eliminated any wild type virus contamination. 
2.11. Adenovirus Growth, Propagation and Analysis 
Recombinant adenoviruses were amplified in 293 cells grown in culture and 
subsequently purified on a discontinuous caesium gradient if required. 
Recombinant purity was analysed using Hind II I restriction analysis of viral 
DNA. 
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2.11.1. Adenovirus Propagation 
Both replication competent Ad-5 dl309 and all the replication deficient 
adenoviruses were propagated in Human Embryonic Kidney (HEK) 293 cells. 
Cells were grown to 80-90% confluency in an appropriate tissue culture 
vessel and seeded with a known adenovirus stock at 106 pfu. Infected cells 
were incubated at 37°C with 5% CO2 for up to 7 days or until the appearance 
of cytopathic effect (cpe), apparent by the rounding up of cells and 
consequently forming of bunches and detaching from the surface of the 
culture dish. Cells were harvested at the stage where half the cells were 
rounded up and formed bunches and half rounded up but still adhering to the 
surface. Cells were scraped off using a cell scraper, transferred with the 
spent medium to a universal container and spun at 1000 rpm in alEC Centra-
7R centrifuge for 10 minutes. The cells pellet was resuspended in an 
appropriate volume of Dulbecco's PBS (with Ca++ and Mg++) and transferred 
to an Eppendorf tube. To obtain the virus, the cell suspension was freeze-
thawed in dry-ice and a 37°C waterbath 3-4 times, the cell debris removed by 
centrifugation at 8000 rpm for 3-5 minutes in a microfuge, and supernatant 
transferred into a fresh tube and labelled appropriately. This crude lysate was 
then either purified on a CsCI gradient or used per se. The crude virus 
suspension was titred for the amount of virus present before proceeding with 
its application. 
2.11.2. Titration of Adenovirus 
Purified virus solution or crude virus preparations were titred for their potential 
of forming individual plaques on 293 cells. This amount reflected the actual 
potency of the virus solution in terms of plaque forming units (pfu). The virus 
suspension was diluted serially down to a dilution of 10-14 in Dulbecco's PBS 
(with Ca ++ and Mg ++ ), and 100lli each of dilutions from 10-5 to 10-14 were 
used to infect 60 mm 293 cell dishes at 70-80% confluency. The dilutions 
were spread evenly over the monolayer by rotating and tilting the dishes and 
incubated at 3rC in a 5% CO2 atmosphere for 30-45 minutes. After the 
adsorption, all free running liquid was aspirated off the monolayer, and the 
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agar overlay was prepared: MEM (supplemented with 10% FCS, 2mM 
Glutamine, 100U/ml of Penicillin and 100flg/ml of Streptomycin) was warmed 
to 37°C and 0.2 volume of 3.2% Noble agar, melted and cooled to 38-40°C, 
was added and mixed thoroughly. The soft-agar medium was overlayed over 
the infected cell monolayer and allowed to solidify at room temperature for 
15-20 minutes. The dishes were observed daily for plaque formation. After 5-
6 days, all dilution plates which showed countable plaques were counted. 
The number of plaques appearing in a plate was multiplied by the dilution 
factor and two or three consequent dilution counts were averaged to give the 
plaque forming units (pfu) per ml. 
2.11.3. Plaque Purification of Adenoviruses 
The phenomenon of a chance recombination between the recombinant virus 
genome and E1A region in the 293 cells necessitates that all recombinants 
are plaque purified at regular time intervals to maintain the purity of the virus 
stock, and avert contamination by fortuitously forming replication competent 
viruses. Also new recombinants were subjected to three rounds of plaque 
purification immediately after their production. The virus lysate/suspension 
was diluted serially down to dilution of 10-8 in Dulbecco's PBS (with Ca ++ and 
Mg++), and 100fli each of dilutions from 10-2 to 10-8 were used to infect 60 
mm 293 cell dishes at 70-80% confluency, spread evenly over the monolayer 
and incubated at 3YOC in a 5% CO2 atmosphere for 30-45 minutes. After the 
adsorption, all liquid was aspirated off the monolayer, and the agar overlay 
was prepared: MEM (supplemented with 10% FCS, 2mM Glutamine, 100 
IU/ml of Penicillin and 100flg/ml of Streptomycin) was warmed to 37°C and 
0.2 volume of 3.2% Noble agar, melted and cooled to 38-40°C, was added 
and mixed thoroughly. The soft-agar medium was overlayed over the infected 
cell monolayer and allowed to solidify at room temperature for 15-20 minutes. 
The dishes were observed daily for plaque formation. After 5-6 days, several 
individual, well isolated plaques were picked and reinfected onto 293 cells for 
amplifying the virus as described in section 2.11.1. Part of the Iysates from 
these dishes were used to extract DNA and their Hind II I digest pattern 
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observed as described. Lysates showing the expected or non wild-type DNA 
Hindlll digest pattern were retained. Retained virus Iysates were diluted 1:4 in 
5X virus storage buffer (100mM NaCI, 50mM Tris-HCI, 5mM MgCI2, 0.5% 
bovine serum albumin (BSA), 50% glycerol), and frozen at -70°C in properly 
labeled tubes. The expected Hind II I digest pattern of a recombinant was 
determined using the Vector NTI software as described in section 2.16. 
2.11.4. Purification of Adenovirus Using CsCI Gradient Centrifugation 
Three to four 175 cm2 tissue culture flasks with 293 cells at 80% confluency 
were seeded with 108 titre virus stock at 1 ml per flask. The virus infected 
cells were taken through the steps of virus propagation to the cell lysate 
stage as describe previously. Cell lysate containing the high titre virus was 
then loaded on to a discontinuous CsCI density gradient prepared in a 14 ml 
transparent tube (Beckman Ultra-Clear™ Centrifuge Tube cat. no. 344060). 
The gradient was made by pipetting 2 ml of 1.45g/ml CsCI (20.5 g of CsCI, 
2.9 ml 500mM Tris pH 7.9, distilled water 25.8 ml) into the tube first followed 
by layering 3 ml of 1.32g/ml CsCI (32 g CsCI, 6.8 ml 500mM Tris pH 7.9, 
distilled water 61.2 ml). A third layer of 2 ml 40% glycerol (40 g glycerol, 
10mM Tris pH 7.9, 1mM EDTA pH 8.0) was pipetted gently onto the caesium 
layers and topped up with virus lysate. Any remaining space from the top of 
the tube was filled up with Dulbecco's PBS (with Ca ++ and Mg ++). The tubes 
were balanced and spun in LKB Bromma 2332 Ultrospin 85 ultracentrifuge 
using RPS40T-859 rotor at 25000 rpm for 1.5 hours at 4°C. The virus band 
was drawn out by piercing the side of the tube with a 18G hypodermic needle 
and the opalescent band with the virus was allowed to drip into a bijou bottle. 
The purified virus was desalted by dialysing against 10mM Tris pH 8.0, 1 mM 
EDTA for 3 hours to overnight with several buffer changes. The virus was 
titred and then stored in 1 X virus storage buffer using 5X virus storage buffer 
(see section 2.11.3.), and stored at -70°C. 
2.11.5. Small-scale Isolation of Viral DNA (minipreps) 
293 cells were grown as described in 60mm culture dishes, to a confluency of 
80-90% and overlayed with a plaque agar suspension, for screening of 
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recombinants, or with crude cell lysate of a high virus concentration (106_ 
108pfu/ml) or with purified viral solution. 100-150IlI of viral solution was 
layered on to the cell monolayer (per 60 mm dish) after aspiration of growth 
medium. After an incubation of 45 minutes with the virus suspension, MEM 
was added and cells incubated till the appearance if cpe and harvested as 
described in section 2.11.1. The cell pellet was resuspended in 600-750IlI of 
Dulbecco's PBS (with Ca++ and Mg++; Gibco-BRL cat. no. 140040) and 
transferred to a sterile 1.5 ml Eppendorf tube. The cell suspension was frozen 
on dry-ice and thawed in a 37°C waterbath with 3-4 repetitions to lyse the 
cells and release virus. Cell debris was removed by centrifugation in a 
microfuge at 8000 rpm for 3-5 minutes and the supernatant containing the 
released virus was collected. 
Cell Iysates containing virus were transferred to fresh Eppendorf tubes and 
digested with Proteinase-K (Sigma cat. no. P-2308) at 1 mg/ml in presence of 
5mM EDTA pH 8.0 and 0.5% SDS at 37°C for 4 hours. The digest mixture 
was phenol-chloroform extracted once, chloroform extracted and then ethanol 
precipitated as described in section 2.5.2. DNA was resuspended in 35-40IlI 
of TE and the solution RNase treated with 1 III of RNase (10 mg/ml). 25-301l1 
of the DNA was employed for restriction analysis, typically by Hindlll 
digestion where the restriction pattern was compared with that of the wild 
type Ad5-d1309 virus or with the known digest pattern of the recombinant 
virus. 
2.11.6. Transduction of Cells by Recombinant Adenovirus 
Cells grown in culture were infected with recombinant adenoviruses to 
establish expression of the transgene. Generally, the appropriate cell line was 
grown to 60% confluency in a 100mm tissue culture dish as described in the 
sub-section of section 2.8.4. The spent medium was aspirated off and 250-
300lli of adenovirus lysate or suspension, at a titre of 10-6 to 10-1°, was 
layered on to the cells and incubated for at least 45 minutes at 37°C. Fresh 
medium was pipetted on the infected cells and incubated at 37°C in a 5% 
CO2 incubator for 24 to 48 hours to allow for expression of the transgene. 
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The transduced cells were analysed qualitatively for gene expression by 
staining with appropriate stains or immunostaining, or harvested for protein 
analysis and western blotting. 
2.12. Gene Amplification and Analysis 
DNA amplification was generally done to obtain larger amounts of DNA for 
subcloning. peR was also used as a first screening step for checking plasmid 
and adenovirus recombinants. Southern analysis was performed to confirm 
recombinants with the appropriate DNA inserts. 
2.12.1. Polymerase Chain Reaction (PCR) 
Polymerase chain reaction was routinely used for amplification of DNA for 
obtaining high amount of insert DNA with specific restriction sites 
incorporated at either ends, facilitating directional cloning. Screening of 
positive recombinant plasmids with the inserts cloned and for checking for the 
presence of recombinant adenoviruses in a mixed population, or for 
contamination of wild type viruses in recombinant stocks, was also carried out 
using peR amplification using the appropriate primers. 
2.12.1.1. DNA Amplification 
A typical peR reaction was carried out in a total volume of 50/J1 using 
Promega peR kit (cat. no. 18038) with 1X peR buffer, 5mM Mg++, 200/JM of 
each dNTPs (made from a 5mM dNTPs mix prepared using 4 dNTPs, 
(Promega cat. no. U1240), 100 ng of template DNA, 1nmol each of the two 
primers. 
Proof-reading polymerase were also used to amplify DNA for subcloning 
purposes. Pfu polymerase (Stratagene cat. No. 600135) was used in a Pfu-
Taq mix of 1:6 and 1 :10. A typical 50/J1 reaction mix consisted of 1X pfu 
buffer, 200/JM each of dNTPs (made from a 5mM dNTP stock mix, 100 ng of 
template DNA, 1 nmol each of the two primers and 0.5/J1 of the polymerase 
mix. The EXPANDTM High Fidelity peR System (Boehringer Mannheim, cat. 
no. 1-681-834) was also used with similar concentrations of dNTPs, template 
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DNA and primers as described above for Pfu (for primer details, see table 
2.1 ) 
All PCR reactions was overlayed with a few drops of light mineral oil (Sigma 
cat. no. M-3516) and subjected to an appropriate thermal cycling program in 
a Hybaid Omni-gene thermal cycler. Thermal cycling programs were 
generally designed with an initial denaturing step at 94°C for 3-4 minutes. 
This was followed by 20-30 cycles of a 45 seconds denaturing at 94 C, 30 
seconds primer annealing and then an extension step at 72 C. Primer 
annealing temperature was kept at 3 to 5 C higher than the calculated 
annealing temperature for the primer pair. Primer extension time was kept at 
1 minute per kilobase of amplified product for Taq, and 1.5 minutes per 
kilo base for proof-reading polymerases. 
2.12.1.2. PCR Screening of Viral Recombinants 
For screening viral recombinants, the viral DNA was obtained as described in 
section 2.11.5. and 1/20th of the DNA used as template for PCR reactions as 
described in the previous section, using appropriate primers. The reactions 
and run on a 1 % agarose gel as described in section 2.4.3. and checked for 
the samples amplifying the DNA bands of the expected sizes. 
2.12.1.3. Screening of Recombinant Plasmids Using Colony PCR Method 
For screening plasmid recombinants for subcloning, the colony PCR method 
was used for primary screening. Several single colonies of transformed E.coli 
DH5a were picked using a sterile tooth pick, and each suspended in 50fll of 
sterile distilled water in a PCR tube. The same tooth pick was then spotted on 
to a fresh, grid-lined bacterial culture plate. This was done to keep the 
colonies viable for later use, and the tubes and corresponding spotted culture 
labeled correctly. The suspended bacteria were then heated at 95-99 C in the 
heating block of a thermal cycler, or boiled in a waterbath for 5 minutes and 
allowed to cool down to room temperature. The cell debris was pelleted by 
microcentrifugation for 2 minutes at 10,000 rpm, and 10fll of the supernatant 
carrying the plasmid DNA transferred to a fresh PCR tube. 
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The bacterial culture plate was incubated at 37°C for overnight and then 
stored at 4°C for storage. PCR reaction was performed using appropriate 
primers on the template DNA in the supernatant as described in the previous 
section. The amplified bands were run on a 1 % agarose gel as described in 
section 2.4.3. and the colonies amplifying the DNA bands of the expected 
sizes were retained for future use. 
2.12.2. Southern Blot Analysis 
DNA was digested with the appropriate enzymes and separated on a 1 % 
agarose gel as described in section 2.4.3. The gel was photographed after 
aligning with a fluorescent ruler, and the 1 kb ladder and any part not required 
was removed using a scalpel blade, before setting up the transfer. The 
transfer to Hybond-N+ membrane (Amersham International pic, cat. no. RPN 
303B), was carried out using O.4M, NaOH buffer as per instruction described 
in the protocol by Amersham. The pre-treatment recommended for DNA 
fragments greater than 10kb was not used due to the absence of any 
fragments of the size. The transfer process was done for 2-3 hours or 
overnight. After successful transfer of the DNA, the membrane was washed 
briefly in 2X SSC (300mM NaCI, 30mM Na citrate), with gentle agitation. Filter 
hybridization was carried out using the appropriate probe, labelled with 32p as 
described in section 2.5.5. The DNA hybridization was carried out using the 
method described in section 2.5.6. 
2.13. RNA Extraction and Purification 
RNA was extracted from isolated tissues or cells grown in culture to study 
expression levels of endogenous and foreign genes at the level of 
transcription. RT-PCR or Northern Blot analysis were used to detect the 
specific RNA species from total RNA isolated. 
2.13.1 RNA Isolation 
Total cellular RNA isolation from tissue samples and cells grown in 
monolayers using RNAzolTMB (Biogenesis Ltd, Poole, England). All tissue 
samples were frozen directly in liquid nitrogen and used immediately or 
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frozen at - 70°C to later use. Frozen tissue was placed in a sterile ceramic 
mortar with pestle which was pre-cooled to freezing temperature by rinsing 
with liquid nitrogen and kept on dry ice. 2 ml of RNAzolTMB was added per 
100 mg of tissue and the tissue crushed to break into smaller pieces and then 
homogenized into a paste consistency. 
Cells grown in monolayer were lysed directly in the tissue culture dish by 
adding 2 ml of RNAzolTMB per 60 mm dish. RNA was solubilized by passing 
the lysate through the blue tip of pipette of a micropipette, a few times. RNA 
extraction for both material was similar from this point onwards. The cell 
lysate/homogenate and transferred to Eppendorf tube. 0.1 volume of 
chloroform was added to the homogenate, capped and shaken vigorously for 
15 seconds and incubated on ice for 5 minutes. The suspension was 
centrifuged in a microfuge for 15 minutes at 4°C at 14000 rpm and the upper 
aqueous phase transferred to a fresh tube. An equal volume of isopropanol 
was added and the tube incubated on ice for 15 minutes. RNA was 
precipitated by centrifugation in a microfuge for 15 minutes at 14000 rpm. 
The supernatant was removed and the RNA pellet washed once with excess 
of cold 75% ethanol by vortexing and subsequent centrifugation for 8 minutes 
at 8000 rpm at 4°C. The pellet was dried briefly for 10-15 minutes, taking care 
not to over-dry, and then dissolved in appropriate amount of TE made in 
DEPC treated water. RNA was run on a 1 % agarose gel prepared with fresh 
TBE buffer and run in cleaned tank with fresh running buffer to check for the 
quality of RNA. If no degradation was observed, the RNA was stored at 
- 70°C until further use. 
2.13.2. Agarose Gel Electrophoresis of RNA 
A 1-1.5% (w/v) denaturing formaldehyde-agarose gel was made up by 
dissolving agarose in 10 ml of 10X MOPS (0.2M 3-[N-morpholino] 
propanesulphonic acid, 50mM sodium acetate, 10mM EDTA, adjusted to pH 
7.0) and 73 ml DE PC treated distilled water. This was allowed to cool and 17 
ml of 37% (v/v) formaldehyde added (final concentration of 0.66M 
formaldehyde) and EtBr was added to a final concentration of 5 I-lg/ml, the 
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solution mixed and poured into a gel mould. 15-20/lg RNA was used and 
samples were concentrated by ethanol precipitation and redisolving in 25/l1 
denaturation buffer (50% formamide (v/v), 1X MOPS, 6% formaldehyde) was 
added. This was heated at 65°C for 5 minutes, cooled on ice and 2.5/l1 of 6X 
loading buffer was added and the samples loaded into the wells and run in 
1 X MOPS buffer. 
2.14. Protein Analysis 
Analysis for the expression of recombinant proteins was carried out using 
SOS-PAGE and subsequent western blotting. Recombinant adenoviruses or 
plasmids were expressed in vitro. using cardiocytes or NIH-3T3 mouse 
fibroblasts systems, the total protein extracted and analysed for presence of 
the recombinant protein. 
2.14.1. Extraction of Proteins for Analysis 
Cells were infected with virus or transfected with expression plasmid vectors 
as described in section 2.11.6., and 48-72 hours later harvested for analysis. 
Cell monolayers were scraped off in Dulbecco's PBS and pelleted by 
spinning at 1000 rpm for 5-10 minutes in alEC Centra-7R refrigerated 
centrifuge. The cells were subjected to either a freeze-thaw cycle or 
detergent lysis followed by TCA precipitation of proteins. 
2.14.1.1. Cell Lysis by Freeze-thawing 
The cell pellet obtained above was resuspended in 700/l1 of distilled water 
containing 1X of protease inhibitor mix made using 1000X stock (40mg/ml 
PMSF; Sigma cat. no. P-7626, 1mg/ml Aprotinin; Sigma cat. no. A-1153, 
1 mg/ml Pepstatin A; Sigma cat. no. P-4265). The cells were subjected to 3 to 
4 cycles of freezing on dry-ice and thawing at 37°C. The cell lysate was 
microfuged briefly to pellet the cell debris and the supernatant collected. 
Protein concentration assay was done on these Iysates and the appropriate 
amount used for loading on the protein gels. 
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2.14.1.2. Detergent-lysis and TCA Precipitation 
The cell pellet was resuspended in 750/l1 of distilled water and 6.25/l1 of 2% 
(w/v) sodium deoxycholate added to lyse the cells followed by 250/l1 of 24% 
(w/v) Trichloroacetic acid (TCA) for precipitating the proteins. The reaction 
was kept on ice for 15 minutes with shaking every few minutes. The TCA 
precipitated protein was pelleted by centrifugation in a microfuge for 5 
minutes at 14000g. The supernatant was discarded and the 75/l1 of 1M Tris 
base (high alkalinity) was added and the Eppendorf tube left at room 
temperature for 30 minutes. The pellet was then resuspended by repeated 
vigorous pipetting and 75/l1 of SOS-sample buffer (40mM Tris, pH 6.8, 4mM 
2-mercaptoethanol, 2% SOS, 10% glycerol, 0.2% bromophenol blue) added 
and the protein mix and boiled for 10 minutes. The protein samples were 
loaded onto PAGE gels for resolving the proteins for western blotting or 
stored at -20°C for later use. 
2.14.2. Quantification of Proteins 
Protein concentrations were determined using the Bio-Rad Protein Assay Kit 
II (cat. no. 500-0002), following the Microassay procedure described in the kit 
protocol. Known standard dilutions of 3.5, 7.0, 14.0, 21.0 and 28 /lg/ml were 
made and 0.8 ml of these standard dilutions were mixed with 0.2 ml of Dye 
Reagent Concentrate in an Eppendorf tube and mixed thoroughly. 0.8 ml of 
sample buffer with .2 ml of Dye reagent was used as a blank. The test 
sample were diluted 1:4, 1:10 and 1:100 and 0.8 ml of these dilutions mixed 
with 0.2 ml of Dye reagent. Absorbance of the test samples and standard 
were measured at 595 nm wavelength against the sample buffer/reagent 
blank after a period of 10 minutes to 1 hour. A graph for absorbance versus 
concentration of standards was plotted. The test sample concentrations were 
read off from this standard curve, and final concentrations determined, taking 
the dilution factor into account. 
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2.14.3. 50S-polyacrylamide Gel Electrophoresis (50S-PAGE) of 
Proteins 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis was carried out 
in vertical slab gels for separating the proteins based on their molecular 
weights, mainly as a first step for carrying out immunoblotting. The gels were 
cast and run in a Hoeffer SE600 Electrophoresis Unit. The resolving gel was 
15% Acrylamide/bisacrylamide 29: 1 made up using 4X resolving gel buffer 
(1.5M Tris-HCI, pH 8.8, 0.4% SOS) polymerized with .01 volume of 10% 
ammonium persulphate and .001 volume TEMEO. The gel solution was 
mixed and poured into an assembled gel sandwich till about 1.5 cm from the 
top of the plate. A few ml of 0.1 % SOS was gently layered up to 1-3 mm 
above the gel, and left at room temperature for 1-2 hours, to allow for the gel 
to polymerize. The stacking gel was made as 5% Acrylamide/bisacrylamide 
29:1, made using 4X stacking gel buffer (0.5M Tris-HCI, pH 6.8, 0.4% SOS), 
polymerized with .01 volume of 10% ammonium persulphate and .001 
volume TEMEO. The comb is placed in position and the stacking gel poured 
above the resolving gel after it has polymerized. After polymerization of the 
stacking gel, the gel unit was transferred to a Hoeffer SE600 Electrophoresis 
Unit, with electrophoresis buffer (25mM Tris, 192mM Glycine, 0.1 % SOS, pH 
8.3). 20-40/Jg of protein mixture, prepared as described in section 2.14.1., 
was loaded per well and run along with Kaleidoscope Prestained Standard 
molecular weight markers (Biorad cat. no. 161-0324), at 80-100V for 3-4 
hours or at 40V overnight, for up to 16-20 hours. If required for western blot 
analysis, the separated protein bands in the resolving gel were transferred to 
a nitrocellulose membrane as described in section 2.14.5.1 and stained, if 
required, as described in section 2.14.3.1. 
2.14.3.1. Staining of SOS-PAGE Protein Gels 
The resolving gel was stained for visualizing protein bands, after the blotting 
process to check for evidence of transfer of proteins and to have a profile of 
the gel. The gel was soaked in Coomassie gel stain (1 % w/v Coomassie Blue 
R-250, 10% acetic acid, 45% methanol)and agitated gently for 10-15 
minutes, after which the stain was decanted gently and the gel rinsed with a 
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few changes of distilled water. The gel was then destained by submerging in 
Coomassie gel destain (10% methanol, 10% acetic acid) for up to 1 hour. For 
complete destaining, the destain solution was changed and left overnight with 
shaking. 
2.15. Analysis of Gene Expression in Transiently Transfected Cells 
Cardiocytes and mouse fibroblast cells were infected with recombinant 
viruses and the expression of the transgene analysed. Initially, 
~-galactosidase encoding adenovirus was used to transfect fibroblasts and 
later the adenovirus encoding skeletal troponin C, tagged with HA antigen, 
was used. Northern blot analysis was also carried out on some specific 
constructs. Western blot analysis was carried out for studying expression of 
the tagged protein. 
2.15.1. ~-galactocidase Expression and Staining 
Cells infected with ~-galactosidase-expressing adenovirus or transfected with 
a ~-galactosidase-expressing plasmid were qualitatively checked for 
expression of ~-galactosidase by staining the cells with X-gal. Cells were 
infected as described in section 2.11.6. and given 36-48 hours for expression 
of the reporter gene. Cells were then treated with Fixing solution (2% 
formaldehyde, 0.2% Gluteraldehyde in PBS) at 4 ml per 60 mm dish for 10 
minutes at room temperature. The fixed cells were washed twice with PBS 
and then stained with X-gal staining solution (1 to 5mM X-gal, 5mM 
Potassium Ferricyanide, 5mM Potassium Ferrocyanide, 2mM Magnesium 
Chloride). The dishes were incubated in a 5% at 37°C for at least two hours 
to overnight and observed for blue stained cells under the microscope. 
2.15.3. Reverse Transcribed - PCR 
Total RNA was isolated from transfected/infected cells grown in culture using 
RNAzolTMB as described in section 2.13.1. The RNA was reverse transcribed 
using MMLV Reverse Transcriptase using the Advantage™ RT-for-PCR Kit 
(Clonetech cat. no. K1402-1). The total RNA was reverse transcribed 
converting the population of mRNA molecules to cDNA by priming the RT 
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reaction with oligo(dT)18 primer. The cONA thus generated was used for PGR 
amplification using the appropriate specific primers using the method 
described in section 2.12.1. 
2.15.4. Northern Blot Analysis 
Total RNA was fractionated on a denaturing formamide/agarose gel as 
described in section 2.13.2., and transferred to Hybond-N+ membrane. 
Before proceeding with the transfer process, the integrity of the RNA 
separated was checked. This was done by visualizing the RNA under UV-
light in the presence of EtBr and looking for undegraded 28S and 18S 
ribosomal RNA bands. The gel was photographed with a fluorescent ruler 
aligned along the side of the gel. The marker ladder, if present, and any 
excess gel, was removed with a scalpel blade, before setting up the transfer. 
Transfer to the Hybond-N+ membrane was performed using the alkali transfer 
protocol outlined by protocols provided by Amersham. Transfer buffer was 
0.5M NaOH and the process was continued for 2-3 hours, followed by rinsing 
the blot with 2X SSG (300mM NaGI, 30mM Na citrate) gently. The filter was 
hybridized with the appropriate probe labelled with 32p as described in 
section 2.5.6. 
2.15.5. Western Blot Analysis 
The hemagglutinin (HA) epitope-tagged skeletal Troponin G expression was 
detected through western blotting by probing with the HA tag specific high-
affinity rat monoclonal antibody. 
2.15.5.1. Western Transfer 
Protein samples were resolved on a SOS-PAGE gel as described in section 
2.14.3. The electrophoretically resolved protein bands on the gel were 
electroblotted on to a ProBind 45 nitrocellulose membrane (Pharmacia 
Biotech, cat. no. 80-1247-86), and the expression of the protein of interest 
detected using immunochemical techniques. The resolving gel, the ProBind 
membrane and the foam were soaked in the transfer buffer (24mM Tris base, 
194mM glycine, 20% v/v methanol) and the gel and membrane were 
sandwiched between blotting paper and foam. The transfer was carried out at 
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room temperature in a Hoeffer FE Series Transphor Electrophoresis Unit at 
100V (constant voltage) for 1-1.5 hours or at 30V for overnight transfers. 
2.15.5.2. Immunodetection of Tagged Foreign Protein 
After the transfer of protein, the nitrocellulose membrane was washed a 
couple of times with Tris-buffered saline (TBS; 50mM Tris-HCI, 150mM NaCI, 
pH 7.5) and non-specific binding sites blocked by covering the membrane 
with 10 ml of Blocking solution (5% skimmed milk in TBS), with shaking for 2 
hours to overnight at room temperature. The membrane was washed 3 times 
with TBS and covered with the appropriate dilution of the protein or 
epitope-tag specific antibody and incubated overnight with shaking at 4°C. 
The membrane was washed 3 times with Wash buffer (TBS with 0.1 % 
Tween®20). and incubated with the compatible Horseradish peroxidase, 
(HRP)-conjugated secondary antibody, diluted in blocking solution, for 1-2 
hours with shaking. Membrane was washed once with washing buffer to 
remove any excess secondary antibody and then three times with TBS to 
remove traces of Tween®20. Excess wash buffer was dripped off for 30-45 
seconds and the membrane transferred to a shallow container with the 
protein side up. 1 ml each of solution A and B of the ECl Western Blot 
detection reagent kit (Amersham Life Sciences RPN-2109) were pipetted into 
one side of the container. The solutions were mixed thoroughly and the 
container tilted so that the surface of the membrane is evenly coated with the 
developing reagents. The membrane was then lifted up using a forcep, 
dripping off the excess liquid, and put in between two pieces of Saran-Wrap. 
The membrane was then immediately exposed to X-ray film for exposure 
times ranging from 5 seconds up to 10 minutes. 
2.15.6. Immunocytochemistry 
This method was specially used to detect the expression of the HA 
epitope-tagged sTnC protein, following the appropriate recombinant 
adenovirus infection on cells grown in tissue culture. For expression studies 
involving immunostaining, the cells were grown in Slide Flask (Nunc cat. no. 
170920) and grown overnight to 48 hours and then infected with the virus at a 
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titre of approximately 105 to 106 as described in section 2.11.6. After allowing 
48-72 hours for expression, the media was aspirated off and the cells were 
fixed with 1-2 ml of freshly prepared 4% paraformaldehyde (Sigma P-6148; 
w/v in PBS), for 10 minutes. The fixed cells were then washed three times 
with PBS allowing 3-5 minutes per wash, and the cells permeabilized by 
incubating with 0.1% Triton X-100 in PBS for 3-5 minutes at room 
temperature. Slides were washed once quickly with 0.1 % Triton X-100, made 
up in distilled water. Non-specific binding sites were blocked by incubating 
the permeabilized cells with the Blocking solution (0.5% Bovine Serum 
Albumin (BSA) Sigma A-4503, in PBS) for 15 minutes. 
Three procedures of immunocytochemistry, employing varying primary 
antibodies were tried to obtain optimal results. The (1) direct method used a 
primary antibody conjugated to a fluorochrome and (2) indirect method used 
unconjugated primary antibody with (a) secondary fluorochrome-conjugated 
antibody or (b) secondary antibody conjugated to biotin. 
2.15.6.1. The Direct Method 
The direct methodology for immunocytochemistry is time saving as it does 
not require the secondary antibody. The cells were grown and treated in a 
similar way as described above. After the permeabilization of cells and 
blocking for non-specific binding, an appropriate concentration of the 
Anti-HA-rhodamine (Boehringer Mannheim, cat. no. 1666959), diluted in 
blocking solution, was used to cover the cells and incubated for 30-45 
minutes. Rhodamine-labeled Phalloidin (Sigma P-1951) was also added 
along with the primary antibody at a concentration of 2!lg/ml to detect the 
cells by staining the actin cytofilaments. The cells were washed 3 times with 
PBS allowing 5 minutes per wash. The flaskeUe part of the slide flask was 
removed and a small drop of Aquamount (BOH 36226-2H) mounting medium 
was dropped on the cells and a clean coverslip placed gently on it avoiding 
any air bubbles being trapped. Any excess mounting medium was blotted off 
and allowed to dry in the dark, at room temperature. After drying, the slides 
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were stored at 4°C or at -20°C until screening under a fluorescent 
microscope using the appropriate filters. 
2.15.6.2. The Indirect Methods 
This method uses unconjugated primary antibody, with a choice of using a 
fluorochrome-conjugated secondary antibody or a biotin-conjugated 
secondary antibody. The biotin-conjugated secondary requires a third 
streptavidin-enzyme or a streptavidin-fluorochrome conjugate. The 
streptavidin-fluorochrome conjugate can be visualized directly, whereas the 
streptavidin-enzyme conjugate is detected using a color development staining 
system. 
2.15.6.2.i. Using Fluorochrome-conjugated Secondary Antibody 
The appropriate cells were grown, infected, and then permeabilized and 
blocked as described above. Following the blocking step, cells were 
incubated with the Anti-protein or Anti-tag mouse monoclonal primary 
antibody in the appropriate dilution made in the blocking solution, for 30 
minutes at room temperature. Phalloidin TRITC (Sigma P-1951) was also 
added as described earlier. The cells were washed three times with PBS and 
incubated with a suitable dilution of the Anti-mouse IgG (whole molecule) 
TRITC-conjugate (Sigma T-2402) secondary antibody for 30 minutes at room 
temperature. Cells were washed three times and the immunostained cells 
mounted by covering with a drop of Aquamount mounting solution and 
placing a coverslip on it. The cells were examined under a fluorescence 
microscope fitted with the appropriate filters or the slides stored at -20°C in 
the dark for later observations. 
2.15.6.2.;;. Using Biotin-conjugated Secondmy Antibody 
This method uses a three-step immunostaining protocol followed by detection 
by Vector® Red staining which can be visualized under an ordinary 
microscope. Cells were grown, infected and permeabilized and blocked as 
described in section 2.15.6. Following the blocking step, cells were incubated 
with the High-Affinity Anti-HA primary antibody (Boehringer Mannheim cat. 
no. 1867423), in the appropriate dilution made in the blocking solution, for 30 
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minutes at room temperature. The cells were washed three times with PBS 
and incubated with appropriate dilution of the Anti-rat Ig-biotin F(ab'h 
fragments secondary antibody (Boehringer Mannheim cat. no. 1348779), 
made in blocking solution, for 30 minutes at room temperature. Cells were 
again washed three times and then incubated with a dilution of 
Streptavidin-Alkaline Phosphate conjugate (Boehringer Mannheim cat. no. 
1089161), made in blocking solution, for 10 Minutes. Cells were again 
washed three times, with PBS and stained as described in section following. 
2.15.6.2.ii.a. Vectol'® Red Staining and Countel'staining 
The alkaline phosphatase immunolabeled cells were then stained using the 
Vector® Red Alkaline Phosphatase Substrate Kit (Vector Laboratories cat. no. 
SK-5100). The Vector® Red substrate working solution was made by adding 
2 drops each of the Reagents 1,2 and 3 of the kit to 5 ml of assay buffer 
(100mM Tris-HCI, pH 8.2 treated with levamisole, Vector® Red, cat. no. 
SP-5000, to inhibit endogenous alkaline phosphatase activity). The substrate 
working solution was made immediately before use and the cells incubated 
with the solution at room temperature, in the dark for 20-30 minutes. After the 
required staining intensity was reached, the cells were washed with assay 
buffer for 5 minutes and then rinsed with distilled water. The cells were then 
counterstained with hematoxylin to stain the nuclei. A few drops of Haemlum 
(Mayer's) solution (BDH cat. no. 35060-4T) was dropped onto the slides and 
incubated for 15-20 seconds and washed of with distilled water. Slides were 
then rinsed with 100% ethanol for 2-5 minutes to increase the intensity of the 
Vector® Red fluorescence if required. Excess liquid was tapped off from the 
slide and the cells mounted using Aquamount (BDH 36226-2H) and 
examined under a light microscope or kept at 4°C for later observations. 
2.16. Vector NTI Software 
The Vector NTI Molecular Biology Software (InforMax Inc. Maryland, USA) 
was used for maintaining the information database and performing electronic 
manipulations on all DNA molecules. Data for all plasmids, adenoviruses and 
Ad5-recombinants was maintained in the Vector NTI software's Molecule 
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manager whereas, sequencing oligonucleotide and PCR primer database 
was maintained in the Primer Manager. 
All the adenoviral plasmid shuttle vectors, additional intermediate plasmids, 
commercially obtained plasmids and cDNA sequences employed in the 
construction of these, were obtained from various sources. The source of the 
Troponin C cDNA sequences, the commercial vectors, the wild-type 
adenovirus 5 genome was Genbank EMBL., which was accessed using a 
GCG package version 9 available on the Glasgow University UNIX 
mainframe. The sequences for adenovirus shuttle vectors obtained from 
Microbix were purchased from the same company on disks and were entered 
into the Vector NTI database. Most plasmid entries were modified to present 
the plasmids diagramatically, clearly showing restriction enzyme sites, 
genetic markers and functional maps. 
Typically, adenoviral shuttle vector for making Ad5 recombinants, were made 
following the cloning steps carried out in actual benchwork, using the simple 
cutting and pasting functions of the Microsoft® Windows® environment. 
Recombinant adenoviruses were then constructed by manipulation of these 
vectors and Ad5-d1309 genome sequences in a similar manner. 
As the sequence for dl309 mutant genome of adenovirus 5 was not available 
from any accessible databank, Ad5-d1309 sequence was extracted out from 
the sequence of the Ad5-d1309 genome-carrying plasmid vector pJM17 
(sequence obtained from Microbix Biosystems Inc.). The pBR322 bacterial 
plasmid sequence of pJM17 was removed by cutting out the Xbal fragment of 
the plasmid and rejoining cohesive Xbal ends to circularize the adenoviral 
DNA. The circular Ad5-d1309 genome was then linearized beginning at 0 mu 
of the adenoviral genome. 
Representation of molecular structures of recombinant adenoviruses were 
made by joining the appropriate shuttle vector and the Ad5-d1309 genome, 
simulating the outcome of a single recombination event between homologous 
regions of shuttle vector and the adenovirus genome. For this purpose, the 
fragment inclusive of bp 1 to the first Sacl site downstream of the SV40-polyA 
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sequence, of the appropriate shuttle vector which carries the foreign gene, 
was copied to the clipboard. This fragment was then pasted immediately 5' to 
the Sacl site at bp 3644 of the Ad5-d1309 genome. The resulting genome is a 
representation of the actual recombinant carrying the gene of interest. A 
Hindlll digest pattern for this recombinant was obtained by using the Vector 
NTI's Analyse/Restriction Site function. This pattern was checked against the 
Hindlll cut fragments of the actual recombinants. 
Vector NTI was also employed for the design of some PCR primers used in 
the study. Primer duplex analysis was also carried out on some previously 
made, empirically designed primers, using the software's PCR primer analyse 
function. 
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Table 2.1.A: DNA Oligonucleotides Used as peR Amplification Primers 
• Troponin C Primers 
Primer name size Description Sequence (5' -;. 3') 
[pair] in Hybridization Location and degenerate bases are bases Orientation shown in italics: Restriction 
sites are underlined 
5' primer incorporating an GGTGGAGTGCGA G153583 34 EcoRI site, used for amplifying 
[C88303 T43429 and full length and some truncated ATTCGGCGACCT sTnC cDNAs. 
C166762] 
bp 27-44 forward GCAACAGAGG 
3' primer for G153583; CACCCTAGGGAG C88303 34 incorporates a 8gll1 site 
[G153583] bp 558-575, reverse ATCTGATCTTGG 
TAGAGGCGAC 
3' primer for modifying the CTTCAGGAAAGA T43429 36 sTnC cDNA to delete the last 
12 amino acid codons and GATCTCGTCAAT [G153583] contains a 8g11/ site. The oligo 
was designed for substituting GCGGCCGTCGTT 
the last 12 codons with HA 
epitope tag sequence 
bp 491-508, reverse 
3' primer for modifying the CCATCATCTTAGA C166762 40 sTnC cDNA, by deleting the 
last 9 codons and substituting GATCTCCTCGTC [G153583] a HA epitope tag sequence: 
Adds a 8g11/ site. GAAGTCAATGCG 
bp 479-517, reverse GCC 
5' primer with characteristics AACAAGACTACTC A1901D04 42 similar to G153583 with an 
extra Xhol site, upstream of GAG GAATTCGGC (s TnC:XhoIiEcoRI) the EcoRI site 
bp 27-44 forward GACCTGCAACAG 
AGGAG 
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Table 2.1.A: DNA Oligonucleotides Used as peR Amplification Primers 
eTroponin C Primers (continued) 
Primer name size Description Sequence (5' ~ 3') 
[pair] in Hybridization Location and degenerate bases are shown bases Orientation in italics: Restriction sites are 
underlined 
5' primer for amplifying full TCATAGTAGAATTC 1669-077 32 length and truncated sTnC 
(sTnC/EcoRI:T-tag) cDNAs, incorporating an TGGAGTGCAAAG EcoRI site. This primer was 
designed to produce SV40 GAGGCG 
large T -antigen epitope 
[sTnC:d8-TlNhel, tagged sTnC cDNA. 
sTnC fulllNheI] bp 13-30 fOlWard 
3' primer for modifying the TCATAGTAGCTAG 1669-073 34 sTnC cDNA designed to 
delete the last 8 codons, (:GAACTCGTCGA (sTnC:d8-T/Nhel) adding a Nhel site and 
substituting with T -antigen AGTCAATGC 
epitope tag sequence 
[s T nC/EcoRI:T -tag] bp 500-520, reverse 
3' primer for modifying the TCA TAG TAG C TA G 1669-074 33 sTnC cDNA by deletion of the 
(sTnC-fuIl/Nhel) last 9 codons for substituting (:CTGCACGCCCTC with HA epitope tag 
sequence: Adds a Nhel site. CATCATC 
[sTnC/EcoRI:T -tag] bp 526-544, reverse 
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Table 2.1.B: DNA Oligonucleotides Used as peR Amplification Primers 
-Adenovirus Primers 
Primer name size Description Sequence (5' --> 3') 
in Hybridization Location and [pair] bases Orientation 
5' primer hybridizing to adenoviral CGGGAAAACT Ad5280-99 20 sequences upstream of the foreign 
insert; designed for screening Ad5 GAATAAGAGG 
[Ad53580-98;rev] recombinants and inserts in 
adenoviral shuttle vectors 
bp 280 to 298 forward 
3' primer hybridizing to adenoviral GCTGCTGCAA Ad53580-98;rev 19 sequences downstream of the 
foreign insert! poly A sequence, for AACAGATAC 
[Ad5 280-99] screening Ad5 recombinants and 
inserts in adenoviral shuttle vectors 
bp 3580 to 3598 reverse 
Ad5-E1A:629/for 5' primer hybridizing to adenoviral ATCGAAGAGG 20 sequences within the E1A region: 
[Ad5-E1 :1045/rev] Used to screen presence of E 1 A TACTGGCTGA 
region in recombinants 
bp 629 to 648 forward 
Ad5-E 1: 1 045/rev 20 3' primer hybridizing to adenoviral CCTCCGGTGA 
sequences within the E1A region: 
[Ad5-E1A:629/for] Used to screen presence of E1A TAATGACAAG 
region in recombinants 
bp 1026 to 1045 reverse 
Ad5-E1;for 18 5' primer hybridizing to adenoviral CTGTGGAATG 
sequences within the E1A region: 
[Ad5-E1 ; rev] Used to screen presence of E1A TATCGAGG 
region in recombinants 
bp 1469 to 1486 forward 
Ad5-E1;rev 18 3' primer hybridizing to adenoviral TCAGACAGGA 
sequences within the E1A region: 
[Ad5-E1 ;for] Used to screen presence of E1A TACCCAAG 
region in recombinants 
bp 2951 to 2968 reverse 
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Table 2.2: DNA Oligonucleotides Used as Sequencing Primers 
Primer name size Gene Location Sequence (5' ~ 3') 
in and bases 
Orientation 
G182861 18 skeletal bp 94-76 GGACCTGGCCTCAGC 
Troponin C reverse 
CTG 
G182927 18 skeletal bp 514-529 GACGAGTTCCTGAAG 
Troponin C forward 
ATG 
C929111 19 skeletal bp 411-429 TGGCTGAGATTTTCA 
Troponin C forward 
GGGC 
sTnC (200-214) 15 skeletal bp 200-214 ATGCTGGGCCAGACA 
Troponin C forward 
sTnC 18 skeletal bp 262-245 CTGCTCATCCACCTC 
(262-245/rev) Troponin C reverse CTC 
sTnC (233-247) 14 skeletal bp 233-247 GA CGCCATCATCGA 
Troponin C forward 
sTnC 15 skeletal bp 368-382 ATCTTCGACAGGAAT 
(368-382/for) Troponin C forward 
sTnC 15 skeletal bp 382-368 ATTCCTGTCGAAGAT 
(382-368/rev) Troponin C reverse 
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Table 2.3: DNA Oligonucleotides Used for Epitope Tagging 
size Sequence (5' ~ 3') . Primer name Description 
in 
bases 
A80698 39 sense oligo for 3 codon GATCTCTTACCCTTAT 
spacer and 9 codon 
influenza virus GATGTCCCTGACTAC 
hemagglutinin antigen 
epitope tag sequence GCCTAAGA 
terminating in a stop 
codon 
A80716 39 complementary GATCTCTTAGGCGTAG 
antisense oligo for 
A80698: The resulting ds TCAGGGACATCATAAG 
DNA has protruding 
termini for ligation to 8g1/1 GGTAAGA 
cut vector/cDNA ends 
1669-075 27 sense oligo for 2 codon CTAGACCCCCCGAGC 
T-tag: spacer and 6 codon SV40 large T-antigen CCGAGACCTAAG Xbal/BamHI/TOP epitope tag sequence 
terminating in a stop 
codon 
1669-076 27 complementary GATCCTTAGGTCTCGG 
T-tag: antisense oligo for T-tag:Xbal/BamHI/ TOP: GCTCGGGGGGT Xbal/BamHI/ The resulting ds DNA 
BOTTOM has protruding termini for 
ligation to Xbal at the 5' 
end and 8amHI at the 3' 
end 
A1901D05 44 3' primer complements to TCATTCGATGGGATC.c the last 8 codons of the 
HA-tag:/BamHI HA epitope tag CTTAGGCGTAGTCAG sequence, designed to 
modify the 3' 8gll1 site to GGACATCATAAGG 
8amHI site, facilitating 
the subcloning of HA 
tagged cDNA with raised, italicised letters 
different cDNAs indicate the mismatched bases 
_ .. _------ .. __ .. _ ..... - ... -
-
• sequence underlined present the 5' protruding termini; double underlined 
sequence shows the stop codon. Bold letters show the coding sequence 
of epitope tags. 
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Chapter 3 
3.0 Subcloning of Promoters and cDNA into Adenoviral Shuttle 
Plasmids 
Skeletal Troponin C cDNA was subcloned into a range of shuttle plasmids 
with ubiquitous and tissue specific promoters. A typical foreign DNA insert in a 
shuttle vector comprised of (5' to 3') a promoter and a sTnC cDNA followed 
by SV40-polyA sequence. sTnC cDNA was first cloned into intermediary 
vectors, then removed by cutting with restriction enzyme sites available in the 
intermediary vector, and then ligated into shuttle vectors. Tissue-specific 
promoters were cloned directly into the shuttle vectors from their source 
plasmids, followed by inserting the sTnC cDNA from the intermediate vector. 
The promoter-cDNA cassette was then cut out and inserted into a basic 
promoter vector with the SV40 polyadenylation signal completing the entirety 
of the insert. Some clones were made using PCR amplification of the cDNA, 
incorporating specific restriction enzyme sites at either ends of the product, 
thereby facilitating cloning. 
3.1. Subcloning of SV40-polyA Signal into Basic Adenoviral Shuttle 
Vectors 
Vectors p~E1sp1A and p~E1sp1B do not have the SV40-polyA sequences 
necessary for mRNA stability. These sequences were cloned in from pCA 13 
and pCA14. p~E1sp1A was cut with Xhol and 8g/l1 (see section 2.4.4.), and 
the large gel fragment separated and gel purified: The Xhol/8g/l1 fragment, 
containing the SV40-polyA sequences and part of the MCS was cut out from 
pCA14, gel purified and ligated (see section 2.4.9.) to the p~E1sp1A 
backbone. This ligation restores the MCS and in addition adds the SV40-
polyA 3' to the MCS (See figure 3.1). Similarly, p~E1sp1B was cut with 
Hindlll and 8g/11 and the backbone ligated to a Hindlll/8g/il fragment from 
pCA 13 carrying the SV40-polyA sequence. In both cases, positive clones 
were screened by cutting with CIa I and 8g/ii. The new clones were 
designated as p~E1sp1A-polyA and p~E1sp1B-polyA. Positive clones were 
sequenced for confirmation of the correct MCS insert and the ligation 
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junctions, using primer Ad5 280-99, before proceeding with further cloning. 
Vectors pL\E1 sp1A-polyA #5 and pL\E1 sp1 B-polyA #8 were retained for 
further subcloning purpose. 
ORI 
Ssp! 
AP, 
'''-..''' 
PL'l E1sp1A 
6409 bp 
/ 
Xba! 
RV 
EeoR! 
'Hind JJJ 
SaIl 
BgI II 
Sac I 
Ad 6 sequence 
, Sac I 
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BamH! S Bgl II 
, ac! 
Xho! \ \ Ad 5 sequence 
Ssp I 
/ 
Xba! \ ~\CMV pr6moter 
Eco RV \' ( 
EcoR! _~~ ~-=~ AP, 
H1I1d JII-
Salr 
SV40 
Sac 
Ad 5 sequence 
Sac I 
pCA-14 
6952 bp 
MCS + polyA fragment is 
ligated into compatible ends 
of 'p~E1sp1A. 
CIa I 
BamHI 
Xhol 
The partial MCS and full SV40 
polyA cassette was removed 
from pCA14 by digesting with 
XhoI and BglII fragment 
Xbal 
.. Eco RV 
',- =~~'~~-~--EcORI 
"E1(1.0-9~~i~:- Hind III 
PL'l E1sp1A-polyA 
6561 bp 
" 
'\ SaIl 
'\ SV40 POLY A 
\"BgI II 
! Sac I ,
J Ad 5 sequence 
;)' 
/ 
/7 
--------,/X: , Sac! 
The adenoviral shuttle 
vector pAE1sp1A-polyA 
retains its original MCS 
and in addition has the 
SV40 polyA sequences 
Fig 3.1: Schematic presentation of steps involved in subcloning of SV40-polyA sequence 
from pCA14, into pAE1sp1A. Similar strategy was also carried out for pAE1sp1B 
(see section 3.1.1.). 
3.2. Subeloning of Skeletal Troponin C eDNA 
The source of the skeletal Troponin C cDNA was pLK419, obtained from Larry 
Kedes' Lab., University of Southern California, CA, USA. This cDNA was 
isolated from a human muscle cDNA library by R. Gahlmann et al and 
completely sequenced (Gahlmann et al' J 1988). The entire sequence of 
skeletal Troponin C cDNA has been published and available from Genbank 
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(accession no. X07898). The cDNA comprised of 677 bp sequence with a 64 
bp 5' untranslated region (UTR) from bp 1-64, a 483 bp coding region from bp 
65 to bp 547 and a 130 bp 3' UTR ranging from bp 548 to 677. The sTnC 
cDNA was cloned into the shuttle vectors with ubiquitously expressing CMV-
IE promoter and with different tissue-specific promoters. 
3.2.1. Subcloning of cDNA into Vector with Ubiquitous Promoter 
The sTnC cDNA was subcloned into adenoviral shuttle vectors with CMV-IE 
promoter, using PCR amplification and direct subcloning of a fragment of the 
cDNA. Both pCA 13 and pLECM vectors were used for this purpose. 
3.2.1.1. Using peR-amplified DNA 
The skeletal Troponin C cDNA was PCR-amplified on plasmid LK419 
template, using 5' primer G153583 which incorporates an EcoRI site, and the 
3' primer C88083 adding a 8g/11 site (see table 2.1.A.) using conditions 
described in section 2.12.1. The PCR product was separated on an agarose 
gel, purified and cut with EcoRI and 8g/ilo pLECM vector was cut with the 
same pair of restriction enzymes and gel purified to lose the smaller fragment 
and the EcoRlI8g/ll-cut PCR product ligated to the vector. The positive clones 
were checked out using EcoRI/8g/il which cuts out the whole 500kb cDNA 
fragment. Six positive clones were obtained and were designated 
pLECM/sTnC and screened further by sequencing (see section 2.7.), for the 
integrity of the inserted PCR product. One clone was retained for further use 
as it was found to contain no mutations. 
Another similar clone of skeletal Troponin C was made using the cloned and 
sequenced PCR product from pLECM/sTnC. This was done to obtain a clone 
having SV40-polyA sequence at the 3' end of the sTnC gene. The EcoRII8g/il 
insert fragment was cut from pLECM/sTnC and ligated into pCA 13 vector, 
which was cut with EcoRI and 8amHI and gel purified to lose the small MCS 
oligonucleotide. The new plasmid was named pCA 13/sTnC and two clones 
were retained for further use. 
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3.2.1.2. Using cDNA Fragment via an Intermediary Vectors 
The fortuitous occurrence of a BstEIl site just upstream of the translational 
start site in the sTnC cDNA, and of an Avril site downstream of the stop 
codon, was exploited for cloning of the cDNA into various vectors via an 
intermediary vector pSP72 (Promega cat. no. P2191; Genbank Accession no. 
X65332) 
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Fig. 3.2: Flowchart highlighting the main steps involved in subcloning of skeletal Traponin 
C cDNA, into intermediary vector pSP72. 
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The sTnC cDNA containing fragment was cut using BstE11 and Avril and gel 
purified by electroelution, as described in section 2.4.5., and then blunt-ended 
using Klenow as described in section 2.4.7. The pSP72 vector was cut with 
Smal and the blunt ends de phosphorylated (see section 2.4.8.), to prevent 
self-ligation. The vector was cleaned using the Micropure EZTM columns and 
the sTnC carrying insert ligated into the blunt ends produced by the Smal cut 
(see fig. 3.2). Positive clones with sTnC cDNA were checked out by cutting 
with the flanking restriction enzyme sites EcoRI and Xbal. The positive cloned 
were further screened for the orientation of the insert by cutting with Xbal and 
Styl: The cDNA inserted in a clockwise orientation produced a 364 bp and a 
181 bp fragment, while the anticlockwise orientated insert showed a 364 bp 
fragment only. A clockwise orientation clone pSP72/sTnC(+) and an 
anticlockwise-inserted clone pSP72/sTnC(-) were selected for further cloning 
purposes. 
3.2.1.2.i. Subcloning cDNA Fragment from Intermediary Vector 
Skeletal Troponin C cDNA was cut from the intermediary vector 
pSP72/sTnC(-) with EcoRI and BamHI and ligated to pCA13 vector cut with 
the same enzyme pair. Positive clones were screened by cutting with BamHI 
and Sstl (Sacl). Positive clones showed a 2 kb and a 953 bp fragment. Five 
positive clones were retained for sequencing the ligation junctions and were 
retained for generating recombinant adenovirus. 
3.3. Subcloning of Tissue-specific Promoters into Shuttle Vectors 
Tissue-specific promoters were inserted into adenoviral shuttle plasm ids as 
first step to obtain promoter-cDNA cassettes which express specifically in 
cardiocytes and myocytes. 
3.3.1. Human Cardiac Actin Promoter Subcloning 
The upstream region of the human cardiac actin (HCA) gene has been 
characterized and cloned (Minty and Kedes, 1986). The cloned DNAs were 
obtained in plasmids LK339 (human cardiac actin; -177 to +70) and LK359 
(human cardiac actin; -485 to +70). Promoters were flanked by EcoRI and 
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Hindlll at the 5' and 3' end of the promoters respectively, in both the 
plasmids. The complete promoter sequence has been published and available 
from the Genbank database (accession no. M13483). 
The human cardiac actin (HCA) promoters, both -177 (-177 to +72) and -485 
(-485 to +72) were cloned into the vector pi1E1sp1A by removing the 
promoters from LK339 and LK357 by cutting with Hindlll and EcoRI and 
ligating to the compatible sites in pi1E 1 sp 1 A. The positive clones were 
checked by cutting with HindllllEcoRI and with Sst I to confirm the presence of 
the promoters in an adenovirus shuttle plasmid. HindllllEcoRI digest showed 
a 259 bp fragment in HCA (-177) and a 549 bp fragment with HCA (-485): 
The Sstl digest cut out a 2 kb fragment, characteristic of the adenoviral shuttle 
vector. The new HCA promoter vectors were designated p1A/HCA (-177) and 
p1A/HCA (-485) and were used for cloning sTnC cDNA. 
3.3.2. Human Skeletal Actin Promoter Subcloning 
The regulatory upstream region of the human skeletal a-actin gene have 
been characterized, cloned and partially sequenced by Taylor, A. et al (Taylor 
et al., 1988). Plasmid clones with two versions of human skeletal a-actin 
promoter were obtained from Larry Kedes' Lab., University of Southern 
California, CA, USA. Plasmid LK496 carried the -1282 to +239 bp of the 
human skeletal a-actin promoter as a 5' Xbal - 3' Hindlll fragment. LK480 
carried the -2000 to +239 region of the gene flanked by Hindlll on either side 
of the promoter. The sequence for the promoter up to -708 has been 
published (Taylor et al., 1988) and available from the Genbank database 
(accession no. M20543). Sequence from -1282 to -709 was obtained from 
Larry Kedes' Lab., University of Southern California, CA, USA. 
The skeletal actin -1282 promoter (-1282 to +239) was cut out as a 
XballHindll1 fragment from plasmid LK496. This fragment was ligated into the 
compatible ends of pi1E 1 sp 1 A and positive clones checked by cutting out the 
same 1520 bp fragment. The plasmid was named p1A/skact(-1282) . 
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The skeletal actin -2000 promoter (-2000 to +239) was cut out as a 2.3 kb 
Hindlll fragment from plasmid LK480 obtained from Larry Kedes' lab. This 
fragment was ligated into pL1E1 sp1 B Hindlll cut and dephosphorylated and 
positive clones screened by cutting with Xbal: The clones with the insert in 
the right orientation showed a 1520 bp fragment. This plasmid vector was 
named p1 B/skact(-2000). 
3.4. Subcloning cDNA with Tissue-specific Promoters 
Troponin C and p-galactosidase cDNA were subcloned with tissue specific 
promoters in a two-step cloning procedure to ensure the presence of SV40-
polyA sequence with the cDNA. was first subcloned into vectors with the 
relevant promoter and then the whole promoter-cDNA was removed and 
inserted into a pL1E1 sp1A-polyA or pL1E1 sp1 B-polyA adenoviral shuttle 
plasmid. 
3.4.1. Cardiac actin promoters with sTnC cDNA 
Skeletal Troponin C cDNA was cloned into the HCA promoter carrying 
adenoviral shuttle vectors, by first cutting out the sTnC cDNA from 
pSP72/sTnC(+) as a SaIl 18g/11 fragment and ligating into compatible ends of 
both p1A/HCA(-177) and p1A/HCA(-485). The new clones were named 
p1A/HCA(-177)/sTnC and p1A/HCA(-485)/sTnC. Positive clones were 
analyzed by cutting with EcoRI; the p1A/HCA(-177)/sTnC cut out a 785 bp 
fragment and the p1A/HCA(-485)/sTnC gave a 1115 bp band. Seven clones 
of p1A/HCA(-177)/sTnC and seven of p1A/HCA(-485)/sTnC were positive 
and were kept for later use. 
Finally, the promoter-cDNA cassette was cloned into a vector with the SV40-
polyA sequence. The pL1E1sp1A-polyA was cut with EcoRI and 
dephosphorylated to prevent recircularization of the plasmid. From 
p1A/HCA(-177)/sTnC and p1A/HCA(-485)/sTnC the promoter-cDNA cassette 
was cut out with EcoRI cutting at the 5' end of the promoter and downstream 
of the sTnC cDNA, and ligated to the EcoRI-linearized pL1E1 sp1A-polyA. 
Positive clones were initially screened by cutting out the insert with EcoRI. 
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New plasmids were named p1A/HCA(-177)/sTnC/pA and 
p1A/HCA(-485)/sTnC/pA. Those showing inserts of the right size were further 
screened for the orientation of the insert by cutting with BamHI and Sstl. 
Inserts with the right orientation, in case of p1A/HCA(-177)/sTnC/pA showed 
fragments of 297 bp and 560 bp and for p1A/HCA(-485)/sTnC/pA, 580 and 
560 bp, along with the characteristic 2 kb Sstl fragment of the parent shuttle 
vector. Seven clones of p1A/HCA(-177)/sTnC/pA and three of p1A/HCA(-
485)/sTnC/pA were retained for making adenovirus recombinants. 
3.4.2. Skeletal Actin Promoters with sTne eDNA 
pSP72/sTnC(+) was used to cut out a BamHI and Bg/li fragment carrying the 
sTnC cDNA and this was ligated to a p1A/skact(-1282) vector, linearized with 
Bg/li and de phosphorylated to prevent self-ligation. The presence and 
orientation of the insert was determined by cutting with Sstl: Insert with the 
right orientation produced fragments of 1420 bp and 150 bp. The new plasmid 
was named p1A/skact(-1282)/sTnC and four clones were retained for future 
use. 
As a final step, the 2112 bp Xbal/EcoRI fragment which comprised of the 
promoter-cDNA cassette, was cut out from a randomly chosen clone of 
p1A/p1A/Skact(-1282)/sTnC and ligated to compatible sites in pilE1sp1A-
polyA. (See figure 3.3) Clones were screened by cutting with Sst I which cut 
out a 1420 and 290 bp fragment from the positive clones: Five clones were 
obtained and one randomly chosen to generate an adenovirus recombinant. 
For cloning of sTnC with larger human skeletal a-actin promoter, the 
pSP72/sTnC(-) was used to cut out a EcoRI and BamHI fragment carrying 
the sTnC cDNA. This fragment was ligated to a p18/skact(-2000) vector, 
which had been cut with the same enzyme pair. Positive clones were 
screened for the presence of insert by cutting with Sstl which produced 
fragments of 2 kb, and a doublet of 888/820 bp. The new plasmid was named 
p1A/skact(-2000)/sTnC, for which four clones were retained. 
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Fig 3.3: A typical strategy adopted for subcloning of sTnG fragment from pSP72/sTnG 
intermediary vector into adenoviral shuttle vectors with tissue-specific promoters. 
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Finally, the complete promoter-cDNA cassette was cut out from a randomly 
chosen clone of p 1 B/skact( -2000 )/s TnC as a CIa 1/ 8g/l1 fragment and ligated 
to compatible sites in p~E1sp1B-polyA. Clones were screened by cutting with 
Styl, which cuts out a 1276 bp and a 330 bp fragment in positive clones in 
addition to 3 fragments of the parent vector sized 685, 998 and 1100 bp: Five 
clones were obtained and one randomly chosen to generate an adenovirus 
recombinant. 
3.5. Subeloning of Epitope-tagged Troponin C eDNA 
Epitope tags were incorporated at the carboxyl end of the Troponin C protein 
by altering the 3' end of the sTnC cDNA. Double-stranded oligonucleotides 
encoding the amino acids of the epitopes were generated and ligated to a 
truncated PCR amplified sTnC cDNA: The template plasmid was LK419 and 
specially designed primers having the desired restriction enzyme sites were 
used for the amplification. Two kinds of epitope tags were added to the 
Troponin C protein; the influenza virus haemagglutinin epitope tag (HA-tag) 
and the SV40 large T antigen epitope tag (T-tag). 
3.5.1. Subeloning of HA-epitope-tagged sTnC eDNA (sTnC:HA) 
The influenza virus epitope tag sequences (Wozniak et al., 1994) were added 
to the 3' end of the skeletal Troponin C cDNA, by substituting the last 12 
codons of the sTnC cDNA with the HA-epitope coding sequence. The HA tag 
sequences were synthesized and added to a truncated PCR product of the 
sTnC. 
3.5.1.1. Generating Double-stranded HA-tag Adaptor 
Two single stranded complementary 39-mer oligonucleotides were 
synthesized for making a double stranded oligonucleotide having coding 
sequences for the influenza virus haemagglutinin antigen epitope terminating 
into a stop codon having 8g/11 sites at either ends. The sense oligonucleotide 
(A80698) and the antisense oligonucleotide (A80716) were annealed by 
heating and slow cooling as described in section 2.4.6.1. and then 
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phosphorylated using T 4 polynucleotide kinase as described in section 
2.4.6.2. and resuspended in TE at a final concentration of 11lg/ml. 
3.5.1.2. Amplification of sTne Truncated (~12) cDNA 
A truncated cDNA was amplified by PCR using Taq polymerase as described 
in section 2.12.1.using plasmid LK419 as the template. Amplification was 
carried out using a top (sense strand) primer (G 153583), which anneals along 
bp 27 to 44 and incorporates an EcoRI restriction enzyme site 5' to the 
amplified DNA. The bottom (antisense strand) primer (T43429) annealed 
(complementary) along bp 491 to 508, adding a 8g/l1 site at the 3' end of the 
final PCR product (see table 2.1.A.). The amplified DNA produced a sTnC 
cDNA with 36 bp of coding sequences (corresponding to 12 amino acids at 
the carboxyl end in the protein) deleted at the 3' end. This PCR product was 
digested with EcoRI and 8g/l1 to produce cohesive termini and was ligated 
into compatible ends in the vector pLECM (see fig. 3.4). Positive clones were 
checked by cutting the insert back out. Six clones were identified as positive 
and each was sequenced till one without a mutation was found. This plasmid 
was called pLECM/sTnC-~ 12; the ~ 12 denoting the deletion of 12 amino 
acids at the carboxyl terminal. The sequenced clone with no mutations was 
used to insert the epitope tag encoding oligonucleotide to complete the cDNA. 
3.5.1.3. Insertion of HA Epitope-tag Adaptor Sequence 
Vector pLECM/sTnC~12 was cut with 8g/11 and dephosphorylated to prevent 
self-ligation. The annealed and phosphorylated HA-tag oligonucleotide was 
ligated with a 1: 1 and 1:2 end-mole ratio of vector to oligonucleotide. Potential 
positive clones were cut with EcoRI/8g/li and the digested miniprep DNA was 
separated on a 2% agarose gel: The digest removed approximately 500 bp 
fragment with a visible faint band of very small size in all positive clones. 
To establish if the insert was present and in the correct orientation, the 
potentially positive clones were sequenced using primer C929111 (see table 
2.2) which reads into the tag. The first clone reading into the tag with the right 
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Fig 3.4: Flow diagram for subcloning strategy of influenza virus hemagglutinin (HA) antigen 
epitope-tagged coding sequence into skeletal Troponin C. 
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frame, and having no mutations was retained for making recombinants and 
further modifications. This clone was named pLECM/sTnC~ 12-HA. 
3.5.1.4. Subcloning sTnC:HA into pCA13 and Intermediary Vector 
The skeletal Troponin C cDNA with HA epitope tag (sTnC~12-HA) was further 
subcloned into pCA 13 to ensure the presence of a SV40-polyA sequence at 
the 3' end of the sTnC~ 12HA cDNA. For this purpose, a PCR cloning 
approach was adopted, using pLECM/sTnC~12-HA plasmid as template to 
amplify the whole sTnC cDNA with the 3' 8g/l1 site modified to a 8amHI 
enzyme recognized sequence. In this case, a simple EcoRI/8g/il fragment 
cutting and ligating approach was not possible due to the presence of two 
8g/11 sites on either side of the tag, with the possibility of losing the tag even in 
a partial digest. The sense-strand (top) PCR primer was A 1901 D04 
(sTnC:XhoI/EcoRI), while the antisense (bottom) primer was A1901D05 (HA-
tag/8amHI; see tables 2.1.A. and 2.3 for primer details). The top primer added 
spacer 
r:1Y~ ,P"~) ;tyr)A$p) iVan !pr~i !~,,~ (,i~~) 0~i~1 STOP 
BglII BglII 
GAG ATC TCT TAC CCT TAT GAT GTC CCT GAC TAC GCC TM GAT CT 3' 
CTC TAG AGA ATG GGA ATA CTA CAG GGA CTG ATG CGG ATT CTA GA 5' 
A 
B 
Primee---- GGA A TA CTA CAG GGA CTG ATG CGG AT e eTA G GGT 
(A1901D05) 
f"""~" ~Jt BamHI 
sTnC- ~12 spacer HA 
~--------------------------------------~528bp 
~---------------------+i'" 489 bp 
Fig 3.5: PCR mutagenesis of BglJI site to BamHI site. The alignment of the 3' primer with the 
two mismatched bases (underlined) is shown in (A). The transformed restriction 
enzyme site on sTnC eDNA facilitates removal and replacement of truncated eDNA, 
without disturbing the epitope tag coding sequence (8). 
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a Xhol and a EcoRI site 5' to, the sTnC cDNA. Whereas the bottom primer 
was complementary to sequences on the HA tag coding region and the stop 
codon but the 3' 8g/l1 site was altered to a 8amHI site (see fig. 3.5). A 1:10 
mix of Pfu proof-reading polymerase and Taq polymerase, in a Pfu buffer, 
was used for PCR amplification as described in section 2.12.1. The PCR 
product was cut with EcoRI and 8amHI and cleaned by phenol/chloroform 
extraction. The digested PCR product was ligated to pCA 13, EcoRl/8amHI-
digested and gel purified vector DNA (see fig. 3.6). 
In addition, the same PCR product was also cloned into compatible sites of 
the vector pGEM-7Zf(+), named as pGEM/sTnC~12:HA (see fig. 3.6), and 
used to make further tagged cDNA, described later. The pCA 13 clones were 
screened by colony PCR method (using primers Ad5 280-99 and Ad5 3580-
98-rev; see table 2.1.B.), and clones showing an amplified product of 1.2 kb 
were retained. Eleven clones were further screened by digesting with 
EcoRI/8amHI and EcoRI/8g/il separately and run on a 2% agarose gel. 
The EcoRI/8amHI digest on cuts out the whole sTnC:HA cDNA of 528 bp 
while a EcoRI/8g/il digest cuts out only the sTnC, leaving out the tag (489 bp 
fragment) and other vector sequences. The difference between the tagged 
and the non-tag fragments was evident on a 2% gel (see fig. 3.9-A). The 
positive clones were kept and sequenced to check the integrity of the PCR 
product. The new clone was named pCA13/sTnC~12:HA and one sequenced 
clone with no mutations and correct reading frame was retained to make 
recombinant adenovirus. 
3.5.1.5. Subcloning sTnC ~9 HA Tag 
Due to the close proximity of the HA tag to one of the Ca ++ binding sites at the 
carboxyl terminal, another tagged skeletal Troponin C cDNA was constructed. 
This cDNA was amplified such that 27 bp at the 3' end of the original coding 
region were deleted and replaced by the HA-tag coding sequences. The final 
protein was designed to have 9 amino acids replaced by HA-tag thereby 
making the tagged sTnC protein longer by 3 amino acids. 
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into pCA 13 and pGEM7Z( +) as 
a EcoRI and BamHI fragment. 
______ Sal1 
~--=~__c_._HilldIlI 
--~---__ £coRi 
(
' _ )~~;;I~;HA 
. pCA13/sTnC~12.HA j\\ BamHI 
\ 
7456 bp ).. \fV40 POLY A 
Ssp I 
"'kl==='-. Ssp ~hage f1 region \ /'" \ ~ " \ \, j "" BglII 
'\\, j Sac 
pGEM/sTnC~12-HA 
3493 bp 
""' T7 promoter 
\ i ~.I Xba I 
Xho I 
BeaR! 
sTnC~12·HA 
BglII 
BamHI 
Sac I 
SP6 promoter 
'" /;:?c 
"'",--",- .i. --.?"./ 
~~-"\~ 
Sac I 
pCA13/sTnCLl12-HA is now a 
completed adenoviral shuttle 
vector and can be used to make 
adenoviral recombinants. 
pGEM/sTnCL'l12-HA was made as an intermediate 
vector to further alter the epitope-tagged sTnC cDNA 
Fig 3.6: Subcloning of HA epitope-tagged sTnC cDNA into the pCA13 shuttle vector and the 
pGEM7Z+, intermediate vector. The tagged sTnC from pGEM/sTnCL'l12-HA was used 
to produce a tagged sTnC cDNA with lesser deletion of amino acids. 
For this purpose the pGEM/sTnC~12:HA was the starting clone which was 
constructed to avoid the cumbersome cloning and screening procedures 
required for cloning in oligonucleotides of the tag. The sTnC~ 12 cDNA was 
removed by cutting with EcoRl/8glll, leaving the HA-tag sequence behind in 
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the pGEM vector. The vector backbone fragment was gel-purified and 
cleaned for later use. 
PCR amplification of a truncated sTnC cDNA from the pLK419 template was 
done using custom-designed primers, using a 1:10 PfulTaq polymerase mix in 
Pfu buffer (see section 2.12.1.). The sense (top) PCR primer was G 153583 
which added an EcoRI site 5' and an antisense (bottom) primer was 
C166762, adding a 8g/11 site at the 3' end of the final PCR product (see table 
2.1.A.). The amplified DNA produced a sTnC cDNA which had 27 bp of 
coding sequences (9 amino acids in the protein) deleted at the 3' end 
(sTnCi19:HA). This amplified DNA was cut with EcoRl/8g/ll, cleaned and 
ligated to the pGEM vector with the HA-tag (see fig. 3.7). The clone was 
named pGEM/sTnCi19:HA and the new insert was sequenced. 
pGEM/sTnCi19:HA #19 was found to contain no mutations and a correct 
reading frame, was used for the next cloning step. 
The EcoRI/8g/il fragment of pGEM/sTnCi19:HA #19 was cut out and ligated 
into the compatible ends of vector pCA 13. Clones were screened by digesting 
with Sstl. All positive clones showed the 2 kb vector fragment and a 936 bp 
fragment coming from the inserted DNA. These were named 
pCA13/sTnCi19:HA for which 16 clones were obtained and one was selected 
at random to generate recombinant adenovirus. 
3.5.1.6. Subeloning sTnCi19:HA eDNA with HCA(-485) Promoter 
The HA-tagged skeletal Troponin C cDNA was cloned into p1A/HCA(-485) 
plasmid to produce a tissue-specific sTnCi19:HA expressing clone (see fig. 
3.8). pCA 13/sTnCi19:HA was cut by performing a complete digest with Hindlll 
followed by a partial digest with 8g/11 and the fragments separated on a 1.2% 
agarose gel. The 750 bp fragment carrying the sTnCi19:HA cDNA and the 
SV40-polyA sequence was cut out and gel-extracted as described. This 
fragment was ligated into a p1A/HCA(-485) vector cut with Hindlll/8g/il and 
cleaned by gel extraction. 
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pGEM/sTnC t, 12-HA 
3493 bp 
_phage f 1 region 
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The troponin C part of the sTnCLl12-HA 
cDNA was removed by a EcoRI and 8g/ll 
digest, leaving behind the spacer and HA 
tag coding sequences in the pGEM vector 
EcoRI skeletal Troponin C coding region SV40 Poly A Signal 
'-+ > ~ 
EcoRi 
Ssp J 
pGEM/sTnCt,9-HA 
3501 bp 
483 bp 
peRl 
/' 
,,/,/r 
sTnC~9-HA 
447 bp 
EeoR! 
sTnCt,9-HA 
~ 
Bglil 
BglIJ 
Another truncated 
troponin C cDNA was 
amplified using PCR. 
The 3' primer was 
designed to produce a 
27 bp deletion and stop 
codon and adding a 
8g11/ site 
The sTnCLl9 was ligated as a EcoRI 
and 8g1/1 fragment into the pGEM 
vector backbone which already 
carried the HA epitope tag to give the 
completed sTnCLl9-HA cDNA 
spacer 
Bgl/l HA 
489bp 
Fig 3.7: Schematic presentation of strategy for obtaining an HA epitope-tagged sTnC cDNA 
having a tagged sTnC protein with only the last 9 amino acids deleted and 
substituted by the HA tag peptide sequence. The subcloning was carried out via an 
intermiediary pGEM vector. 
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spacer 
.TnCA' B,m ~ HA 
EeaRI '~ \ .. BamHI 
1 .. ~ 
BgllI 
Ssp I ,CMV promoter 
AP \ . 
rl~~ Hil/dIl/ EcoRI 
sTnC",,9-HA 
(
7 
r pCA13/sTnC~9-HA \' BgllI -- Bali/HI 
SV40 POLY A 
sTnC",,9-HA 
489bp 
sTnCil9-HA eDNA was removed 
from pGEM/sTnC~9-HA as EcoRI 
and BamHl fragment and ligated 
into compatible sites of pCA 13 
\ 746"p l 
~ j \. /' \ ' 
'" // 
BgllI 
Sac 
pCA13/sTnC~9-HA is a completed 
adenoviral shuttle vector and can be 
used to make adenoviral recombinants 
"'-." • ,::Y ~_ =\ /7 -~......,...-=--~-~~~ 
Sac I 
The sTnCil9-HA eDNA was removed along 
with the SV40 polyA sequence, by cutting 
the cassette out as a Hindl/l and BglfI 
partial-digest fragment 
The HA epitope tagged skeletal 
Troponin C eDNA and SV40 polyA 
cassette was ligated into the Hindl/l 
and Bgl/I cut p1A1HCA(-485) 
Ad 6 sequence 
'<:;!P I (7 ...... 0) 
Clal I Hal/HI 
, / ,\1101 
I Xbal 
ORI 
APr li,;..:.i ... - /ieoR!' -~~cc-_ ----- - Hed?1 ~- ---. HCA PROMOTER 
------.,E1(1.0·9.8) 
p1AfHCA(-485)/sTnCd9:HAfpolyA 
7653 bp 
Sac! 
lied? I 
------BgllI 
Hal/HI 
\~V40 POLY A 
HglIJ 
Ad 6 sequence 
APr 
Cia I 
Ad. 5 se.qu. ence/ .1./'(17.0.1 l amHI Ssp I I 1/ / Xba I ~. ~(/ EcoRV ~==-t= '"--~~--~ .f~Z~~OMOTER 
-----; E1(1.0-9.8) 
p1A1HCA(-485) 
6964 bp 
x,~~~~~t \~,\ Bgi II 
\\ I Sac I 
Ad 5 sequence 
I 
pCA13/sTnC~9HA/polyA is a 
completed adenoviral shuttle 
vector and can be used to 
make adenoviral recombinants. 
Fig 3.8: Subcloning of HA epitope-tagged sTnC cDNA (sTnC~9-HA) into the pCA 13 shuttle 
vector and subsequently into the tissue-specific Human Cardiac Actin; HCA(-485) 
promoter adenoviral shuttle plasmid. 
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Putative clones were screened by cutting with EcoRI and 8g/l1 and separating 
on a 1.5% agarose gel. Positive clones showed a 535 bp sTnCtl9 fragment, a 
500 bp HCA(-485) fragment and a HAtag/SV40-polyA fragment of 190 bp 
(see fig. 3.9-8). 14 clones were obtained and named as p1A/HCA(-
485)/sTnCtl9:HA one was chosen randomly to generate recombinant 
adenovirus. 
A B 
EcoRI EcoRi 
alld 
BamHI 
,\ I kb ladder 
1.0 kb 
500 bp 
489 bp 
pCA 13/sTnCL'l12-HA 
EcoRi 
alld 
BglII \ 
535 bp A.,!lM: 
500bp 
190bp-
I kb ladder 
/ 
1.0 kb 
t-500bp 
220 bp 
p1A1HCA(-485)/sTnCL'l9:HA 
Fig 3.9: Restriction digests of adenoviral shuttle vectors pCA 13/sTnC~ 12-HA and 
p1A1HCA(-485)/sTnC~9-HA. A. pCA13/sTnC~12-HA DNA digested with 
EcaR! and BamH! removes the full, HA-tagged sTnC cDNA. EeaR! and BglII 
digest cuts out a tagless, truncated sTnC cDNA fragment. The DNA fragments 
were separated on a 2% agarose gel. B. p1A/HCA(-485)/sTnC~9-HA. DNA 
digested with EcaR! and BglII removes a 535 bp fragment with the tagged 
sTnC cDNA, a 500 bp frgament of HCA (-485) promoter and a 190 bp 
fragment comprising of the HA tag and the SV40-polyA sequence. DNA 
fragments were separated on a 1.5% agarose gel. 
3.5.2. Subcloning of SV40 large T Antigen Epitope Tag with sTne 
First, a double stranded oligonucleotide with sequences encoding the T-
antigen epitope tag (Yoshihara and Hall, 1993) was made and ligated into the 
pCA 13 vector. This adenovirus shuttle plasmid vector could be used to clone 
cDNA for expressing proteins which required an SV40 large T antigen epitope 
tag at the carboxyl terminal. DNA amplified by PCR using the original cDNA 
template was ligated 3' to the epitope tag, such that the reading frame was 
not disturbed. This amplified DNA was modified such that it eliminated a part 
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of the 3' sequences to accommodate the tag sequences, keeping the final 
protein to the same length. Also the stop codon was eliminated and 
appropriate restriction sites incorporated using custom-made primers 
3.5.2.1. Generating Double-stranded SV40 Large T Antigen Epitope Tag 
Oligonucleotide 
An adaptor-duplex was designed for adding SV40 T antigen epitope tag at the 
carboxyl terminal of the sTnC protein. Two single-stranded 27-mer 
oligonucleotides were designed such that one strand contained the complete 
1 kb ladder 
SV40 Large T antigen 
Epitope Tag Annealing 
B 
1 kb ladder 
2.0 
1. pCA 13 control, with no insert. 
2 & 4. pCA13 with T tag insert. 
bp 
3. peA 13, self-ligated vector (no tag). 
Fig 3.10: Subcloning of SV40 large T antigen epitope tag sequence into pCA13. A. Single-
stranded oligonucleotides and ds annealed DNA were run on a 2% agarose gel to 
confirm annealing. The Annealed ds-DNA migrates to a postion between the two 
parent oligos The bottom oligo probably has a secondary structure and shows more 
staining and faster migration. B. The T-tag subclones were screened by colony PCR 
using adenoviral primers. The PCR products were run on a 2% agarose gel and a 15 
bp difference could be detected between clones with and without a T-tag insert. 
coding sequence for epitope tag, while the other oligonucleotide was 
complementary to the first. These two oligomers hybridized such that the core 
sequence coded for the epitope tag, with 5' protruding ends compatible for 
ligating to restriction enzyme sites. The sense (coding) oligonucleotide was 
1669-075 (T-tag:XbaI/BamHI TOP) and its complementary oligonucleotide 
was 1669-076 (T-tag:XbaI/BamHI BOTTOM; see table 2.3), which hybridized 
to form an epitope tag-encoding double-stranded (ds) adaptor-duplex, having 
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a Xbal compatible protruding end at the 5' and a BamHI protruding end at the 
3' terminal of the adapter-duplex. The Xbal end was able to ligate to DNA cut 
with Nhel, Avril and Spel, in addition to Xbal itself. The two oligomers were 
annealed by heating and cooling down slowly (also see fig. 3. 1 O-A), and then 
phosphorylated using T 4 polynucleotide kinase enzyme as described in 
section 2.4.6. 
3.5.2.2. Subeloning of Tag Adaptor into pCA13 
The vector pCA 13 was cut with Xbal and BamHI and the large fragment gel-
purified. The SV40 large T antigen epitope tag adaptor-duplex was ligated 
into the pCA 13 vector with a 1: 1 and 1:2 end-mole ratio of vector to adaptor-
duplex. Putative positive clones were screened by colony PCR using primers 
Ad5:280-99 and Ad5-3580-98;rev (see fig. 3.10-B). 
These primers amplified a 763 bp fragment on the positive clone DNA 
templates and a 748 bp product on a negative (pCA 13 only) clone template. 
The PCR products were run on a 2% agarose gel: The positive clones were 
selected on the basis of comparison of the putative positive clone amplified 
DNA with a pCA 13-only, negative template. The positive clones showed a 
slower migration and the 15 bp difference in the fragments was evident (see 
fig. 3.10-B). These clones were named pCA13:T and were sequenced using 
properly and were kept for later use. 3 clones were found to carry the tag 
sequence inserted. 
3.5.2.3. Subeloning of sTnC~8 and sTnC-full eDNA into pCA13:T 
Two truncated cDNAs named sTnC~8 and sTnC-full were generated by 
amplification of LK419 cDNA template using EXPANDTM High Fidelity PCR 
System (Boehringer Mannheim, cat. no. 1681834). sTnC~8 was skeletal 
Troponin C cDNA which was amplified with specially designed primers, 
Results: Subc/oning 133 
29 mer sense and antisense 
oligonucleotides were annealed to 
produce a double stranded DNA 
encoding the 6 amino acid SV40 virus 
large T antigen epitope tag peptide and 
a 2 amino acid spacer junction 
Bgl II 
CMV promoter Sal] 
Ssp ] ~ Ad 6 seq. \ • Hind II] 
Xbal 
i - / __ ~~J~co R V 
~ --:- Xba] 
Chapter 3 
spacer (2 a.a) 
, \ T antigen epitope tag (6 a.a) STOP BamHl { f== 
SV40 large T antigen epitope tag 
33 bp 
This adaptor-duplex DNA was designed 
to produce a 5' Xbal and a 3' BamHI site 
to facilitate cloning into the pCA 13 
adenoviral shuttle vector APr, ~>~--~""c~\ sac!, EcoR] 
1fI" ' "\'Y,, T antigen epitope tag r '~ 
I '~ 
(
/ \\,' Ban1H] 
\
1\1 pCA13:T-tag ,)f~\S~:;]~LYA 
6967 bp ! \ 
! Sac] 
! \ j' \\ /, 
, ) M6~ 
'''~~~=~>"\,,,,;'>''/ 
Sac] 
Two truncated cDNAs were 
amplified by PCR from the 
sTnC cDNA template 
(pLK419) with specially 
designed primers 
EcoR! 
EcoR! Truncated sTnC Nile! 
( ( 
sTnCLl8 
456 hp 
sTnC1l8 cDNA has the last 8 codons deleted, 
the sTnC native stop codon and a Nhel site 
added at the 3' end. 
The vector pCA13:T-tag can be 
used for inserting a T antigen tag at 
the COOH-terminal of any protein. 
skeletal Troponin C coding SV40 Poly A Signal 
PCR 
483 bp Nile] Nhe] 
EcoR! sTnC Nile! 
1 \ ( 
sTnC·fulllength 
480 bp 
sTnC full length cDNA has the sTnC native 
stop codon omitted and a Nhel site added at 
the 3' end. 
Both truncated sTnC cDNAs were ligated into the EcoRI and Xbal sites (Nhel 
compatible) of pCA13:T, to obtain the tagged sTnC1l8:T and sTnC:T cDNA 
Ssp J 
AP,. 
pCA13/sTnC:T 
7493 bp 
J 
! 
T·tag 
iEcoRI sTn CLl8 spacer ~ 
" !'", BamHI 
. j-~~~~~~~~~~ r 
sTnC-L18 tagged with T antigen epitope 
483bp 
jEcoRi sTnC spacer Hag 
"!~~~~~~~rBiV"HI 
Full length sTnC tagged with T antigen epitope tag 
507 hp 
Fig 3.11: Flow diagram for subcloning of SV40 large T antigen epitope tag sequence with 
skeletal Troponin C. Two types of tagged cDNAs were made by modifying the 3' 
end of sTnC cDNA. 
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producing a cDNA with the last 24 bases of wild type sTnC cDNA eliminated. 
This was done by using the 5' primer 1669-077 (sTnC/EcoRI:T-tag) which 
added an EcoRI restriction enzyme site immediately 5' to its hybridization site 
(from sequence 13 bp to 30 bp on the sTnC cDNA). The 3' (antisense) primer 
was 1669-073 (sTnC-d8-T/Nhel) which hybridized from bp 500 to 520 and 
added a Nhel site 3' to the cDNA. This cDNA had coding sequence for all but 
the last 8 amino acids of the protein and after cloning into pCA 13:T, the sTnC 
protein with the last eight amino acids replaced by aT-tag epitope should be 
expressed. 
Similarly, the sTnC-full was amplified using the LK419 template with the same 
5' primer as sTnC~8 but with a different 3' (antisense) primer. Antisense 
primer was 1669-074 (sTnC-fuIl/Nhel) which was complementary to bp 526 to 
544 of the sTnC cDNA eliminating only the stop codon. This primer also 
incorporated a Nhel site at the 3' end of the cDNA facilitating cloning into the 
pCA 13:T. Thus the new amplified cDNA had the complete coding sequence 
I kb ladder I kb ladder 
A B 
2.0 kb 2.0 kb 
1.0 kb 1.0 kb 
700 bp 730 bp 
500 bp 500 bp 
410 bp 410bp 
1. pCA 13--tag without insert. 1. pCA 13--tag without insert. 
2. pCA13-T-tag with sTnC~8 insert. 2 & 3. pCA13-T-tag with sTnC-full insert. 
Fig 3.12: Restriction digests of SV40 large T antigen epitope tagged sTnC cDNA inserts. 
EcoRI and 8gll1 digests of DNA minipreps of subclones of A. pCA13/sTnC~8:T 
and B. pCA13/sTnC:T. The 700 bp (approx.). fragment cuts out the sTnC with 
the tag sequence and the poly A sequence .. 
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for the protein and after cloning into pCA13:T, a full sTnC protein with 
additional T-tag sequence should be expressed (see fig. 3.11). 
Both PCR amplified truncated cDNAs were cut with EcoRI and Nhel and then 
ligated to the pCA 13:T plasmid vector which was cut with EcoRI and Xbal. 
Potential clones were screened by digesting with EcoRI and 8g/ii. Positive 
clones cut out an approximately 700 bp and a 410 bp fragment with the 
sTnCll8 insert (fig. 3.12-A), and approximately 730 bp and 410 bp fragments 
with the sTnC-full insert (fig. 3.12-B). The new clones were named 
pCA 13/sTnCll8:T, with the 118 denoting the deletion of the last eight amino 
acids of the wild type protein and pCA 13/sTnC:T, for non deleted T tagged 
Troponin C. 
Positive clones were further screened by sequencing the whole span of the 
PCR product and the tag sequences. Clones with insert having the correct 
reading frame and no base mutations were retained for making recombinants. 
The SV40 T antigen tagged skeletal Troponin C clones were made as an 
alternative for the HA tagged sTnC. These plasmids were not analyzed for 
expression in this project. Recombinant adenoviruses were not generated 
using these plasm ids, as these developments were beyond the scope of the 
current project. 
3.6. Adenoviral Shuttle Vectors and Other Plasmids Constructed During 
the Project 
The range plasmids constructed during the project comprise of adenoviral 
shuttle vectors, intermediary vectors and modified basic vectors. The 
completed adenoviral shuttle vectors (Tables 3.3 -3.7) are ready for using to 
make recombinant adenoviruses. Modified basic vectors (Table 3.1), 
comprised of basic shuttle vectors which had promoter or SV40 poly A signal 
inserted, while intermediary vectors (Table 3.2) were commercially available 
vectors, used to subclone sTnC gene, and both sets of plasmids were 
employed for further subcloning to obtain completed shuttle vectors. 
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l e
D
N
A 
pS
P7
2/
sT
nC
 (+
) 
n
o
n
e
 
sT
nC
 
sT
nC
 c
o
di
ng
 re
gi
on
 re
m
o
ve
d 
u
si
ng
 B
stE
11
 a
n
d 
Av
ril
 fr
om
 
Sa
il, 
Xb
al
, B
am
H
I, 
[sT
nC
], 
Ec
oR
I, 
pL
K4
19
, a
n
d 
in
se
rte
d 
a
s 
a
 b
lu
nt
-e
nd
 fr
ag
m
en
t i
nt
o 
th
e 
Sm
al
 
Cl
al
, E
co
R
V,
 B
gi
ll 
b 
si
te
 o
f p
SP
72
, i
n 
fo
rw
ar
d 
o
rie
nt
at
io
n 
pS
P7
2/
sT
nC
 (-
) 
n
o
n
e
 
sT
nC
 
sT
nC
 c
o
di
ng
 re
gi
on
 re
m
o
ve
d 
u
si
ng
 B
st
EI
l a
n
d 
Av
ril
 fr
om
 
Ec
oR
I, 
[sT
nC
], 
Ba
m
H
I, 
Xb
al
, S
al 
I, 
pL
K4
19
, a
n
d 
in
se
rte
d 
a
s 
a
 b
lu
nt
-e
nd
 fr
ag
m
en
t i
nt
o 
th
e 
Sm
al
 
H
in
dl
ll,
 X
ho
l C
 
si
te
 o
f p
SP
72
, i
n 
an
 r
e
ve
rs
e
 o
rie
nt
at
io
n 
p1
A1
HC
A(
-17
7)/
sT
nC
 
H
CA
(-1
77
) 
sT
nC
 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 re
m
o
ve
d 
fro
m
 p
SP
72
 (+
), 
u
si
ng
 S
ai
l 
Cl
al
, B
am
H
I, 
Xh
ol
, X
ba
l, 
IB
gl1
i r
e
st
ric
tio
n 
di
ge
st
, i
s 
lig
at
ed
 in
to
 c
o
m
pa
tib
le
 s
ite
s 
in 
Ec
oR
V,
[pr
om
ote
r-c
DN
A]
, E
co
R
I, 
p1
A1
HC
A(
-17
7) 
pl
as
m
id
. 
Cl
al
, E
co
R
V,
 B
gi
ll 
p1
A1
HC
A(
-48
5) 
Is
Tn
C 
H
CA
(-4
85
) 
sT
nC
 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 re
m
o
ve
d 
fro
m
 p
SP
72
 (+
), 
u
si
ng
 S
ai
l 
Cl
al
, B
am
H
I, 
Xh
ol
, X
ba
l, 
IB
gl1
i r
e
st
ric
tio
n 
di
ge
st
, i
s 
lig
at
ed
 in
to
 c
o
m
pa
tib
le
 s
ite
s 
in 
Ec
oR
V,
[pr
om
ote
r-c
DN
A]
, E
co
R
I, 
p1
A1
HC
A(
-48
5) 
pl
as
m
id
 
Cl
al
, E
co
R
V,
 B
gi
ll 
p1
A1
sk
ac
t(-
12
82
)/s
Tn
C 
sk
ac
t( -
12
82
) 
sT
nC
 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 re
m
o
ve
d 
fro
m
 p
SP
72
 (+
), 
u
si
ng
 
Cl
al
, B
am
H
I, 
Xh
ol
, X
ba
l, 
Ec
oR
V,
 
Ba
m
HI
/B
gll
1 
re
st
ric
tio
n 
di
ge
st
, i
s 
lig
at
ed
 in
to
 B
gi
ll 
si
te
 in
 
Ec
oR
I, 
H
in
dl
ll,
 S
al
l,[p
ro
mo
ter
-
p1
A1
(sk
ac
t-1
28
2) 
pl
as
m
id
. 
cD
N
A]
, E
co
R
I, 
Cl
al
, E
co
R
V,
 B
gi
ll 
p 1
 B/
sk
ac
t( -
20
00
 )/s
 T n
C 
sk
ac
t( -
20
00
) 
sT
nC
 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 re
m
o
ve
d 
fro
m
 p
SP
72
 (-
), 
u
si
ng
 
Cl
al
, S
ai
l, 
Ec
oR
I, 
[pr
om
ote
r-c
DN
A]
, 
Ec
oR
l/B
am
HI
 re
st
ric
tio
n 
di
ge
st
, i
s 
lig
at
ed
 in
to
 c
o
m
pa
tib
le
 
Ba
m
H
I, 
Bg
ili.
 
si
te
s 
in 
p1
A1
(sk
ac
t-2
00
0) 
pl
as
m
id
. 
a-
o
n
ly
 re
st
ric
tio
n 
e
n
zy
m
e 
si
te
s 
a
va
ila
bl
e 
in 
a
de
no
vi
ra
l s
hu
ttl
e 
ve
ct
or
s 
a
ls
o 
a
re
 s
ho
w
n 
he
re
. 
b-
m
o
re
 s
ite
s 
co
m
pa
tib
le
 to
 a
de
no
vi
ra
l s
hu
ttl
e 
ve
ct
or
s 
ar
e 
a
va
ila
bl
e 
5'
 o
f S
ai
l, 
bu
t a
re
 n
o
t u
se
d 
du
e 
to
 p
re
se
nc
e 
o
f a
 p
ot
en
tia
l A
TG
 s
ta
rt 
co
do
n 
in 
th
e 
Sp
hl
 s
ite
. 
c-
m
o
re
 s
ite
s 
co
m
pa
tib
le
 to
 a
de
no
vi
ra
l s
hu
ttl
e 
ve
ct
or
s 
a
re
 a
va
ila
bl
e 
5'
 o
f E
co
R
I, 
bu
t a
re
 n
o
t u
se
d 
du
e 
to
 p
re
se
nc
e 
o
f a
 p
ot
en
tia
l A
TG
 s
ta
rt 
co
do
n 
a
t t
he
 ju
nc
tio
n o
f C
la
l a
nd
 E
co
R
I. 
R
es
ul
ts
: 
Su
b c
lo
ni
ng
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Ch
ap
te
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I 
I 
Ta
bl
e 
3.
3.
 
Co
m
pl
et
ed
 V
ec
to
rs
 w
ith
 C
on
st
itu
tiv
e 
Pr
om
ot
er
 a
n
d 
Sk
el
et
al
 T
ro
po
ni
n 
c
D
N
A
 
P
la
sm
id
 
P
ro
m
ot
er
 
G
en
e 
D
es
cr
ip
tio
n 
P
ol
y 
A 
pL
EC
M
/s
Tn
C 
CM
V-
IE
 
sT
nC
 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 D
N
A 
is 
PC
R-
am
pl
ifie
d 
w
ith
 5
' E
co
RI
 a
nd
 3
' 8
gll
1 
re
st
ric
tio
n 
E1
b 
e
n
zy
m
e 
sit
es
, a
n
d 
lig
at
ed
 in
to
 c
o
m
pa
tib
le
 s
ite
s 
in 
pL
EC
M
 p
la
sm
id
. 
pL
EC
M
I s
Tn
C1
l1
2:
HA
 
CM
V-
IE
 
sT
nC
1l
12
 
Tr
un
ca
te
d 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 D
N
A 
is 
PC
R-
am
pl
ifie
d 
w
ith
 5
' E
co
RI
 a
nd
 3
' 8
gll
1 
E1
b 
re
st
ric
tio
n 
e
n
zy
m
e 
sit
es
, a
nd
 li
ga
te
d 
in
to
 c
o
m
pa
tib
le
 s
ite
s 
in 
pL
EC
M
 p
la
sm
id
. T
he
 
H
A 
e
pi
to
pe
 ta
g 
do
ub
le
-s
tra
nd
ed
 o
lig
on
uc
le
ot
id
e 
is 
th
en
 in
se
rte
d 
as
 a
 8
gl1
1 
fra
gm
en
t 
pC
A 1
3/
sT
nC
-(P
CR
) 
CM
V-
IE
 (-
29
9-+
72
) 
sT
nC
 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 D
N
A 
is 
PC
R-
am
pl
ifie
d 
w
ith
 5
' E
co
RI
 a
nd
 3
' 8
gll
1 
re
st
ric
tio
n 
E1
b 
e
n
zy
m
e 
sit
es
, a
nd
 li
ga
te
d 
in
to
 E
co
R
I/8
am
HI
 s
ite
s 
in 
pC
A1
3.
 
pC
A1
3/
sT
nC
 
CM
V-
IE
 (-
29
9-+
72
) 
sT
nC
 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 re
m
o
ve
d 
fro
m
 p
SP
72
 (-
), 
u
si
ng
 8
am
H
I/8
gl
il 
re
st
ric
tio
n 
SV
40
 
di
ge
st
, i
s 
lig
at
ed
 in
to
 c
o
m
pa
tib
le
 s
ite
s 
in 
pC
A 1
3 
pl
as
m
id
. 
R
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ul
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: 
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bc
lo
ni
ng
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ap
te
r 3
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bl
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4.
 
Co
m
pl
et
ed
 V
ec
to
rs
 w
ith
 T
is
su
e-
sp
ec
ifi
c 
Pr
om
ot
er
s 
an
d 
s
Tn
C 
c
D
N
A
 
Pl
as
m
id
 
Pr
om
ot
er
 
G
en
e 
D
es
cr
ip
tio
n 
Po
ly 
A 
p1
A1
HC
A(
-17
7)/
sT
nC
/po
lyA
 
H
CA
(-1
77
) 
sT
nC
 
Pr
om
ot
er
-s
Tn
C 
cD
N
A 
ca
ss
e
tte
 is
 re
m
o
ve
d 
fro
m
 p
1A
1H
CA
(-1
77
)/s
Tn
C,
 
SV
40
 
a
s 
Ec
oR
I f
ra
gm
en
t a
n
d 
lig
at
ed
 in
to
 p
t-.
E1
sp
1A
-p
ol
yA
. 
p1
A1
HC
A(
-48
5) 
/s
Tn
C/
po
ly
A 
H
CA
(-4
85
) 
sT
nC
 
Pr
om
ot
er
-s
Tn
C 
cD
N
A 
ca
ss
e
tte
 is
 re
m
o
ve
d 
fro
m
 p
1A
1H
CA
(-4
85
)/s
Tn
C,
 
SV
40
 
a
s 
Ec
oR
I f
ra
gm
en
t a
n
d 
lig
at
ed
 in
to
 p
t-.
E1
sp
1A
-p
ol
yA
. 
p1
 A
ls
ka
ct
( -1
28
2)
/sT
nC
/po
lyA
 
sk
ac
t( -
12
82
) 
sT
nC
 
Pr
om
ot
er
-s
Tn
C 
cD
N
A 
ca
ss
e
tte
 is
 re
m
o
ve
d 
fro
m
 p
1A
1s
ka
ct
(-
SV
40
 
12
82
)/s
Tn
C,
 as
 X
ba
l/E
co
RI
 fr
ag
m
en
t a
n
d 
lig
at
ed
 in
to
 
pt-
.E
 1 s
p 1
 A-
po
ly
 A.
 
p1
 B
/s
ka
ct
( -2
00
0)
/sT
nC
/po
lyA
 
sk
ac
t(-
20
00
) 
sT
nC
 
Pr
om
ot
er
-s
Tn
C 
cD
N
A 
ca
ss
e
tte
 is
 re
m
o
ve
d 
fro
m
 p
1B
/s
ka
ct
(-
SV
40
 
20
00
)/s
Tn
C,
 a
s 
Xb
al
lB
am
H
I f
ra
gm
en
t a
nd
 li
ga
te
d 
in
to
 
pt-
.E
1 s
p1
 B
-p
ol
yA
. 
p1
A1
HC
A(
-48
5)/
sT
nC
t-.9
:H
AI
 po
ly
A 
H
CA
(-4
85
) 
sT
nC
t-.
9:
HA
 
sT
nC
t-.
9:
HA
 c
D
N
A 
a
n
d 
SV
40
 p
ol
y 
A 
se
qu
en
ce
 a
re
 r
e
m
o
ve
d 
fro
m
 
SV
40
 
pG
EM
/s
Tn
Ct
-.9
:H
A,
 u
si
ng
 E
co
R
I/8
g/
ll 
di
ge
st
 a
n
d 
lig
at
ed
 in
to
 
p 1
 Al
H
C
A(
 -4
85
) 
R
es
ul
ts
: 
Su
b c
lo
ni
ng
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Ta
bl
e 
3.
5:
 
A
de
no
vi
ra
l S
hu
ttl
e 
Ve
ct
or
s 
w
ith
 In
flu
en
za
 V
iru
s 
H
em
ag
gl
ut
in
 A
nt
ig
en
 (H
A)
 E
pi
to
pe
 T
ag
 
Pl
as
m
id
 
Pr
om
ot
er
 
G
en
e 
D
es
cr
ip
tio
n 
Po
ly
-A
 
pL
EC
M
I s
Tn
C~
12
:H
A 
CM
V-
IE
 
sT
nC
~1
2 
Tr
un
ca
te
d 
sT
nC
 c
od
in
g 
se
qu
en
ce
 D
N
A 
is 
PC
R-
am
pl
ifie
d 
w
ith
 5
' E
co
RI
 a
nd
 3
' B
gl
li 
re
st
ric
tio
n 
E1
b 
e
n
zy
m
e 
sit
es
, a
nd
 li
ga
te
d 
in
to
 c
o
m
pa
tib
le
 s
ite
s 
in 
pL
EC
M
 p
la
sm
id
. T
he
 H
A 
e
pi
to
pe
 ta
g 
do
ub
le
-s
tra
nd
ed
 o
lig
on
uc
le
ot
id
e 
is 
th
en
 in
se
rte
d 
as
 a
 B
gl
li 
fra
gm
en
t 
pC
A 1
3/
sT
nC
~ 1
2:
H
A 
CM
V-
IE
 
sT
nC
~1
2 
sT
nC
~1
2 
cD
N
A 
is 
PC
R-
am
pl
ifie
d 
fro
m
 th
e 
pL
EC
M
I s
Tn
C~
12
:H
A 
pl
as
m
id
. D
eg
en
er
at
e 
3'
 
SV
40
 
pr
im
er
 is
 u
se
d 
to
 m
u
ta
te
 th
e 
Bg
lli 
re
st
ric
tio
n 
e
n
zy
m
e 
si
te
 to
 B
am
HI
 s
ite
, a
nd
 th
e 
fra
gm
en
t 
lig
at
ed
 in
to
 E
co
R
l/B
am
HI
 s
ite
s 
in 
pC
A 1
3.
 
pC
A 1
3/
sT
nC
~9
:H
A 
CM
V-
IE
 
sT
nC
~9
:H
A 
sT
nC
~9
 c
D
N
A 
is 
re
m
ov
ed
 fr
om
 th
e 
in
te
rm
ed
ia
ry
 v
e
ct
or
 p
G
EM
I s
Tn
C~
9-
HA
, 
an
d 
th
e 
fra
gm
en
t 
SV
40
 
lig
at
ed
 in
to
 E
co
R
l/B
am
HI
 s
ite
s 
in 
pC
A1
3.
 
pG
EM
I s
Tn
C~
12
:H
A 
n
o
n
e
 
sT
nC
~1
2:
HA
 
sT
nC
~1
2:
HA
 c
D
N
A 
w
a
s 
re
m
ov
ed
 fr
om
 p
CA
13
/s
Tn
C~
12
:H
A 
as
 a
 E
co
R
l/B
am
HI
 fr
ag
m
en
t a
nd
 
n
on
e 
lig
at
ed
 in
to
 c
o
m
pa
tib
le
 e
n
ds
 o
f p
G
EM
-7
Z(+
). 
pG
EM
I s
Tn
C~
9:
HA
 
n
o
n
e
 
sT
nC
~9
:H
A 
Th
e 
sT
nC
~1
2 
pa
rt 
o
f t
he
 s
Tn
C~
12
:H
A 
cD
N
A 
w
as
 r
em
ov
ed
 fr
om
 p
GE
M/
sT
nC
~1
2:
HA
, 
le
av
in
g 
n
on
e 
th
e 
HA
 ta
g 
be
hi
nd
. N
ew
 tr
un
ca
te
d 
sT
nC
 c
od
in
g 
se
qu
en
ce
, (
sT
nC
~9
) 
w
a
s 
PC
R-
am
pl
ifie
d 
w
ith
 
Ec
oR
I a
nd
 B
gi
ll 
en
ds
, a
nd
 u
se
d 
to
 r
ep
la
ce
 th
e 
re
m
ov
ed
 fr
ag
m
en
t p
ro
du
cin
g 
a
 s
Tn
C~
12
:H
A 
ta
g 
cD
NA
. 
R
es
ul
ts
: 
Su
b c
lo
ni
ng
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6:
 
A
de
no
vi
ra
l S
hu
ttl
e 
Ve
ct
or
s 
w
ith
 S
V4
0 
La
rg
e 
T-
a
n
tig
en
 (T
) E
pi
to
pe
 T
ag
 
P
la
sm
id
 
P
ro
m
ot
er
 
G
en
e 
D
es
cr
ip
tio
n 
P
ol
y-
A
 
pC
A1
3-
T 
CM
V-
IE
 
n
o
n
e
 
SV
40
 la
rg
e 
T-
an
tig
en
 e
pi
to
pe
 ta
g 
se
qu
en
ce
 in
se
rte
d 
as
 a
 X
ba
i/B
am
HI
 o
lig
o,
 in
to
 p
CA
13
. T
hi
s 
SV
40
 
co
n
st
ru
ct
 c
an
 b
e 
u
se
d 
to
 in
co
rp
or
at
e 
th
e 
T -
a
n
tig
en
 e
pi
to
pe
 ta
g 
a
t t
he
 3
' e
nd
 o
f c
D
N
A 
fo
r a
n
y 
pr
ot
ei
n,
 in
 o
rd
er
 to
 ta
g 
th
e 
pr
ot
ei
n 
w
ith
 a
 C
O
O
H-
te
rm
in
al
. 
pC
A1
3/
sT
nC
i1
8-
T 
CM
V-
IE
 
sT
nC
i1
8:
T 
Tr
un
ca
te
d 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 is
 P
CR
-a
m
pl
ifie
d 
w
ith
 5
' E
co
RI
 a
nd
 3
' N
he
l r
e
st
ric
tio
n 
e
n
zy
m
e 
SV
40
 
sit
es
, a
nd
 li
ga
te
d 
in
to
 c
o
m
pa
tib
le
 s
ite
s 
in 
pC
A1
3-
T,
 to
 p
ro
du
ce
 a
 s
Tn
Ci
18
:T
 c
D
N
A.
 
pC
A1
3/
sT
nC
-T
 
CM
V-
IE
 
sT
nC
:T
 
sT
nC
 c
o
di
ng
 s
e
qu
en
ce
 is
 P
CR
-a
m
pl
ifie
d 
w
ith
 5
' E
co
RI
 a
nd
 3
' N
he
l r
e
st
ric
tio
n 
e
n
zy
m
e 
sit
es
, 
SV
40
 
e
lim
in
at
in
g 
th
e 
st
op
 c
o
do
n 
on
ly.
 T
he
 m
o
di
fie
d 
cD
N
A 
is 
lig
at
ed
 in
to
 c
o
m
pa
tib
le
 s
ite
s 
in 
pC
A1
3-
T,
 to
 
pr
od
uc
e 
a
 s
Tn
C:
T 
cD
NA
, c
o
di
ng
 fo
r f
ul
l-l
en
gt
h 
sT
nC
 w
ith
 T
-a
nt
ig
en
 e
pi
to
pe
 ta
g.
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7.
 
Co
m
pl
et
ed
 V
ec
to
rs
 w
ith
 T
is
su
e-
sp
ec
ifi
c 
Pr
om
ot
er
s 
an
d 
l3
-g
al
ac
to
si
da
se
 R
ep
or
te
r G
en
e 
P
la
sm
id
 
P
ro
m
ot
er
 
G
en
e 
D
es
cr
ip
tio
n 
P
ol
y-
A
 
p 1
 Al
H
C
A(
 -17
7)/
J3
-ga
l 
H
CA
(-1
77
) 
J3
-g
al
ac
to
sid
as
e 
J3
-g
al
ac
to
sid
as
e 
e
n
co
di
ng
 s
e
qu
en
ce
 is
 re
m
o
ve
d 
a
lo
ng
 w
ith
 th
e 
SV
40
 
SV
40
 
po
lyA
, f
ro
m
 p
CA
 17
, a
s 
a
 B
am
H1
1 
Bg
ill 
fra
gm
en
t, 
an
d 
lig
at
ed
 in
to
 th
e 
Bg
ill 
si
te
 o
f t
he
 in
te
rm
ed
ia
ry
 v
e
ct
or
 p
1A
1H
CA
(-1
77
) 
p1
A1
HC
A(
-48
5) 
1 J
3-g
al 
H
CA
(-4
85
) 
J3
-g
al
ac
to
sid
as
e 
J3
-g
al
ac
to
sid
as
e 
e
n
co
di
ng
 s
e
qu
en
ce
 is
 re
m
o
ve
d 
a
lo
ng
 w
ith
 th
e 
SV
40
 
SV
40
 
po
lyA
, f
ro
m
 p
CA
17
, a
s 
a
 B
am
H1
1 
Bg
ill 
fra
gm
en
t, 
an
d 
lig
at
ed
 in
to
 th
e 
Bg
ill 
si
te
 o
f t
he
 in
te
rm
ed
ia
ry
 v
e
ct
or
 p
1A
1H
CA
(-4
85
) 
p1
 A
ls
ka
ct
( -1
28
2)1
 J3
-ga
l 
sk
ac
t( -
12
82
) 
J3
-g
al
ac
to
sid
as
e 
J3
-g
al
ac
to
sid
as
e 
e
n
co
di
ng
 s
e
qu
en
ce
 is
 re
m
o
ve
d 
a
lo
ng
 w
ith
 th
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Chapter 5 
4.0 Recombinant Adenovirus Construction 
For all adenoviral construction work, a mutant of adenovirus type 5 (Ad5) 
named dl309 (described in section 1.3.5.1) was used as the backbone for 
generating replication-defective recombinants. Recombinant adenoviruses 
were constructed using two methods employing varying sources of the viral 
backbone DNA. 
4.1. Recombinant Construction and Improvement of Methods 
Initially, the method developed by Thomas Shenk, was employed to generate 
recombinant adenoviruses. Due to some shortcomings of this method, 
another method using an altered source of the viral backbone, developed by 
Frank Graham et a/. was used. Both methods are based on recombinant 
adenovirus generation by homologous recombination. 
4.1.1. Conventional Method of Recombinant Adenovirus Production 
This method of adenovirus construction is based on homologous 
recombination between Ad5 viral genome DNA and compatible adenoviral 
shuttle plasmid vector DNA, carrying the gene of interest. These DNA are 
cotransfected into Human Embryonic Kidney (HEK) 293 cells, where they 
recombine to generate replication-defective recombinant adenovirus (see 
section 1.3.6). 
The Ad5-d1309 genomic DNA is obtained in large amounts by first obtaining a 
high titre, CsCI-purified Ad5-d1309 virus preparation as described in section 
2.11.4, and digesting the protein coat by Proteinase-K (see section 2.11.5.) to 
release the viral DNA. The DNA is then phenol-chloroform extracted and 
ethanol precipitated and quantified as described in section 2.5. A known 
amount of DNA is then digested with Xbal, which cuts within the E 1 region 
making it non-functional. This Xbal-cut Ad5-d1309 genome is then 
cotransfected with a pLES53-based adenoviral shuttle vector (see fig 1.3.4), 
with the expression cassette of interest. 
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4.1.1.1. Lipofection and Recombinant Screening 
Transfections were performed by lipofection using DOT AP as described in 
section 2.9.2. 5fl9 of Ad5-d1309 DNA and 5fl9 of pLES53-based vector 
plasmid was used for the transfection into 293 cells. Cells were grown in liquid 
medium for four to five days and then harvested and freeze-thawed to release 
any virus generated. The cell lysate was then plated onto fresh 293 cells 
using a range of 10-fold serial dilutions for isolation of single plaques of newly 
made virus. Cells infected with viral dilutions were overlaid with MEM 
containing 0.6% noble agar after which they were cultured for several days. 
Plaques which began appearing after 4-5 days were picked and reinfected 
onto fresh 293 cells until completion of a full cpe. Amplified plaques were 
then harvested for extraction of viral DNA as described in section 2.11.5. 
Comparison of Hindlll digests for recombinants and Ad5-d1309 virus were 
then performed. 
The screening of the plaques by this method was time-consuming, as a 
considerable number of the plaques screened showed an Ad5-dI309-like 
pattern for the Hindlll digest. This may have been due to religation of the Xbal 
cut Ad5-dI309, resulting in an intact Ad5-d1309 genome. This resulted in a 
bias towards production of the parental Ad5-d1309 virus rather than 
homologous recombination taking place to generate a recombinant. 
4.1.2. Frank Graham's Method of Recombinant Production 
The large plasmid method uses the same Ad5-d1309 mutant adenovirus 
backbone as the Tom Shenk's method, but with the virus genome in a 
plasmid form such that large scale production of viral DNA, is not required. 
Frank Graham and colleagues have modified the viral genome such that it 
has the ability to replicate in a bacterial E.coli DH5 host and can be purified by 
CsCI density gradient centrifugation (see section 2.3.2.1.1.). The large 
adenoviral plasmid pJM17 (Microbix Biosystems Inc., Toronto, Canada; 
described in section 1.3.7.1) was used in the generation of majority of the 
recombinants in the present study. pJM17 can yield progeny that comprise 
90-95% recombinants. In the event of parental type virus arising, this may 
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either be due to chance elimination of the bacterial pBR322 fragment after 
transfection or a rare recombination event occurring between the plasmid and 
the E1 region of the 293 cell genome. 
4.1.2.1. Transfections and Recombinant Screening 
5 to 15f.lg each of pJM17 and the appropriate adenoviral shuttle vector was 
typically transfected into 293 cells by the CaP04 transfection method. After 
exposure to the DNA/CaP04 containing transfection mix for 6-8 hours, cells 
were overlaid with a modified soft agarose medium and dishes were cultured 
for several days (see section 2.10.2.). Dishes were examined daily for 
plaques, which typically began appearing from day 5 of culturing, but could 
arise up to 13 days after transfection. Plaques appearing as holes on the cell 
sheet with rounded up cells in the center, were picked as they are detected, 
and reinfected on to fresh 293 cells to amplify the virus. The reinfected cells 
were harvested when they reached full cpe, and freeze-thawed to release the 
virus. At this stage, half of this lysate was used for extraction of viral DNA as 
described in section 2.11.5. 
Viral DNA was digested with Hindi II , separated on a 1% agarose gel and 
compared with the restriction pattern of the parental type (Ad5-dI309) viral 
DNA. The restriction pattern of a variety of different viruses was compared to 
a simulated digest carried out on Vector NTI software (see section 2.16.). All 
potential recombinants whose restriction digest pattern corresponded with that 
identified by the Vector NTI program were retained and subjected to plaque 
purification to eliminate potential parental virus contamination. 
After plaque purification, some viruses were subjected to screening by PCR 
using E1 region specific primers (for details see section 2.1.B.). Verified 
recombinant adenovirus isolates without any parental virus contamination 
were amplified on a large scale and subjected to CsCI density gradient 
centrifugation and stored at -70°C in storage buffer as described in section 
2.11.3. 
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4.2. Optimization of Recombinant Construction Methods 
The pLECM-based construction method was used at the early stages of the 
current project, but proved to be inefficient in our hands. A high background of 
the parental Ad5-d1309 virus was obtained which may have resulted from 
religation of the Xbal-cut cohesive termini. Such religation would result in a 
functional genome with an intact E1A region, which is likely to have an 
adaptive advantage over the recombinant virus. Thus, under these 
circumstances, a larger number of parental type virus than recombinants 
would be generated. Presence of parental-type virus makes the recombinant 
isolation process lengthy and necessitates the screening of 50 or more 
plaques for a recombinant to be found. 
The transfection protocols used in the T. Shenk's methods proved inefficient 
when the Microbix plasmids were used. Use of pJM17 plasmid should result 
predominantly in production of recombinant viruses. When Shenk's method 
was employed, cells were grown in liquid medium and harvested after 4 days 
or left to show signs of cpe and then reinfected to screen for any 
recombinants generated. This method resulted once more in a frequency of 
recombinant of about 1 %, making the isolation procedure cumbersome. Two 
recombinant adenoviruses were generated using this method, only after 
screening up to 100 plaques for each. 
4.2.1. Optimized Method for Recombinant Isolation 
A third protocol which represented a modification of the method of Frank 
Graham et al. (Graham and Van der Eb, 1973; Graham and Prevec, 1995) 
was then successfully employed to generate recombinants reproducibly. The 
media and other reagents used were all standard commercially available 
products, which were chosen to assist in minimizing the inter-experiment 
variability. 
4.2.1.1. Transfections 
Low passage 293 cells were split at low density and grown to a confluency of 
70-80%, which normally takes about 48 hours. One day before the 
transfection, the original medium on the cells was replaced by fresh MEM with 
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5% FCS and 2.5mM Glutamine, to induce slow growth of cells: Slow growing 
293 cells were found to be an essential requirement for allowing uptake and 
consequent homologous recombination of the plasmids. 
Production of the transfection mix remained the most intrinsically variable step 
of the protocol. This transfection stage involved mixing the HBS-Phosphate 
and DNAI CaCI2 mix, forming a fine CaP04/DNA precipitate which is 
endocytosed by the 293 cells. The 1 X HEPES-buffered-saline-phosphate 
(HBS-P04) was obtained by making a 2X HBS-phosphate buffer and diluting 
with equal volume of the DNA/CaCI2 solution as described in section 2.10.1. 
Different mixing methods were tried and it was found that mixing by adding 
the DNA/CaCI2 solution to an equal volume of 2X HBS-P04 (with 10/-lg/ml of 
salmon sperm carrier DNA) immediately was the most efficient for obtaining a 
fine precipitate and avoiding a flocculant precipitate. The gradual, drop-wise 
addition method generally gave flocculant precipitate which could result in 
cellular toxicity, but on shorter incubation did result in successful recombinant 
plaques. 
4.2.1.1.i. Role of Carrier DNA 
The use of carrier DNA in the transfection procedure was also a critical factor 
in obtaining recombinant adenoviruses. This maybe due to better transfection 
efficiencies obtained by using additional DNA. It has been postulated that this 
carrier DNA may act as a decoy, engaging most of the DNA-degrading 
enzymes encountered at a stage after the DNA/CaP04 uptake and during its 
transport to the nucleus of the cell. This would make it possible for the pJM17 
and the smaller shuttle vector plasmids to enter the nucleus un-degraded and 
undergo homologous recombination. 
4.2.1.2. Agarose Overlay 
Following the cotransfection, the 293 cells were overlayed with soft agar 
medium composed of 2X Basal Minimal Eagle's (BME) medium and 2.2% 
Low Melting Point (LMP) agarose with 5% Foetal calf serum. 2X BME and 2X 
MEM, also used in the overlay, are commercially available from Gibco in 
batches of reproducible quality. BME was chosen over 2X MEM as the media 
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in the first overlay for its similarity of constituents to the regular MEM 
particularly glucose at 1 g/Iitre: Amino acid and vitamin composition of this 
medium was marginally lower, however, this factor is seen to contribute to 
the essential requirement of slow growth of cells post transfection. The 
overlay-purpose MEM had 4.5 times more glucose, even though all other 
components were the same as the regular MEM. Highly purified FCS (Gold 
CELLect foetal bovine serum from ICN-Flow) was incorporated into the 
agarose overlay to avoid the toxicity associated with regular serum. 
All subsequent overlays were carried out using 2X MEM. The overlay 
contained 10% regular FCS. This FCS was not deleterious for the cells in the 
second overlay onwards, but sometimes induced breaking in the cell 
monolayer, giving a false effect of plaques. 
Genuine viral plaques were seen to appear between 9 to 13 days after 
transfection. Generally 3-4 plaques were obtained in a transfection using 
10/-tg of pJM 17 and 10/-tg of the appropriate shuttle vector, which represented 
a suboptimal efficiency for recombinant generation. In general, 60% of 
plaques represented true viral plaques containing correct, while 40% of the 
plaques did not give rise to a cpe upon reinfection: These latter plaques may 
represent product of defective adenoviral particles arising due to anomalous 
homologous recombination. The highest number of plaques obtained was 9 in 
one case, but on a number of occasions, only a single plaque was obtained 
which was found to represent a recombinant with the correct DNA digest 
pattern. 
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4.4. Recombinants Made and Studied 
Attempts to generate recombinant adenoviruses were made using a range of 
shuttle plasm ids with various foreign gene inserts. The plasm ids used and the 
success achieved is presented in table 4.1. All putative recombinants were 
initially screened by comparison with Vector NTI simulated Hindlll digest 
patterns for each, as described in section 2.16. The parental Ad5-d1309 virus 
digested with Hindlll produces fragments of sizes 8010, 5446, 5322, 4597, 
3437, 2937, 2802, 2081, 994 and 75 base pairs. The 75 bp fragment was not 
taken into consideration because it does not differ between recombinants and 
wild type virus, and cannot be visualized on the 1 % agarose gels used in our 
analysis. The 3437 bp and the 2802 bp fragments of the parental type virus 
pattern differ in all recombinants and were absent or altered in size. Additional 
bands are seen in the digest pattern depending upon which Hindlll sites are 
removed or added along with the inserted foreign DNA fragment from the 
shuttle vector. The 3.4 kb and 2.8 kb fragments may thus increase or 
decrease in size or alternatively give rise to smaller fragments. 
4.4.1. Recombinant Adenoviruses Constructed Using Shenk's Method 
One recombinant adenovirus was constructed using the conventional (T. 
Shenk's) protocols for recombinant generation. 5/Jg each of Ad5-d1309 Xbal 
cut DNA and the shuttle plasmids pLECM/sTnC were cotransfected using 
DOTAP and putative recombinants screened as described in section 2.10.3. 
Numerous plaques were screened of which one plaque displayed a 
recombinant type pattern i.e. the 2.8 kb fragment missing and additional 
bands appearing. This recombinant was retained for further screening by 
southern blot analysis and named to as Ad5/CMV/sTnC. 
This recombinant was analysed by southern blotting as described in section 
2.12.2. The membrane was probed with a skeletal Troponin C specific probe 
described by Gahlman et al., 1988. The probe DNA was obtained as a 460 
nucleotide, Hindlll and EcoRI fragment from plasmid LK975. The DNA was 
separated using a 1 % agarose gel and extracting the DNA out as described in 
sections 2.4.3. and 2.4.5 and labeling with [a_32P]dCTP as described in 
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section 2.5.6. Ad5/CMV/sTnC recombinant was made and analyzed as a 
collaborative work with Dr. Yvonne Alexander (H.P. Labs). 
The recombinant showed hybridization of skeletal Troponin C cDNA specific 
probe to an approximately 6.5 kb Hindlll fragment, confirming the presence of 
the foreign gene insert (see fig. 4.1.). The reason for the different Hindlll 
digested fragment size for these recombinants may represent an anomalous 
A 1 
-6.5 kb 
2 
8.0 kb 
3437 bp 
2937 bp 
2802 bp 
B 
sTnC -
1. AdS/CMV/sTnC recombinant adenovirus 
2. AdS-d1309 parental adenovirus (control) 
2 
Fig 4.1: Southern blot analysis of skeletal Troponin C-expressing recombinant adenovirus. 
A. AdS/CMV/sTnC recombinant and AdS-d1309 parental type virus DNA isolated, 
digested with Hindlll and resolved on a 1 % agarose gel. DNA from the gel was 
blotted on to Hybond N+ membrane and probed as described in section 2.12.2. 
B. Hybridization of radiolabeled sTnC-specific probe to the Hindlll fragment 
confirming the presence of sTnC gene in the recombinant virus. 
recombination event. Nonetheless, the latter did not interfere with the 
incorporation of the promoter-cDNA cassette or subsequent foreign gene 
tra nscri ptio n. 
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4.4.2. Recombinant Adenoviruses Constructed Using Frank Graham's 
Method 
A number of recombinants were generated using this protocol and were 
confirmed by matching the restriction digest patterns with those generated by 
the Vector NTI software. 
10/-lg each of the large adenoviral genome carrying pJM17 plasmid and the 
small adenoviral shuttle plasmids was used. Plaques obtained from 
transfected and agarose-overlaid plate, were amplified as described in section 
2.10.3. The DNA was subjected to Hindlll digest to determine whether the 
recombinants were correct. The presence of a correct cDNA insert was also 
confirmed by PCR analysis (see section 2.12.1). 
4.4.2.1. AdS Epitope Tagged Troponin C Recombinants 
Adenovirus recombinants expressing Troponin C protein tagged with a HA 
antigen epitope tag were made, both with the ubiquitous CMV-IE promoter 
and the tissue-specific HCA(-485) promoter. The shuttle plasmid 
pCA13/sTnC~9:HA was used to make the CMV-IE driven tagged troponin C 
recombinant. Hindlll digest pattern for this recombinant exhibited the parental 
background pattern with the 3437 bp fragment altered to 3426 bp which was 
not noticeable on a 1 % agarose gel. However, the 2.8 kb fragment was 
replaced by approximately 750 bp and revealed the recombinant nature of 
virus, designated Ad5/CMV-IE/sTnC~9:HA (see fig. 4.2). The tissue specific 
Ad5 recombinant was made using the shuttle plasmid p1A/HCA(-
485)/sTnC~9:HA: The Hindlll digest pattern was similar for the 3437 bp 
fragment as explained above but the 2.8 kb fragment was replaced by one 
approximately 950 bp (see fig. 4.2). This recombinant was designated as 
Ad5/HCA( -485)/s TnC~9: HA. 
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8.0 kb 
6.0kb 
4.0 kb 
3.0kb 
2.0kb 
1.0 kb 
500 bp 
§ 3426 
§ 945 
3.0kb 
2.0kb 
1.0 kb 
500bp 
§ new or altered fragments appearing in recombinants only 
1& 4: Ad5/HCA(-485)/sTnCL19-HA recombinant 
2 & 3: Ad5/CMV-IE/sTnCL19-HA recombinant 
5: Ad5 recombinant showing an unexpected pattern 
1 2 3 
cc 
8010 1 kb 8010 
5446 5446 
5322 5322 
4597 4597 
3437 3426 
3426 bp 2937 2937 
2802 2081 
2081 994 
994 757 
75 75 
945 bp 
757bp 1. Ad5-d1309 
2. 1 kb marker DNA 
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4 
eeOC •. 
8010 
5446 
5322 
4597 
3426 
2937 
2081 
994 
945 ! 
75 
3. Ad5/CMV-IE/sTnCL19-HA recombinant 
4. Ad5/HCA(-485)/sTnCL19-HA recombinant 
Fig 4.2: Hindlll digest patterns of HA epitope-tagged skeletal Troponin C-expressing 
recombinant adenoviruses. A. Recombinant DNA digested with Hindlll and 
resolved on a 1% agarose gel. B. Simulated Hindlll digest fragment pattern 
produced by the Vector NTI software, for recombinant viruses shown in A and the 
parental Ad5-d1309 for comparison. Fragment lengths of the three viruses shown in 
the table were also generated by Vector NTI: Lengths shown in Bold/italics are 
characteristic of the recombinant. Lane 3 & column 3 of B corresponds to lanes 2 
and 3 of A, while lane 4/column 4 of B shows expected results of virus shown in lane 
1 and 4 of A. 
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4.4.2.2. AdS Troponin Recombinants with Tissue-specific Promoters 
Recombinants with the sTnC coding driven by Human cardiac actin (HCA) 
tissue-specific promoter were made using the shuttle plasmid 
p1A/HCA(-485)/sTnC/pA and p1A/HCA(-177)/sTnC/pA, containing the full 
length and truncated HCA promoters respectively. The Hindlll digest pattern 
for the full length HCA(-485)/sTnC recombinant was similar to the parental 
virus pattern but with the 3437 bp fragment replaced by approximately 2.9 kb 
while the 2802 bp fragment was replaced by smaller 950 and 580 bp 
fragments (see fig. 4.4). The recombinant was designated Ad5/HCA(-
485)/sTnC. The shorter HCA promoter recombinant displayed a 2889 
fragment in place of 3437 bp fragment, while the 2802 bp fragment replaced 
by 640 and a 580 bp fragments when digested with Hindlll (see fig. 4.3). This 
recombinant was designated Ad5/HCA(-177)/sTnC. 
The Adenovirus encoding skeletal Troponin C cDNA under human skeletal a-
actin promoter were made similar to procedures described above. The shuttle 
plasmid p18/skact(-2000)/sTnC/pA was used to generate a recombinant 
adenovirus with skeletal Troponin C coding sequence transcribed using the 
full length human skeletal a-actin promoter. The Hindlll digest of the 
recombinant virus was based on the parental background pattern with the 
3437 bp fragment replaced by one slightly increased to 3446 which displayed 
a difference which was undetectable on a 1 % agarose gel. The 2.8 kb 
fragment was replaced by a 2.2 kb and a 360 bp fragment (see fig. 4.4) This 
recombinant was designated Ad5/skact(-2000)/sTnC. To make adenovirus 
coding sTnC under the control of the Skeletal actin (-1282), the p1A/skact(-
1282)/sTnC/pA plasmid was employed. The Hindlll digest pattern displayed a 
replacement of 3437 fragment with one of 2.9 kb, and the 2.8 kb fragment 
replaced by a 1.9 kb and a 580 bp fragment, by comparison to the parental 
type Hindlll digest pattern (see fig. 4.5). The recombinant virus was 
designated Ad5/skact(-1282)/sTnC. 
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6.0kb 
5.0kb 
4.0kb 
3.0kb 
8010 1 kb 8010 I 
5446 5446 
5322 5322 
4597 4597 
8.0 kb 2937 3437 
6.0kb 2889 2937 
4.0 kb 
2081 2802 
994 2081 
3.0kb 639 994 
2.0kb 581 75 
75 
1.0 kb 
1. Ad5/HCA(-177)/sTnC recombinant 
2. 1 kb ladder marker 
500bp 3. Ad5-d1309 
Fig. 4.3: Hind II I digest pattern of cardiocyte-specific skeletal Troponin C-expressing 
recombinant adenoviruses transcribed by the shorter Human Cardiac Actin 
promoter. A. Recombinant virus DNA digested with Hind II I and resolved on a 1% 
agarose gel. (The gel on the left is the same as the one on right but was run longer 
to resolve the fragment doublet at 2.9 kb.) B. Simulated Hind III digest fragment 
pattern produced by the Vector NTI software for recombinant viruses and the 
parental Ad5-d1309 for comparison. Fragment lengths of the two viruses shown in 
the table were also generated by Vector NTI: Lengths shown in Bold/italics are 
characteristic of the recombinant. Lane & column 3 of B corresponds to the two 
lanes shown in A. 
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I kb ladder 
582 bp 
360bp 
1.0 kb 
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945 bp 
* fragments of lengths shown on the right side of the gels are observed only in recombinants 
1. Ad5/HCA(-485)/sTnC 
2. Ad5/skact( -2000)/sTnC 
B 1 2 3 A I~;~;c:;;'~';'; ,;c !';;,<;:'C' 
8010 8010 1 kb 8010 
5446 5446 5446 
5322 5322 5322 
4597 4597 4597 
8.0 kb 2937 3446 3437 
6.0 kb 2889 2937 2937 
3446bp ~ -~~--
2889 bp ---
(do.,bl,O ~_ - - 4.0kb 
2244 bp 
3.0kb 
2081 2244 2802 
994 2081 2081 
945 994 994 
582 361 75 
2.0kb 
75 75 
945 bp 1.0 kb 1. Ad5/HCA( -485)/sTnC recombinant 
582 bp 2. Ad5/skact( -2000)/sTnC recombinant 
500bp 3. 1 kb ladder marker 
360bp 4. Ad5-d1309 
Fig. 4.4: Hindlll digest pattern of cardiocyte-specific (human cardiac actin full-length promoter 
driven), and myocyte-specific (skeletal a-actin full-length promoter driven) skeletal 
Troponin C-expressing recombinant adenoviruses. A. Recombinant virus DNA 
digested with Hind II I and resolved on a 1 % agarose gel. (The three pictures are of 
the same gels run for increasing length of time, in order to resolve and confirm the 
fragment doublets appearing at approximately 3 kb.) B. Simulated Hind II I digest 
fragment pattern produced by the Vector NTI software for recombinant viruses and 
the parental Ad5-d1309 for comparison. Fragment lengths of the three viruses shown 
in the table were also generated by Vector NTI; lengths shown in Bold/italics are 
characteristic of the recombinant. Lane & column 1 of B corresponds to lane 1 of A, 
while lane/column 2 of B shows expected results of virus shown in lane 2 of A. 
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I kb ladder 
6.0kb 
4.0 kb 
3.0 kb 
1892 bp 2889 bp 
2.0 kb 
1892 bp 
1. Ad5/skact(-1282)/sTnC 
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8010 1 kb 8010 
5446 5446 
5322 5322 
4597 4597 
2937 3437 
2889 2937 
2081 2802 
1892 2081 
994 994 
579 75 
75 
1. Ad5/skact( -1282)/s TnC recombinant 
2. 1 kb ladder marker 
3. Ad5-d1309 
Fig. 4.5: Hind II I digest patterns of parental Ad5-d1309 virus and Ad5/skact(-1282/sTnC 
recombinant virus with shorter skeletal a-actin promoter for tissue specific 
expression in myocytes. A. Recombinant virus and parental virus DNA digested 
with Hind II I and resolved on a 1% agarose gel for comparison. B. recombinant 
adenovirus DNA digested and separated on a 1 % agarose gel. (both pictures are of 
the same gels run for increasing length of time, in order to resolve and confirm the 
fragment doublets appearing at approximately 3 kb.) C. Simulated Hind II I digest 
fragment pattern produced by the Vector NTI software for recombinant viruses and 
the parental Ad5-d1309 for comparison. Fragment lengths of the two viruses shown 
in the table were also generated by Vector NTI; lengths shown in Bold/italics are 
characteristic of the recombinant. Lane & column10f C corresponds to lane 2 of A 
and 1 of B. Lane/column 3 of C shows expected DNA digest pattern of of virus 
shown in lane 1 of A. Fragment lengths of table shown in B 
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4.5. Additional Recombinants Screening Procedures 
The majority of recombinants were initially screened by peR using Ad5 
primers, before a Hindlll digest or southern analysis was carried out. 
Recombinants were also checked for purity by screening for contamination by 
parental-type virus, using E1-specific primers (see table 2.1-8). 
peR analysis was carried out using the Ad5 primers which hybridized to bp 
280-289 (sense primer) and bp 3580-3598 (antisense primer) on the wild type 
adenovirus genome. These primers were designed to flank any foreign DNA, 
promoter-cDNA cassette insert and amplify the same in a peR reaction (also 
see table 2.1-8.). 
I kb ladder 
3.lkb 
2.0kb 
1.0kb 
500 bp 
1. pJM17 (control) 
2. Ad5/skact( -2000)/sTnC 
3. Ad5/HCA(-485)/sTnC 
Fig 4.6: Screening of Ad5 recombinants by PCR analysis. PCR amplification was done 
using viral DNA isolated from recombinants as template DNA. The Ad5 280-99 
and Ad5 3580-99 primers amplified a 3.1 kb (approximately) fragment on the 
Ad5/skact(-2000)/sTnC recombinant. The Ad5/HCA(-485)/sTnC DNA template 
amplified a 1500 bp fragment using the same primer pair. The control pJM 17 
cannot amplify the DNA under conditions used and shows non-specific bands. 
On the Ad5-d1309 virus genome template, the Ad5 primers amplify a 3319 bp 
fragment using these primers whereas on an E1 region-deleted adenovirus 
genome, a fragment of 138 bp is amplified. The pJM17 plasmid template 
which contains a p8R322 bacterial plasmid insert at 1339 bp, would amplify a 
fragment of size 7690 under altered peR conditions, but no product is 
obtained under the peR conditions used for screening the recombinants. The 
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Ad5 primer pair will amplify different size fragments depending upon the 
length of the promoter-eDNA cassette contained in the recombinant 
adenovirus (see fig. 4.6). 
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Chapter 5 
5.0 Expression Studies 
A number of recombinant adenoviruses produced in this project were 
analyzed for expression under culture conditions. Expression studies were 
either carried out at the RNA level using Northern analysis or at the protein 
level using Western blot analysis and Immunocytochemistry. Reporter gene-
expressing Ad5/~-gal recombinant virus was used to establish transduction 
protocols in vitro. and in vivo. NIH3T3 mouse fibroblasts, primary neonatal rat 
cardiocyte and cardiac fibroblasts were the standard in vitro. systems used for 
studying expression. 
The ~-galactosidase-expressing adenovirus (obtained from Prof. Ron Hayes, 
University of St. Andrews), was used to standardize the in vitro. virus 
transduction protocols at the initial stages of the project. Typically, Ad5/~-gal 
adenovirus was transduced at a titre of 107-108 pfu/ml into cells in culture as 
described in section 2.11.6. Infected cells were given 36-48 hours for 
expression of the reporter gene. The cells were then fixed and stained with X-
gal as described in section 2.15.2. 
5.1. Analysis of Skeletal Troponin C Expression 
Due to non-availability of skeletal Troponin C-specific antibody, the protein 
was tagged with the human influenza virus hemagglutinin (HA) epitope tag at 
the DNA level. The protein expression was analysed using the HA epitope 
tag-specific antibody using western blots and immunocytochemistry. Wild type 
(non-tagged) sTnC-expressing recombinant adenoviruses could only be 
studied at the transcriptional level for reasons described above and were 
studied using Northern blot analysis. 
5.1.1. Northern Blot Analysis 
The expression of the wild-type skeletal Troponin C-expressing recombinant 
adenovirus, Ad5/CMV-IE/sTnC, was analysed by Northern Blot analysis. 
Neonatal rat cardiocytes were isolated and cultured in 60mm dishes as 
described in section 2.8.4, and infected with the Ad5/CMV-IE/sTnC virus 
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solution at a titre of 105_106 pfu/ml, following the procedure described in 
section 2.11.6. The cells were allowed 48-72 hours for expression of the 
transgene and the total RNA isolated using RNAzolTMB as described in 
section 2.13. The quality of RNA was checked on a 1 % agarose gel and then 
quantified as described in section 2.5.4. 
10119 of each of the test and control RNA samples were fractioned on a 1 % 
denaturing formaldehyde-agarose gel made up in MOPS buffer as described 
in section 2.13.2. The separated RNA was transferred to Hybond N+ 
membrane using the alkali transfer protocol as described in section 2.15.4. 
The membrane was probed with a skeletal Troponin C specific probe 
described by Gahlman et aI, 1988. Probe DNA was obtained by removing a 
460 nucleotide, Hindlll and EcoRI fragment from plasmid LK975, separating 
on a 1 % agarose gel and extracting the DNA out as described in sections 
Northern Blot Analysis of sTne-expressing Recombinant Adenovirus 
2 3 
A 
B 
1. Control; uninfected cardiocytes only 
2. Ad5/CMV/sTnC recombinant adenovirus 
3. Control; cardiocytes infected with Ad5/p-gal 
Fig 5.1: Northern blot analysiS of Ad5/CMV/sTnC recombinant adenovirus. Ad5/CMV/sTnC 
recombinant was analyzed for expression at the level of transcription by infecting 
cultured cell with viruses and extracting total RNA. 20l1g of each sample of RNA 
was resolved on a 1 % formamide-agarose gel and analYSis was carried out as 
described in section 5.1.1. A. Resolved total RNA was probed with sTnC-specific 
radiolabeled DNA. Lane 2 shows hybridization of sTnC-specific probe to a 
transcript indicating expression of the gene of interest. B. Total RNA was probed 
with 288 ribosomal RNA to show equal loading of samples, as described in 
section 5.1.1. 
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2.4.3. and 2.4.5. DNA was labeled with [a-32p]dCTP as described in section 
2.5.6. The membrane was reprobed with human ribosomal 28S RNA 
oligonucleotide (Clonetech Ltd. cat. no. 9034-1). This analysis was carried out 
in collaboration with Dr. Yvonne Alexander, Dept. of Medicine and 
Therapeutics. 
5.1.2. Western Blot Analysis 
The recombinant adenoviruses generated were infected into cells and 
subsequently analysed for expression of the skeletal Troponin C protein in 
vitro. The protein was tagged with the human influenza virus hemagglutinin 
(HA) epitope, at the carboxyl terminal as described in section 3.1.5. The 
tagged protein expression was analysed by western blot analysis and 
immunocytochemistry of cultured fibroblasts and cardiocytes infected with the 
HA epitope tagged sTnC expressing recombinant adenoviruses. The HA 
epitope tag was inserted at the DNA level, by deleting bases encoding the 9 
amino acids from the carboxyl terminal end of the sTnC protein cDNA. The 
deletion was substituted by a 12 amino acid HA tag encoding sequence 
thereby making the protein longer by 3 amino acids. 
5.1.2.1. Virus Infection and Sample Preparation for Western Blot Analysis 
Cells were split into 100mm tissue culture dishes and grown to approximately 
50 or 60% confluency as described in section 2.8.4. Cardiocytes were isolated 
and cultured as described in section 2.8.4.5., and cultured in 60mm dishes for 
72 hours before they were infected with the viruses. 
Four 100mm dishes with N I H3T3 were infected with 150111 of (1), PBS only 
for cell line control; (2), virus solution of Ad5-d1309 for adenovirus control; 
(3), virus solution of Ad5/CMV-IE/sTnC~9-HA; and (4), virus solution of 
Ad5/HCA(-485)/sTnC~9-HA, at an estimated titre of 106-107 pfu/ml. The cells 
were incubated at 3rC in 5% CO2 for 48-60 hours to allow the virus to 
express the foreign protein. 
Cardiocytes were infected in the same manner as described above for 3T3 
cells, but the medium was supplemented with 1 X BrdU to prevent the growth 
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of cardiac fibroblasts. Infections were done with 100fli of (1) PBS only, for 
cardiocyte-only control and with virus extracts at an estimated titre of 106-107 
pfu/ml of (2) Ad5/CMV/sTnCL'l9-HA and (3) Ad5/HCA(-485)/sTnCL'l9-HA. 
Cardiocytes were then incubated at 3rC in 5% CO2 for 48-60 hours to allow 
the virus to express the foreign protein. 
Infected NIH3T3 cells and cardiocytes were harvested as described in section 
2.14.1 and freeze-thawed to extract the proteins as described in section 
2.14.1.1. The Iysates were transferred to a fresh tube and frozen at -20°C 
until being subjected to electrophoretic separation on a SOS-PAGE gel. 
The protein concentration of the samples was determined using the Biorad 
Protein Assay Kit as described in section 2.14.2. Cell lysate containing 
approximately 100fl9 of total protein from each sample was taken in a fresh 
tube and an equal volume of SOS-sample buffer (40mM Tris, pH 6.8, 4mM 2-
mercaptoethanol, 2% SOS, 10% glycerol, 0.2% bromophenol blue) added, 
mixed and boiled for 10 minutes in a boiling waterbath. Samples were allowed 
to cool down to room temperature and one fifth (20fl9) of each protein sample 
was loaded on SOS-PAGE gels to resolve the proteins for western blotting, or 
stored at -20°C for later use. 
5.1.2.2. 50S-Polyacrylamide Gel Electrophoresis and Electroblotting 
SOS PAGE gels were made and run as described in section 2.14.3. The 
resolving gel strength was 12% Acrylamide/bis 29: 1 with 2% stacking gel. 
Test samples with appropriate controls were loaded. 10fll prestained protein 
standards (Kaleidoscope Prestained Standards, Biorad cat. no. 161-0324) 
were also loaded as markers for checking the protein migration in gels, and 
run at 30V for overnight (about 16 hours) at room temperature or until the blue 
dye had migrated to the bottom of the gel. After the desired separation was 
reached, the protein bands were transferred from the gel to the membrane by 
electroblotting at 100V for 1 to 1.5 hours as described in section 2.15.5.1 in a 
pre-chilled buffer at room temperature. The protein transfer was confirmed by 
the successful transfer of prestained protein markers. 
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5.1.2.3. Immunoblotting 
After the transfer of protein, the blot was probed with HA tag-specific antibody 
using the protocol described in section 2.15.5.2. The primary and secondary 
antibodies were reconstituted and stored as stock solutions according to the 
instructions of the manufacturer, and diluted as required with 1 % skimmed 
milk in TBS. Briefly, the membrane was washed once with Tris-buffered saline 
(TBS) and non-specific binding sites blocked with 10 ml of Blocking solution 
(5% skimmed milk in TBS), with shaking for at least 2 hours at room 
temperature. The membrane was washed with TBS and incubated with the 
primary anti-HA high-affinity rat monoclonal (clone 3F10) antibody (Boehringer 
Mannheim cat. No. 1-867-431) diluted 1:1000 (100ng/ml) in 1% skimmed 
milklTBS) and incubated overnight with shaking at 4 cC. The membrane was 
washed 3 times with TBS T Wash buffer (TBS with 0.1 % Tween®20) allowing 
approximately 5 minutes for each wash. 
The membrane was then incubated with the anti-rat peroxidase-conjugated 
secondary antibody (anti-rat Ig-POO, Fab fragments; Boehringer Mannheim 
cat. No. 1-348-752). The secondary antibody was diluted 1 :3000 in 1 % 
skimmed milklTBS with 0.05% Tween®20, and incubated for 1-2 hours at 
room temperature, with shaking. Membrane was washed three times with TBS 
T wash buffer to remove any excess secondary antibody and then three times 
with TBS to remove traces of Tween®20. Excess fluid was dripped off and the 
membrane transferred to a shallow container with the protein side up, and 2ml 
each of premixed solution A and B of the Eel Western Kit (Amersham Life 
Sciences RPN-2109) were pipetted into one side of the container. The two 
solutions were mixed thoroughly, and tilted to coat the surface of the 
membrane completely. The membrane was then drip-dried and layered 
between two pieces of Saran-Wrap and exposed to X-ray film for exposure 
times ranging from 5 seconds up to 10 minutes. Fig. 5.2 shows a 15 seconds 
exposure of the blot. 
5.1.2.4. Western Blot Analysis Results 
The Ad5/CMV-IE/sTnC~9-HA recombinant adenovirus showed expression of 
the HA-tagged sTnC protein in NIH3T3 mouse fibroblast cells (see fig. 5.2., 
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Lane 4). The immunostained protein was estimated as a protein with 
molecular weight of approximately 21 kD although sTnC wild type protein has 
Western Blot Analysis of Cells Infected with Recombinant Adenoviruses 
41.8 kD-
30.6kD-
- sTne 
17.8kD-
6.9kD-
2 3 4 5 
1. Control; Uninfected Cardiocytes 
2. Control; uninfected 3T3 mDuse fibroblast cells 
3. Ad5-d1309 infected 3T3 mouse fibroblast cells 
4. Ad5-CMV-IE/sTnCLl9-HA infected 3T3 mouse fibroblast cells 
5. Ad5-HCA(-485)/sTnCLl9-HA infected 3T3 mouse fibroblast cells 
Fig 5.2: Western Blot analysis of cardiocytes and cultured 3T3 fibroblasts infected with 
recombinant skeletal Troponin C (HA-tagged) expressing adenoviruses. 20l-1g 
of total protein from infected cells was loaded on the gel, and the resolved 
protein bands blotted onto a membrane. The HA epitope-tagged protein was 
probed with the high-affinity HA primary rat monoclonal antibody and detected 
using anti-rat Ig-Peroxidase secondary antibody and ECl chemiluminescence 
method (see text for details). Molecular weights were estimated from the 
prestained markers used and are represented in kilodaltons (kD). lane 4 
shows the expression of the HA epitope tagged sTnC at approximately 21 kD. a 
calculated molecular weight of 18 kD. It is known that the gel pH affects the 
migration of proteins (Yates and Greaser, 1983) which could have brought 
about incorrect co-migration of the markers used and the sample. Also the 
Results: Expression Studies 168 
Chapter 5 
Troponin C molecule may have been contaminated by other cellular proteins 
which failed to dissociate from it during denaturation in sample preparation or 
during migration in the SOS-PAGE gel. 
The Ad5/HCA(-485)/sTnC~9-HA recombinant (fig. 5.2, lane 5) did not show 
any expression in the 3T3 cells as was expected due to the tissue-specific 
nature of the Human Cardiac Actin promoter. Ad5-d1309 (fig. 5.2, lane 3) was 
used as a parental virus background control. This control was included to 
assess if any viral protein may react with the anti-HA primary antibody, 
producing a false positive result. This virus showed a background similar to 
the no-virus control (uninfected 3T3 cells) which was the standard background 
control for the expression system (fig. 5.2, lane 2). 
The overall background of the blot was high due to higher amount of protein 
loading and the use of a directly conjugated secondary antibody, contrary to 
the recommendation of the protocols outlined in the primary antibody 
manufacturers guidelines. This problem can be overcome by use of a biotin-
conjugated secondary antibody followed by a streptavidin-peroxidase labeling. 
Also, using less than 10IJg of sample can also minimize the background on 
the blot, as highlighted in the manufacturer's protocols. 
After successful detection of expression by ubiquitously-expressing 
Ad5/CMV-IE/sTnC~9-HA, by immunoblotting, the equivalent virus 
recombinant, but under the control of the cardiac actin promoter, was 
analyzed for expression. This was carried out using immunofluorescence 
microscopy of Ad5/HCA(-485)/sTnC~9-HA infected primary neonatal rat 
cardiocyte culture. The Ad5/CMV-IE/sTnC~9-HA was also analyzed in the 
latter system and in NIH3T3 fibroblasts, by immunocytochemical analYSis. 
5.1.3. Immunocytochemistry 
The HA epitope-tagged skeletal Troponin C protein expression by the 
recombinant adenovirus was further confirmed by immunocytochemical 
analysis of virus infected cells in culture. Three procedures of 
immunocytochemistry, employing varying primary/secondary antibodies and 
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immunodetection methodology were employed. The first was a direct method 
using primary anti-HA antibody conjugated to Rhodamine. The second was an 
indirect method using primary anti HA antibody with a secondary Rhodamine-
conjugated antibody. The third method was similar to the second but with a 
secondary antibody conjugated to biotin. Detection of the immunolabeled cells 
was done using a Streptavidin-Alkaline Phosphatase conjugate followed by 
staining with Vector® Red staining procedure. 
5.1.3.1. Cell Culture and Viral Transduction 
NIH3T3 mouse embryo fibroblast cells were grown in tissue culture slide 
chambers (Nunc cat. no. 170920) and were seeded at a very low density and 
the fibroblasts were grown until they reached a 50 to 60% confluency. Primary 
neonatal rat cardiocytes were cultured in 60 mm dishes. The cells were then 
infected with adenovirus lysate at a titre of approximately 106 to 107 pfu/ml as 
described in section 2.11.6. 
5.1.3.2. Optimization of Immunostaining Procedures Employing HA-tag 
Antibody 
Three Immunochemical methods were performed as described in section 
2.15.6. Briefly, the media was aspirated off and cells fixed with 2 ml of freshly 
prepared 4% paraformaldehyde for 10 minutes. Fixed cells were then washed 
three times with PBS allowing 3 minutes per wash, and cells permeabilized by 
incubating with 0.1% Triton X-100 in PBS, for 5 minutes at room temperature. 
Cells were washed once quickly in 0.1 % Triton X-100 made with distilled 
water. Permeabilized cells were incubated with Blocking solution (0.5% 
Bovine Serum Albumin, fraction V, in PBS) for 15 minutes to block non-
specific binding sites. The flaskette chambers were removed at this stage and 
the immunostaining was carried out for the different methods. From the three 
methods tried, the indirect method using the biotin-conjugated secondary 
antibody was successful. The other two methods failed to give as discrete 
results as the one obtained with the former method. 
The Direct immunostaining method employed HA-tag specific primary, mouse 
monoclonal antibody, conjugated to rhodamine, eliminating the use of a 
secondary antibody. After fixing the cells and blocking non-specific sites (as 
Results: Expression Studies 170 
Chapter 5 
outlined above), the Anti HA rhodamine (Boehringer Mannheim, cat. no. 1 
666 959) stock was diluted in blocking solution to 1 mg/ml and cells incubated 
with it for 30-45 minutes at room temperature. Phalloidin TRITC at 2mg/ml 
was added along with the primary antibody to detect cells by staining the actin 
cytofilaments. Cells were washed 3 times with PBS allowing 5 minutes per 
wash. The flaskette cover was removed and a drop of Aquamount mounting 
medium (BOH 36226-2H) was dropped on the cells and a clean coverslip 
placed gently on it avoiding any air bubbles being trapped. Any excess 
mounting medium was blotted off and allowed to dry in the dark at room 
temperature. Once dried, the slides were stored at 4°C or at -20°C until 
screening under a fluorescent microscope using the appropriate filters. 
The Indirect immunostaining methods involving different primary and 
secondary antibodies were used. For these methods, the two-step 
immunostaining procedure involved a secondary antibody conjugated to 
rhodamine. Following the blocking step, cells were incubated with the primary 
Anti-HA mouse monoclonal antibody (Boehringer Mannheim cat. no. 1 583 
816) at 2mg/ml dilution made in the blocking solution, for 30 minutes at room 
temperature. Phalloidin TRITC was also added as described earlier. Cells 
were washed three times with PBS and incubated with a 1 :2000 dilution of the 
Anti-mouse IgG-TRITC secondary antibody (sigma T-2402), for 30 minutes at 
room temperature. Cells were washed three times and the immunostained 
cells mounted by placing a drop of mounting solution and placing a coverslip 
on it. The cells were examined under a fluorescence microscope fitted with 
the appropriate filters or the slides stored at -20°C in dark for later 
observations. 
These two methods were unable to detect the expression of the HA tagged 
sTnC. A possible explanation could be the primary antibody used which was a 
common factor in both the methods. 
5.1.3.3. Immunostaining Using Biotin-conjugated Secondary Antibody 
This method used a three-step immunostaining protocol which immunolabeled 
the protein of interest with alkaline phosphatase (AP) enzyme. AP is then 
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detected by a substrate conversionl color production reaction using the 
Vector® Red staining Kit (Vector Laboratories cat. no. SK-5100), which can be 
visualized under an ordinary light microscope. In addition, primary antibody 
used was a new high-affinity anti-HA rat monoclonal antibody which had 
proved successful in western blot analysis. 
For the purpose of immunostaining, NIH3T3 mouse fibroblasts were infected 
as described in section 2.11.6. with (1), PBS only, as a control; and (2), 
Ad5/CMV-IE/sTnC~9-HA recombinant virus. The Cardiocytes were infected 
with (1), Ad5/CMV/sTnC; (2), Ad5/HCA(-485)/sTnC~9-HA; and 
(3) Ad5/CMV/sTnC~9-HA. Following infection, both 3T3 cells and cardiocytes 
were incubated for 48-72, hours, prior to analYSis for expression of the 
protein. The cells were then fixed and blocked as described in section 2.15.6. 
Following blocking, the cells were treated as described in section 2.15.6.2.iL 
Briefly, the blocked cells were incubated with a 1: 1 000 (1 OOng/ml) working 
concentration of Anti-HA High-Affinity primary rat monoclonal (clone 3F10) 
antibody (Boehringer Mannheim cat. no. 1 867 431) diluted in blocking 
solution, for 30 minutes at room temperature. Cells were washed three times 
with PBS and incubated with a 1: 1 00 dilution (2mg/ml) of Anti-rat Ig-biotin 
F(ab')z, fragments, secondary antibody (Boehringer Mannheim cat. no. 1 348 
779), for 30 minutes at room temperature. Cells were washed three times with 
PBS and then incubated with 1 :3000 dilution of Streptavidin-AP conjugate 
(Boehringer Mannheim cat. no. 1 089 161) for 30 minutes. Cells were again 
washed three times with PBS. 
S.1.3.3.i. Vector® Red Staining 
The alkaline phosphatase-immunolabeled cells were stained using the 
Vector® Red Alkaline Phosphatase Substrate Kit (Vector Laboratories cat. no. 
SK-5100) as described in section 2.15.6.2.iLa. 2.5ml of assay buffer (100mM 
Tris HCI, pH 8.2) was taken and 25ml of levamisole stock (100X) added to 
inhibit endogenous AP activity of the cells. The substrate working solution was 
made immediately before use, by adding a drop each of reagents 1, 2 and 3 
of the kit to the 2.5ml of assay buffer and mixing thoroughly. 
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Cells were incubated with the freshly made substrate solution at room 
temperature, in the dark for 20-30 minutes, or until the required staining 
intensity was reached. Cells were washed with assay buffer for 5 minutes and 
then rinsed in distilled water. A drop of hematoxylin solution (Haemlum 
(Mayer's) solution; BOH cat. no. 35060-4T) was added to each slide and 
incubated briefly for approximately 15 seconds, and then rinsed in distilled 
water. Slides were then further rinsed with 100% ethanol for 2-3 minutes to 
increase the intensity of the Vector® Red fluorescence. Excess liquid was 
tapped off from the slide and the cells and mounted, using Aquamount as 
described in section 2.15.6.2.iLa, and examined under a light microscope or 
kept at 4°C for later observations. 
5.1.3.4. Immunocytochemistry Results 
Immunocytochemical analysis of infected mouse fibroblasts and primary 
cardiocytes proved useful in confirming the expression of HA tagged sTnC by 
the recombinant adenoviruses. The NIH3T3 cells showed expression of the 
Ad5/CMV-IE/sTnCLl9-HA, which was anticipated from infections of mouse 
fibroblasts with a CMV promoter (fig. 5.3.B). The Ad5/CMV-IE/sTnCLl9-HA 
recombinant also expressed in primary cardiocyte cultures, where 
immunostaining of both cardiac fibroblasts and cardiac myocytes was 
observed (fig. 5,,~,C), 
Ad5/HCA(-485)/sTnCLl9-HA recombinant virus did not show expression in 
NIH3T3 cells when tested by western blot analysis (see fig. 5.2) and therefore 
it was not subjected to further analysis by immunocytochemistry, in the same 
expression system. However, cultured cardiocytes were used and this virus 
showed visible expression in a few cells (fig. 5.4.B). No staining was observed 
in the cardiac fibroblasts, whereas somewhat inconspicuous, but visible red 
staining could be observed in groups of cardiocytes. Some intracellular 
staining was observed without any distinct morphological indication of cellular 
structures. This pattern of staining indicated the possibility of localization of 
the tagged Troponin molecule in the sarcomeres of the cardiocytes resulting 
in decreased visibility of the staining due to intricacies of the myofilament 
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structure. The brighter staining observed may be attributed to the tagged 
molecules stained in ruptured cardiocytes. Nevertheless, the absence of 
staining in the cardiac fibroblasts and some staining in cardiocytes reflected 
strong evidence of tissue-specific expression of the recombinant adenovirus. 
The non-infected controls used in the immunocytochemical staining showed 
no background staining in NIH3T3 cells (fig. 5.3.A). The non-tagged virus 
control used in cardiocyte culture also did not show any background staining 
eliminating the possibility of false positive results being produced by the sTnC 
protein (fig. 5.4.A). 
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Immunocytochemistry of mouse fibroblast cells 
infected with recombinant adenoviruses 
A, 
I. 
.. 
, 
" 
~B~ 
A. NIH3T3 (no-virus control); cells treated with PBS only 
B. NIH3T3 cells infected with Ad5/CMV-IE/sTnC~9-HA recombinant 
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Fig. 5.3:lmmunocytochemical analysis of NIH3T3 mouse fibroblast cells in culture, infected 
with recombinant virus expressing the skeletal Troponin C tagged with HA epitope 
tag. Cells were immunolabeled with alkaline phosphatase and stained with Vector 
Red stain; (see section 5.1.3.3.i for details). 
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1 
A. Ad5/CMV-IE/sTnC recombinant (non-tagged) 
B. Ad5/HCA(-485)/sTnCL\.9-HA recombinant 
c. Ad5/CMV-IE/sTnCL\.9-HA recombinant 
Chapter 5 
Fig. 5.4: Immunocytochemical analysis of primary cardiocytes in culture, infected with 
recombinant adenoviruses expressing skeletal Troponin C tagged with HA epitope. 
Arrow in B points to cardiocytes showing some visible staining indicating tissue-
specific expression of the virus used. Arrows in C point to stained cardiac fibroblasts 
and groups of stained cardiocytes indicating non-specificity of the recombinant 
adenovirus used. 
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Chapter 5 Appendix 
A-5.1. Western Blot Analysis 
In order to probe into the anomaly seen in migration of the epitope tagged 
protein described in section 5.1.2.4, further western blot analysis was carried 
out on the recombinant adenoviruses using the cultured neonatal cardiocyte 
system. The premise of the experiment was to compare the native cardiac 
troponin C protein in the cardiocytes with the HA epitope-tagged sTnC 
transgene protein. 
A-5.1.1. Cell Culture and Viral Transduction 
Neonatal rat cardiocytes were isolated and cultured as described in section 
2.8.4.5., and maintained in 60 mm dishes for 72 hours before they were 
infected with the viruses. The cells were then infected with adenovirus lysate 
at a titre of approximately 105 to 106 pfu/ml as described in section 2.11.6. 
Seven 60mm dishes of neonatal cultured cardiocytes were treated as follows; 
(1), was untreated cardiocytes, while the rest of dishes were infected with 
100!!1 of (2), PBS only, (3), virus suspension of Ad5-d1309 for adenovirus 
control, (4), virus suspension of Ad5/CMV/sTnC, (5), Ad5/CMV-
IE/sTnCi19-HA, (6) virus suspension of Ad5/HCA(-485)/sTnC, (7), virus 
suspension of Ad5HCA(-485)/sTnCi19-HA. The cells were incubated at 3rC 
with 5% CO2 for 72 hours to allow the virus to express the foreign protein. 
A-5.1.2. Sample Preparation and 50S-PAGE 
Treated cardiocytes were harvested as described in section 2.14.1 and 
freeze-thawed to extract the proteins as described in section 2.14.1.1. The 
Iysates were transferred to a fresh tube and estimated for protein content as 
described in section 2.14.2. Cell lysate containing approximately 40!!g of total 
protein from each sample was taken in a fresh tube and an equal volume of 
SOS-sample buffer (40mM Tris, pH 6.8, 4mM 2-mercaptoethanol, 2% SOS, 
10% glycerol, 0.2% bromophenol blue) added, mixed and boiled for 10 
minutes in a boiling waterbath. Samples were allowed to cool down to room 
temperature and one fifth (5-8!!g) of each protein sample was loaded on SOS-
PAGE gels to resolve the proteins for western blotting, along with 20!!1 of 
prestained protein standards as described in section 5.1.2.2. In addition, to 
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the samples and markers, 500ng of purified Human cTnC protein (cat. no. 
TrTd2, Advanced Immunochemical Inc. CA, USA) was also loaded as a 
positive control for anti-cTnC antibody. This protein was diluted into a total 
volume of 20111 and mixed with an equal volume of 6X SOS loading buffer and 
boiled for 10 minutes in a waterbath before loading on the gel. 
A-S.1.3. Immunoblotting 
The immunoblotting for the influenza virus hemagglutinin epitope tag was 
carried out as described in section 5.1.2.3. Similar methods were used for the 
cardiac Troponin C protein screening, with some modifications. The 
membranes were first probed with the cardiac Troponin C antibody and then 
reprobed after stripping, with the HA-epitope-specific antibody. 
A-S.1.3.1. Probing with Cardiac Troponin C Antibody 
For probing the native cardiac Troponin C protein, anti-Troponin C mouse 
monoclonal antibody (clone 1A2, cat. no. HG2AC3-1A2, Advanced 
Immunochemicallnc., CA, USA), was used. The antibody was diluted 1:1000 
(2.2llg/ml.) in 1 % skimmed milklTBS and incubated at RT for 4 hours. The 
secondary antibody was HRP anti-mouse IgG (sheep) (cat. no. S081-201, 
SAPU, Lanarkshire, Scotland), diluted 1: 1000 with 1 % skimmed milklTBS. 
A-S.1.3.2. Stripping of Membrane and Reprobing 
After probing with the cardiac Troponin C antibody, the membrane was 
stripped by incubating at 50°C with 100mM 2-mercaptoethanol, 2% SOS, 
62.5mM Tris-HCI pH 6.7, for 45 minutes, with occasional agitation. The 
membrane was then washed with large volumes of TBS-T, twice, 10 minutes 
each time at RT. 
The membrane was then blocked using 5% skimmed milklTBS for 2 hours 
and reprobed with the HA-specific antibody as described in section 5.1.2.3. 
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Western Blot Analysis of Neonatal Rat Cardiocytes Infected with 
Recombinant Adenoviruses 
12345678 12345678 
~: ..... " :,'y,'''''' ...... . 
:cA· 42.9 kD B l-42.9kD 
31.8kD 
'-31.8kD 
17.8 kD 
-17.8kD 
12345678 
i!-42.9kD 
'!-31.8 kD 1. Control; Cardiocytes only 
2. Control; Tris-Saline only 
3. Ad5-dI309; Virus Control 
4. Ad5/CMV/sTnC 
17.8 kD 
5. Ad5/CMV-IE/sTnCil9-HA 
6. Ad5/HCA(-485)/sTnC 
7. Ad5/HCA( -485)/sTnCil9-HA 
8. Cardiac Troponin C, purified protein 
Fig 5.5: Western Blot analysis of cultured neonatal cardiocytes infected with recombinant 
skeletal Troponin C (HA-tagged) expressing adenoviruses. 5-8fl9 of total protein 
from infected cells and purified cTnC protein were resolved on the gel, and the 
protein bands blotted onto a membrane. A. The membrane was first probed with 
anti-cardiac Troponin C, mouse monoclonal primary antibody: Purified cTnC protein 
(Lane 8) was used as a positive control for the anti-cTnC antibody. All lanes show 
the presence of the native cTnC protein. B. The membrane was stripped and 
reprobed with the high-affinity HA primary rat monoclonal antibody. Lane 5 shows 
the expression of the HA epitope tagged sTnC at approximately 21 kD. C. The two 
autoradiographs were then superimposed for comparing the bands obtained in the 
two experiments. The HA-tagged sTnC protein from the transgene has slower 
mobility (-21 kD) compared to the native cTnC protein (18kD). No cross-reaction of 
the cTnC antibody was obtained with the sTnC-HA tagged protein. Molecular 
weights were estimated from the prestained markers used and are represented in 
kilodaltons (kD). 
A-S.1.4. Results and Discussion 
The native cardiac Troponin C (cTnC) of the cardiocytes was detected by the 
anti-cTnC antibody. However, the expression detected was very low and only 
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detected after a 2 hour exposure of the ECl-treated membrane to the film as 
shown in Fig. 5.5-A. This may be due to lower affinity of the primary antibody 
and possibly due to less sample loaded. 
The sTnC-HA expression was detected in cardiocytes infected with the 
ubiquitously-expressing recombinant adenovirus Ad5/CMV-IE/sTnC~9-HA, as 
shown in Fig. 5.5 B. No expression was detected in the tissue-specific 
Ad5/HCA(-485)/sTnC~9-HA, possibly due to very low activity of this promoter. 
The two autoradiographs were superimposed, revealing a clear difference in 
the migration of the native cTnC and the HA-tagged sTnC expressed by the 
transgene (Fig 5.5-C). The HA-tagged sTnC migrated slower than the native 
cTnC from the cardiocytes, with an estimated molecular weight of 
approximately 21 kO, as observed previously (see section 5.1.2.4.). 
Furthermore, the sTnC protein did not cross-react with the anti-cTnC antibody 
as was expected. This could be due to the conditions used for anti-cTnC 
probing, which were not optimal, as seen by the low level of detection of the 
native cardiocyte cTnC. 
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Chapter 6 
6.0 Discussion 
The current project has resulted in the development of a range of 
replication-defective adenoviruses. Made to express skeletal Troponin C 
gene. Some of these adenoviral recombinants have been analyzed for 
expression and successfully express the sTnC gene in fibroblasts and 
cardiocytes. The adenoviral vectors obtained were designed to express the 
sTnC gene constitutively, or in a tissue-specific manner, by placing the gene 
under control of ubiquitously-expressing and muscle-specific promoters. 
6.1. Subcloning of sTnC Gene in Adenoviral Shuttle Vectors 
Development of adenoviral shuttle vector constructs with promoter-sTnC 
cDNA cassette, was the first step for making recombinant adenoviruses. 
Different strategies of subcloning were adopted to ensure integrity of the 
cDNA, and stability of transcription from the foreign DNA cassette. During the 
course of subcloning of sTnC, a range of useful plasmids were constructed 
(see Tables 3.1-3.7) which have wider and more general applications for 
future use in Adenovirus recombinant construction. 
6.1.1. Insertion of SV40 poly A Sequence into Basic Adenoviral Shuttle 
Vectors 
Achievements, of the work carried out include the improvement of basic 
adenoviral shuttle vectors, by adding a SV40 poly A sequence, at the 3' end 
of the multiple cloning site of plasmid vectors pilE1sp1A and pilE1sp1B. A 
strong polyadenylation (poly A) signal is important for heterologous gene 
expression. Both the adenoviral E1 band SV40 poly A, are known to confer 
stability on the transcribed transgene RNA (Berkner, 1992), with more efficient 
termination of transcript being observed with cDNA having the SV40 pA signal 
sequence (Berkner ef al., 1987). 
The pLES53-based plasmid pLECM is expected to utilize the indigenous poly 
A signal of E 1 b gene of the adenovirus. This sequence is located at bp 4038 
(van Ormondt and Galibert, 1984), which is 3' to the site of foreign DNA 
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insertion, and is known to perform well in obtaining efficient foreign gene 
expression (Berkner, 1992). 
6.1.2. Subcloning Promoter-sTnC gene Cassette in Adenoviral Shuttle 
Vectors 
Skeletal Troponin C cDNA was subcloned into the adenoviral shuttle 
plasmids, with the constitutive, Cytomegalovirus Immediate Early (CMV-IE) 
promoter, and tissue-specific promoters such as Human Cardiac a-actin 
(HCA) and Human Skeletal a-actin (SkAct). In the course of subcloning the 
sTnC with tissue-specific promoters, several basic vectors containing 
promoters were also obtained. These vectors are useful for subcloning any 
gene desired, and were used to subclone the ~-galactosidase reporter gene 
and phosphodiesterase (POE) gene (J. Queen, personal communication), 
with HCA and SkAct promoters. 
Cloning of sTnC coding region DNA into the center of the multiple cloning site 
(MCS) of the pSP72 vector, has provided the gene with several commonly 
used restriction enzyme sites, on either side of sTnC gene, thereby facilitating 
any further subcloning of this gene. The sTnC cDNA is pSP72 is inserted in 
either orientation, which further increases the choice of restriction enzyme 
sites which can be used to remove the insert. 
6.1.3. Development of Epitope-tagged sTnC and Subcloning into 
Adenoviral Shuttle Vectors 
As the skeletal Troponin C protein is not recognized by a specific antibody, 
the direct assessment of expression of the wild-type skeletal Troponin C 
transgene at the translational level, was not possible. In order to carry out 
protein expression studies of the sTnC transgene, the protein was tagged with 
influenza virus hemagglutinin (HA) and the simian virus 40 (SV40) T-antigen 
epitope tags, enabling detection of expression using immunochemical 
techniques. The tags were inserted at the DNA level, by deletion of 
3' sequences of the sTnC cDNA by PCR amplification and inserting a 
synthesized oligonucleotide coding for the epitope tag sequences (see figs. 
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3.4 -3.8 and fig. 3.11). The 3' insertion of the epitope tag sequence 
corresponded to the tag appearing at the carboxyl-terminal of the translated 
protein. Both the HA and T-antigen tagged sTnC cDNAs were made and 
subcloned into the adenoviral shuttle plasmid pCA 13, which has a CMV-IE 
constitutive expressing promoter. 
Two different forms of the deletion/substitution tagged construct were made 
for sTnC with HA epitope tag. Initially, sTnC~ 12-HA was designed by deleting 
the last 12 codons of the sTnC coding sequence and the stop codon. This 
deletion was replaced by a 3 codon spacer and a 9 codon HA tag sequence, 
terminating in a stop codon. 
The 12 amino acid (36 base pair) deletion from the carboxyl-terminal end (3' 
end in the cDNA) of the protein, encroaches on the high-affinity Ca++-binding 
site IV, which extends from amino acids 140 to 151 of the 160 amino acids 
sTnC protein (Parmacek and Leiden, 1991). In order to eliminate this 
imperfection of the sTnC~ 12-HA construct, another tagged skeletal 
Troponin C molecule was designed with a lesser 3' deletion (sTnC~9-HA.). 
This protein is designed with a deletion of 9 codons (27 base pairs) from the 
coding region and the stop codon, and addition of 36 base pairs (3 codon 
spacer and a 9 codon HA tag) sequence, terminating in a stop codon. This 
modification increases the size of the coded protein molecule by 3 amino 
acids. The sTnC~9-HA construct was also cloned with the HCA promoter in 
the adenoviral shuttle vector p~E1 sp1A. 
The T-antigen tagged sTnC (sTnC~8-T) was designed with a deletion of 8 
codon from the coding region of sTnC gene, and the stop codon. A sequence 
coding for 2 codon spacer and 6 codon T-antigen epitope sequences, and a 
stop codon, were added to the truncated cDNA to produce 8 amino acid-
deleted sTnC, with a carboxyl-terminal T-antigen epitope tag. Another tagged 
protein cDNA, sTnC-T was made, which did not have any deletion in the sTnC 
coding region. In this modified sTnC, only the stop codon was eliminated and 
replaced by sequence coding for 2 codon spacer and 6 codon T-antigen 
epitope sequences and a stop codon. This addition made the sTnC protein 
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longer by 8 amino acids. The two sTnC-T tag constructs were subcloned into 
the pCA 13 adenoviral shuttle plasmids. 
The HA and T-antigen tagged sTnC cDNA were made as two alternate 
epitope tag-sTnC constructs for establishing protocols for detection of 
expression of skeletal Troponin C in heart cells in vitro. and in vivo. With the 
success of the HA tagged sTnC in in vitro. expression studies, the T-antigen 
tagged sTnC constructs were not pursued further. However, the strategy of 
subcloning of T-antigen tag constructs in pCA 13, was performed in such a 
way that an intermediary vector pCA13-T was also obtained. This construct is 
in effect the pCA 13 plasmid with aT-antigen tag inserted 3' to the multiple 
cloning site (MCS) of the vector. PCA13-T can be used to make carboxyl-
terminal, T-antigen tag constructs of any gene, using methods outlined in 
section 3 .. 5.2.2. (also see fig. 3.11). 
6.2. Recombinant Adenovirus Construction 
Several adenoviral shuttle vector constructs with skeletal Troponin C and 
reporter genes were made during the project (see Tables 3.3 -3.7), with the 
ultimate aim of obtaining a recombinant adenovirus expressing the genes. 
Two methods of recombinant generation were tried, of which the T. Shenk's 
method did not yield good results in our hands. Frank Graham's method gave 
better results, but only after some modifications on the protocols. The CaP04 
transfection method, based on the protocols outlined before (Hitt et a/' J 1995; 
Spector and Samaniego, 1995; Graham and Prevec, 1997), was used, after 
further optimization of protocols. Precipitate formation and efficiency of 
transfection was highly dependent on variables such as the quality of DNA 
used, presence of carrier DNA, mixing method and duration of exposure of 
cells to the CaP04-DNA precipitate. The physiological status of the 293 cells 
such as conflluency, doubling time and passage number (Spector and 
Samaniego, 1995), were factors which affected final outcome of the 
transfection i.e. generation of recombinant virus. However, despite the 
difficulties, 8 recombinants were successfully generated. 
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The recombinants obtained were initially checked against the simulated digest 
patterns carried out using the Vector NTI software. Some of the recombinants 
selected for the correct Hindlll digest pattern, were screened by PCR using 
Ad5 specific primers which amplified a specific length of DNA, if the foreign 
DNA insert was present. All recombinants were screened for presence of E 1 
region by PCR using E1 specific primers (Dion et a/., 1996), and were found 
to be negative, indicating the purity of the replication-defective adenoviruses. 
6.3. Analyzing Foreign Gene Expression by the Adenoviral Vectors 
Recombinant adenoviruses generated during this project were analysed for 
expression by northern blotting, western blotting and immunocytochemistry of 
cells infected in vitro. 
6.3.1. Transcriptional Analysis of the Constitutively-expressing sTnC 
Adenovirus 
The NIH3T3 mouse fibroblast cell line was used, for in vitro. analyses of 
expression of the sTnC transgene, under the control of the CMV promoter, 
which shows a ubiquitous expression in all cells. The NIH3T3 cell line was 
chosen for its acceptance as a good in vitro. mammalian expression system. 
Moreover, as a non-muscle cell line, NIH3T3 cells do not have endogenous 
skeletal Troponin C gene activity. Northern blot analysis was carried out on 
total RNA isolated from NIH3T3 cells, infected with Ad5/CMV/sTnC 
recombinant adenovirus. RNA extracted from cells infected with control and 
sTnC adenovirus and probed with the 460 base sTnC-specific probe 
(Gahlmann and Kedes, 1990). Successful hybridization of the labeled probe 
to the RNA, showed presence of sTnC RNA transcripts in the infected cells, 
while no such hybridization was present in the control cells. 
6.3.2. Translational analysis of the HA Epitope-Tagged sTnC 
Adenovirus Recombinant 
The HA tagged sTnC-expressing adenoviral constructs were also analysed at 
the protein level, by transducing NIH3T3 cells in vitro. and performing western 
blot analysis and immunocytochemistry. A few different combinations of 
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primary and secondary antibodies were tried, both with western analysis and 
immunocytochemistry, before success was achieved. The primary antibody 
that performed well in both systems was a high-affinity Anti-HA, rat 
monoclonal antibody. The secondary antibody for westerns was an anti-rat 
HRP-conjugated antibody, whereas, a biotin-conjugated anti-rat Ig, secondary 
antibody, detectable by a streptavidin-Alkaline Phosphatase conjugate 
produced good results in immunocytochemistry. 
Western blot analysis of NIH3T3 cells infected with control and recombinant 
adenoviruses, showed overexpression by the Ad5/CMV-IE/sTnC~9-HA 
transferred gene, with no similar background observed in the mock-infected or 
Ad5-dI309-infected controls. No tagged protein expression was detected in 
the cells infected with Ad5/HCA(-485)/sTnC~9-HA, which was anticipated. 
This recombinant adenovirus is expected have a cardiac-specific expression, 
due to the presence of a human cardiac actin full-length promoter. 
6.3.4. In situ analysis of the HA Epitope-Tagged sTne Adenovirus 
Recombinant Expression Using Immunocytochemistry 
The positive results of the western blot analysis showing overexpression of 
the sTnC~9-HA protein by adenovirus was an successful achievement of this 
project. To further assess the possibility of detecting the HA tagged sTnC 
protein expression in situ, immunocytochemical analyses were carried out on 
infected NIH3T3 cells. Ad5/CMV-IE/sTnC~9-HA-infected and mock-infected 
NIH3T3 cells were immunostained using a variety of methods described in 
section 2.15.6. Positive results from the western analysis suggested the 
greater efficacy of the high-affinity anti-HA primary antibody in epitope 
detection, which was used, and gave comparable results in 
immunocytochemistry. 
Ad5/CMV-IE/sTnC~9-HA-infected and mock-infected NIH3T3 cells, showed in 
situ expression of the sTnC~9-HA protein in the virus infected cells, with no 
background staining in the mock-infected samples. In this analysis, the high-
affinity anti-HA primary antibody was used and the secondary antibody was 
an anti-Rat Ig-biotin conjugate, which was labeled using a streptavidin-
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alkaline phosphatase conjugate. Color development of labeled cells was 
achieved with Vector® Red staining. The three-step immunolabeling 
procedure was adopted to eliminate background staining and was highly 
successful in achieving the desired goal. 
6.3.5. In situ Analysis of Tissue-specific Expression of the HA Epitope-
Tagged sTnC Adenovirus 
Neonatal rat cardiomyocytes were used for assessing expression of 
Ad5/HCA(-485)/sTnC~9-HA recombinant, which expresses the HA tagged 
sTnC protein (sTnC~9-HA) under the control of the full-length, cardiac 
muscle-specific, human cardiac actin promoter. Immunocytochemical staining 
showed no detectable expression in the cardiac fibroblasts, which are non-
myogenic cells of the heart, and some visible staining in the cardiomyocytes. 
This result was in agreement with the anticipated behaviour of a cardiac 
promoter in heart cells. The adenovirus constitutively expressing the tagged 
protein, (Ad5/CMV-IE/sTnC~9-HA), showed expression in both 
cardiomyocytes and cardiac fibroblasts, while no staining was observed in 
cells infected with ubiquitously-expressing non-tagged wild-type skeletal 
Troponin C adenovirus, indicating the specific staining of the HA tag antibody. 
6.3.6. Additional Expression Analyses Required 
Three of the eight skeletal Troponin C adenoviral vectors, developed in this 
project have been analyzed and express the sTnC gene in vitro. Other 
adenoviral constructs which were designed with the wild-type sTnC gene 
under the transcriptional control of muscle-specific promoters, were not 
analyzed for expression, due to limitations of time for the project. However, 
the Ad5/HCA( -485)/sTnC~9-HA has shown the utility of using such promoters 
in gene transfer protocols. 
Functional analysis of the Adenovirus recombinants expressing sTnC was 
outwith the scope of this project. However, functional studies have been 
initiated, and are being carried out with our collaborators. Ad5/CMV/sTnC 
virus is being studied by Dr K. Webster's group at the University of Miami, 
Florida, who are carrying out edge detection analysis on cardiocytes in 
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culture, with normal and simulated conditions of ischemia. Similarly, methods 
for measurement of contractility of rat neonatal cardiomyocytes, in culture are 
being optimized, by our collaborators Dr. G. Smith at the Department of 
Physiology, University of Glasgow. Contractility and other physiological 
studies will further characterize the functional efficacy of these gene transfer 
vectors. 
6.4. Future Experiments Following from Our Vector Development 
Studies relating to in vivo. sTnC gene transfer and expression and protein 
isoform substitution can be immediately initiated using the recombinant 
viruses made in this project. Contractility studies using the virus can also be 
carried out both in vitro. and in vivo., or using ex vivo models such as isolated 
muscle fibres. 
6.4.1. In vivo. Expression Studies using sTnC-HA tag-expressing 
Adenovirus 
Establishment of working immunocytochemistry protocols for HA-tagged sTnC 
expression in vitro, was another milestone of the project. Therefore, an 
immediate follow-up of this project could encompass the use of the 
sTnC~9-HA protein-expressing viruses for in vivo. studies. This development 
will be useful for evaluating the extent of adenovirus-mediated gene transfer 
and expression, by transducing hearts in vivo., and using 
immunohistochemical analysis. Furthermore, the Ad5/HCA( -485)/sTnC~9-HA 
recombinant can be used for studying targeted gene delivery to the heart 
in vivo. In addition, subcellular localization studies can be carried out in vitro. 
or in vivo., using gold-immunolabeling, using electron microscopy, to establish 
the incorporation of the transgene protein into the myofilaments. 
Gene expression analysis of sTnC recombinant adenovirus with muscle-
specific promoters will add to the completeness of the adenovirus vectors, 
and mandatory before use of these viruses in any further functional studies. 
Due to non-availability of a sTnC-specific antibody (J. Potter; M. Greaser, 
personal communications), expression analysis at the translational level is 
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impractical. Thus northern analysis using sTnC-specific probe (Gahlmann and 
Kedes, 1990) should be able to indicate the presence of transcriptional activity 
of sTnC gene in cells infected with the virus. Myogenic cell lines such as 
C2C12 can be an acceptable in vitro. expression system for these viruses. 
The C2C12 cells can differentiate into myotubes, and express active 
transcriptional factors which can activate transcription from muscle-specific 
promoters (Bains et al., 1984). Though some skeletal Troponin C mRNA 
activity will be present in the cell line, inclusion of appropriate mock-infected 
and non-sTnC viral controls can aid in establishing sTnC transcription from 
the transgene. The level of sTnC mRNA in C2C12 myogenic cells infected 
with sTnC-expressing adenovirus, is anticipated to be higher by several 
orders of magnitude, than the endogenous levels of the C2C12 cells. 
6.4.2. Protein Substitution by Ectopic Overexpression of Alternate 
Isoforms of Contractile Protein Components 
Protein isoform substitution by overexpression of alternate isoforms in 
myogenic cells, are known to influence the regulation of the native contractile 
protein isoform of the cell (Palermo et al., 1995). Foreign gene expression has 
been found to downregulate expression of the endogenous isoform of the 
transgene by a feedback mechanism, either at the mRNA or protein level. 
This phenomenon has been observed in myosin light chain isoform 
overexpression studies in transgenic mice. The transgenics expressed the 
ventricular myosin light chain-2 transgene (MLC-2c) gene, both in the atria 
and ventricles of the adult animal heart, under the control of alpha-cardiac 
myosin heavy chain gene (a-MHC) promoter. Ectopic expression of transgene 
in the atria resulted in a complete replacement of the atrial myosin light chain-
2 protein isoform, although the endogenous isoform mRNA levels remain 
unchanged. In contrast, ventricular expression of the transgene had no effect 
at the protein level, despite an eight fold increase in transgene MLC-2v 
transcript le\lels. This demonstrated that sarcomeric protein stoichiometry is 
maintained rigorously via posttranscriptional regulation and that protein 
replacement can be achieved through a single transgenic manipulation. 
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Overexpression of skeletal Troponin C in cardiomyocytes using adenovirus 
and replacement of the endogenous cTnC isoform by the transgene, should 
be of interest in studying isoform regulation in myocytes. Similar studies with 
Troponin I (Tnl) isoform substitution, have shown nearly complete 
replacement of endogenous cardiac Troponin I with slow skeletal Tnl (Westfall 
et a/., 1997). Such a study may yield information on contractile protein gene 
regulation during heart failure and hypertrophy. 
6.4.3. Functional Analysis of sTnC-Expressing Adenoviruses 
The long-term goal of designing sTnC-expressing adenovirus was to study the 
effect of partial substitution of the endogenous cardiac isoform of Troponin C 
in cardiomyocytes, with the skeletal isoform, using a gene transfer approach. 
To assess the functional alterations produced by such substitution, studies 
can be performed on neonatal rat cardiocytes, transduced with skeletal 
Troponin C-expressing adenoviruses, under normal conditions and in 
conditions of simulated ischemia. Contractility and motion characteristics of 
the transduced and control cardiomyocytes can be determined using 
computerized motion edge analysis of single cardiomyocytes (Webster et a/., 
1996). Single transduced cardiomyocyte preparation can be used to study the 
effects of the transgene expression on Ca ++ -activated force, under conditions 
of reduced pH (Metzger et a/., 1993). Similarly, contractile behaviour of the 
transduced cell can be studied in hypoxia and other correlates of ischemia, 
induced by altering the environment of the culture of cardiomyocytes. Ca ++-
activated force measurements can also be carried out on isolated cardiac 
muscle fibres obtained from an in vivo. transduced myocardium, using 
modifications of methods already described (Palmer and Kentish, 1994; 
Parsons et a/., 1997). Parameters such as Ca ++ -sensitivity and Maximum 
Ca ++ -activated force can also be measured in fibres with the substituted 
isoform of protein. 
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6.5. Properties of Our Viral Mediated Strategies for Manipulating Ca ++-
Sensitivity 
The adenovirus constructs made in this project have certain characteristics 
which may be of interest in elucidating the mechanism involved in the 
phenomenon of Ca++-sensitivity. Some adenoviral constructs can be also 
useful in studying promoter responses to ischemia. 
6.5.1. Tagged Troponin C as Mutants 
The carboxyl-terminal hemagglutinin (HA) epitope tagged skeletal Troponin C 
cDNA made during this project were principally designed to enable protein 
expression and sub-cellular localization studies. However, these sTnC 
molecules may also be of special interest as a deletion-substitution mutant of 
skeletal Troponin C. The 12 codon deletion from the carboxyl-terminal end of 
protein, present in sTnC~ 12:HA, alters three amino acids of the high-affinity 
metal binding site IV (Parmacek and Leiden, 1991). Thus the tagged protein 
my be deficient in Ca ++ binding, at this high-affinity site. Similarly, sTnC~9-HA­
expressing adenovirus will also be of interest as an altered protein. Although 
the site IV is intact, this protein contains the tag which increases the length of 
the protein by 3 amino acids. 
The carboxyl-terminal domain of Troponin C is postulated to have a structural 
role of maintaining the stability of the Troponin complex, presumably through 
TnC-Tnl interactions (Zot and Potter, 1987), with the metal-binding sites 
playing a critical role. Site III has been found to be more critical for TnC 
association with the fibres, while site IV appears not to be essential for the 
structural stability of TnC within the thin filament. Moreover, alteration of sites 
I and II lower the binding affinity of TnC to the thin filament while mutations in 
sites III and IV affect the Ca++-sensitivity of force development (Szczesna et 
al., 1996). 
The observations that mutations of carboxyl-terminal metal-binding sites 
causing alteration in Ca ++ -sensitivity, are of great interest and relevance to the 
tagged sTnC molecules designed in this project. Future, physiological studies 
using the adenoviruses expressing the tagged sTnC~ 12-HA and sTnC~9-HA 
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protein (Ad5/CMV-IE/ sTnCil12-HA and Ad5/CMV-IE/ sTnCil9-HA), are 
expected to yield interesting data reflecting the effect of overexpression of the 
protein on the Ca++-sensitivity of contraction in transduced cardiomyocytes. 
6.5.2. Myogenic Promoter Studies using Adenovirus 
The human cardiac a-actin (HCA) and human skeletal a-actin (SkAct) 
promoters used for making sTnC adenovirus recombinants have been 
characterized in detail for their muscle-specific activation of transcription 
(Minty and Kedes, 1986; Parker et al., 1992). The SkAct promoter has been 
studied in more detail for its activation during myocardial cell hypertrophy 
(Bishopric and Kedes, 1991). The response of the SkAct promoter to a variety 
of growth factors, hormones and proto-oncogenes have also been extensively 
characterised and a number of specific regulatory domains subsequently 
identified (Bishopric et al., 1992; Parker et al., 1992; Karns et al., 1995). 
Transcription of the SkAct gene is known to respond to certain components of 
ischemia, specifically hypoxia/reoxygenation cycles in vitro. (Webster ef al., 
1993). 
The available information on SkAct promoter, makes the availability of a sTnC 
adenovirus vector controlled by this promoter of potential interest. This virus 
can be used in in vitro. models of ischemia, to assess the response of this 
promoter to components of the ischemic process. As both SkAct( -2000) and 
SkAct(-1282) promoter-driven adenoviruses are available, further 
characterization of response elements of the promoter can be made. In 
addition to ischemia, SkAct promoters responsive to hypertrophy can be 
studied on single cardiomyocytes, using modifications of methods already 
described (Sadoshima et aI., 1992; Shyu et al., 1995). 
6.6. An Overview of Adenovirus-Mediated Strategies for Gene Therapy 
in the Heart 
With the success of construction and subsequent demonstration of expression 
of the sTnC-expressing viruses, the groundwork has been laid for applying 
these viruses to animal heart gene transfer experiments. However, with 
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respect to the development of a potentially therapeutic adenoviral vector, and 
its transition to in vivo. studies and subsequent clinical trials, several issues, 
must be considered. Factors pertaining to the safety and efficacy of 
adenoviral vectors and the therapeutic gene itself, need to be addressed 
before our, or other related vector could be used for gene therapy protocols. 
Many gene transfer approaches have been outlined for myocardial ischemia 
and heart failure (Leor et a/., 1996; Leor et al., 1997). Any gene transfer 
method for improving contractile function of the failing myocardium must 
comply with certain criteria, which are fundamental to all gene therapy 
protocols. First, an appropriate gene or genes are chosen for manipulation 
and secondly, an efficient system should exist for delivering the therapeutic 
nucleic acids (DNA, RNA or oligonucleotides). There should be appropriate 
control of regulated expression of the transferred gene, to obtain expression, 
when required. In this project, Troponin C is the molecule targeted for 
alteration of Ca++-sensitivity of cardiomyofilaments, by overexpression of the 
skeletal isoform, using an adenoviral gene transfer vector. Use of myogenic 
promoters is expected to provide the requisite control over expression of the 
transgene in cardiomyocytes. 
6.6.1. Justification for Targeting Troponin C 
The Troponin C protein of the thin filament has been under study for several 
years, for its role in eliciting Ca++-induced contractile response in myocytes. 
Recently, drugs called calcium sensitizers, have been formulated, to influence 
the Ca ++ responsiveness of muscle, mainly by modulation of the Troponin C 
protein. These drugs are important due to findings that rCa ++]i is rarely altered 
in heart failure (Liao et al., 1994). 
6.6.1.1. Contractile Dysfunction of Heart Following an Ischemic Episode 
Following ischemia, normal contractile function requires several days of 
reperfusion to fully recover to its normal level (Jennings and Reimer, 1991). 
On reperfusion, the reversibly injured myocardium undergoes a 
hypofunctional state of depressed mechanical function that has been termed 
"Myocardial Stunning" (Braunwald and Kloner, 1982; Katz, 1992). The cause 
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of stunning has not been established (Jennings and Reimer, 1991) but ATP 
depletion and the delay in replenishing levels of ATP have been postulated to 
account for this phenomenon (Katz, 1992). Ca ++ transients are known to be 
sustained (Marban, 1997) or even increased (Kusuoka et al., 1990) in stunned 
myocardium, which implies that myofilament responsiveness to Ca ++ is 
abnormally low. It is now widely accepted that the decreased Ca ++ -sensitivity 
of the contractile proteins presents a likely mechanism to underlie the altered 
mechanical function of the "stunned" myocardium (Kusuoka et al., 1990; 
Marban, 1997). The intracellular pH and Pi are normal in stunned myocardium 
as reperfusion is complete (Kusuoka et al., 1990). Thus Ca ++-desensitization 
is unlikely to be due to these two metabolites. 
6.6.1.2. Decline in Ca ++ Sensitivity of Myofilaments in Ischemia 
The decline in Ca ++-sensitivity of myofilaments is an intrinsic effect of ischemia 
causing contractile dysfunction, which is more pronounced in stunned 
myocardium. Components of ischemia, such as hypoxia are known to 
decrease calcium responsiveness of the myofilaments (Hajjar and Gwathmey, 
1990), which leads to contractile dysfunction and heart failure. Amelioration of 
the desensitization is therefore a viable option for recovering the 
compromised contractility of a compromised heart. Contractile recovery of 
stunned myocardium is imminent due to restored blood flow. However, if large 
parts of the left ventricle are affected, causing impaired global left ventricle 
function, the extent of stunning can be reduced by inotropic stimulation 
without causing further damage to the myocardium (Heusch and Schulz, 
1996). 
6.6.1.3. Possible Role of Ca ++ Sensitizers in Restoration of Contractility 
Pharmacological modulation of Ca++-sensitivity is seen as a promising 
strategy for treatment of acute or chronic heart failure. Calcium sensitizers 
comprise a group of drugs which increase the Ca ++ responsiveness of 
myofilaments by exerting a positive inotropic effect, without increasing Ca ++ 
levels (Korbmacher et al., 1997). The overall Ca++ responsiveness is seen as 
a composite of two fundamental components; Ca ++ -sensitivity and maximal 
Ca++-activated force (see sections 1.2.6). 
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Several pharmacological calcium sensitizer are being studied for their positive 
inotropic effects and the molecular mechanism underlying their characteristic 
behaviour. Most calcium sensitizer compounds are found to have a twin 
activity of POE inhibition which maybe due to different enantiomers of the 
compound (Lues et al., 1993; Ravens et al., 1996). Calcium sensitization is 
achieved in a variety of ways by this group of compounds. Pimobendan 
increases the affinity of Troponin C for Ca ++ (Lee et al., 1989). Levosimendan 
stabilizes the Ca ++ -induced conformational change of Troponin C (Haikala et 
al., 1995), whereas MCI-154, EMO 53998 and EMO 57033 increase calcium 
sensitivity by direct interference with the myosin-actin interaction (Lee and 
Allen, 1991; Gross et al., 1993; Haikala et al., 1995; Pan and Johnson, 1996). 
6.6.1.4. Troponin C as a Therapeutic Target 
The strategy of skeletal Troponin C gene transfer and subsequent 
overexpression in cardiomyocytes can be seen as having certain parallel 
features with the pharmacological calcium sensitizing agents. Studies with 
these will provide information on effects produced by increased Ca ++ affinity 
and the effect it has on the overall myofilament. For example, levosimendan a 
calcium sensitizing agent was designed to bind to cardiac Troponin C. This 
compound binds the N-terminal domain of cTnC, stabilizing its conformation 
when it is calcium activated (Pollesello et al., 1994). The inotropic effect of this 
drug was due to conformational stability of the Troponin C rather than 
increased affinity for Ca ++, and is found to be pH independent (Haikala et al., 
1995). This finding corroborates the postulate of pH induced alteration in the 
tertiary structure of Troponin C, and its role in desensitization of the 
myofilament in acidosis (Wang et al., 1987). In addition, the Troponin C 
isoform substitution experiments (Moss et al., 1986) and transgenic study 
(Metzger et al., 1993) have provided convincing information on the role of this 
molecule in responding to intracellular Ca ++. The Troponin C molecule is 
under extensive study and several mutated forms of this protein have been 
made to dissect the function of this molecule in contraction (Gusev et al., 
1991; Szczesna et al., 1996; Akella et al., 1997). In light of the above 
observations, overexpression of the skeletal isoform in cardiomyocytes was 
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postulated to confer resistance to desensitization of myofilaments, during 
ischemia. 
6.6.2. Critical Review of Adenoviral Vectors in vivo. 
Several attributes of the adenovirus have made this virus a vector of choice 
for gene transfer in general, and especially as gene transfer vector for the 
myocardium. Notable properties advantageous for cardiac gene transfer 
include the ability of adenoviral vectors to infect non-dividing cells, such as 
cardiac myocytes (Guzman et al., 1993; Kass-Eisler et al., 1993; Barr et al., 
1994) and their capacity to accommodate foreign DNA inserts of up to 7.8 kb 
(Bett et al., 1994). In addition high titers of up to 1 X 1010, are obtained, which 
can be improved by concentrating further, following purification, to 1 x 1012 
plaque forming units (pfu) per ml, (French, 1997), are an added advantage for 
achieving widespread gene transduction in the ventricular walls. 
Nevertheless, the adenoviral vectors are not without faults, and in vivo. gene 
transfer experiments have experienced problems. These problems have 
arisen with use of the first-generation adenoviruses, which have reached the 
stages of clinical trial protocols. Different strategies are being evolved to 
overcome the deficiencies of this otherwise efficient vector. 
6.6.2.1. Shortcomings of Adenoviral Vectors 
First-generation adenovirus-mediated gene transfer experiments have 
demonstrated an exceptional efficiency of virus uptake and gene expression 
in a variety of in vivo. models. Unfortunately, high-efficiency gene delivery is 
often not accompanied by long-term gene expression of the transferred gene, 
mainly due to induction of host immune response toward the adenovirus. 
Persistence of transgene expression by an adenoviral vector in an in vivo. 
system may not be essential in all cases of myocardial gene therapy, but can 
be a factor of interest in some applications. Moreover, factors influencing 
expression are generally of interest, for modulating the overall efficiency of the 
virus. 
Generally, maximal gene expression peaks during the first week of infection 
and rapidly declines to basic undetectable levels, 80 days after infection 
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(Kass-Eisler et al., 1993). Experience in adenovirus-mediated cystic fibrosis 
(CFTR) gene transfer in mice and non-human primates, indicate the transient 
nature of the transgene, lasting less than 21 days, and is also associated with 
development of inflammation. Immuno-modulation in trial animals has been 
found to maintain the viral genome stably in the transduced host cells for over 
12 months (Kass-Eisler et al., 1996). C3H-scid and Balb/c-scid 
immunodeficient mice, infected with human a1-antitrypsin-expressing 
adenovirus show indefinite gene expression from transduced hepatocytes 
(Barr et al., 1995). Also, poor transduction efficiencies are often observed 
when the same virus is re-administered due to anti-adenovirus antibodies 
induced during the first administration (Christ et al., 1997; DeMatteo et al., 
1997). 
6.6.2.1.a. Immune Response to Adenoviral Vectors 
Earlier attempts of adenoviral gene transfer into heart indicated no evidence 
of viral toxicity in vivo. (Barr et al., 1994; Muhlhauser et al., 1996). However, 
some studies found the adenoviral vectors to induce an inflammatory 
response when used in high titers (Leor et al., 1996). The ability to use high 
titers of virus is the most attractive feature for use of adenoviral vectors, 
especially in myocardial applications. Any associated toxicity with such a 
feature in in vivo. gene transfer, is liable to cancel out the advantageous 
effects. 
Adenovirus vectors retain about 80% of the viral genetic information, which 
are presumed to show a "leaky" expression, if induced by an E1-like 
transactivator activity of the host cell (Yeh and Perricaudet, 1997). This leads 
to low levels of viral protein expression, causing morphological alterations of 
host cell, known as a cytopathic effect (Zhang and Schneider, 1994; Wang 
and Finer, 1996). Such basal expression of viral antigens often contributes to 
a cellular immune response leading to the destruction of the transduced cells 
by T-Iymphocytes (Wang and Finer, 1996; Christ et al., 1997). The T-
lymphocyte response results in viral elimination after a primary treatment of 
recombinant adenovirus, and is often followed by a potent humoral response, 
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which obstructs an effective subsequent adenoviral gene transfer (DeMatteo 
et a/., 1997; Gahery-Segard et a/., 1997). 
Production of anti-adenovirus antibodies and vector clearance by the cellular 
immune response have emerged as the major impediments to successful 
gene therapy (DeMatteo et a/., 1996; Christ et a/., 1997; DeMatteo et a/., 
1997). In order to deal with the immunogenicity of the adenoviral vectors, new 
vectors are being developed, with additional deletions (Kochanek et a/., 1996; 
Parks et a/., 1996; Wang and Finer, 1996). However, with the current first 
generation vectors, certain strategies of in vivo. gene transfer have been 
suggested to circumvent the inevitable immune response (DeMatteo et a/., 
1996; Kass-Eisler et a/., 1996). Such procedures include the induction of 
tolerance to adenovirus in animals at the neonatal stage, and using viruses of 
varying serotypes where repeated administration of the therapeutic virus may 
be required (Kass-Eisler et a/., 1996). 
Immunosuppression provides an alternative tool with potential for clinical 
application of adenovirus-mediated gene therapy (DeMatteo et a/., 1996). This 
has been supported by sustained gene expression observed in 
immunodeficient or immunologically naive rodents (Stratford-Perricaudet et 
a/., 1992). Treatment regimens with immunosuppressive drugs such as 
cyclophosphamide, FK506 (lian et a/., 1997) or with monoclonal antibodies 
that block either the T cell receptor or co-stimulation pathways, also allow 
prolonged transgene expression and/or read ministration of adenoviral vectors 
(DeMatteo et a/., 1996; Christ et a/., 1997). Antigen presentation in the thymus 
of neonates is an important way of T-cell clone deletion which can eliminate 
the adenovirus-specific cellular response (lian et a/., 1996). This approach 
can potentially be employed to inhibit any immune response to reporter gene 
or therapeutic proteins which the virus has been engineered to encode (Kass-
Eisler et a/., 1996). 
Viral backbone modification has also been employed to tackle the problem of 
immune response against adenovirus-infected cells. Several recombinant 
generation systems use deletion derivatives of the viral genome that are 
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made by eliminating dispensable viral genes (Kochanek et al., 1996; Parks et 
al., 1996; Wang and Finer, 1996). Adenovirus itself, like other viruses has 
evolved strategies for escape from immune surveillance of the hosts. The 
gp19k gene found in the adenovirus E3 region is known to down-regulate 
major histocompatibility complex class-1 expression on the cell surface, 
enabling the infected cell to escape recognition by cytotoxic T cells (Wold and 
Gooding, 1991; Lee et al., 1995). Vectors including the immuno-modulatory 
gp19k gene, fail to stimulate T-cell proliferation and thus elicit a cellular 
immune response against the cells infected by the adenovirus vector (Lee et 
al., 1995). Most first-generation vectors used, have a viral backbone (e.g. 
Ad5-dI309), where the E3 region is deleted to accommodate more DNA in the 
E1 region. 
6.6.2.1.b. Replication-Competent Adenovirus (RCA) Generation 
Another noteworthy predicament with first-generation adenovirus-mediated 
gene transfer, is the generation of replication-competent adenovirus (RCA) 
during the propagation of the replication-defective adenovirus (RDA) in the 
permissive 293 cells. This cell line provides the E 1 gene function in trans to 
the E 1-deleted adenovirus recombinants and is extensively used as a system 
to generate and propagate replication-defective recombinant adenoviruses 
(Ali et al., 1994; Graham and Prevec, 1995; Hitt et al., 1995; Graham and 
Prevec, 1997). 293 cells have a large fragment of the left-end part of the Ad5 
genome, that includes the left ITR, the packaging sequence, the complete E1 
region with the protein IX coding sequence, and the distal part of gene IVa2, 
integrated into human chromosome 19 (19q13.2) (Louis et al., 1997; Yeh and 
Perricaudet, 1997). 
Recently, purity of the RDAs has come under question, in light of the fact that 
homologous recombination between the E1-viral genome and E1 sequences 
integrated in the 293 cells, can produce adenovirus which are replication 
competent. This phenomenon may occur during the process of viral 
propagation and contaminate the recombinant with parental-type adenovirus 
(Louis et al., 1997; Yeh and Perricaudet, 1997). These RCAs are similar to 
the wild-type adenovirus and can propagate in non-permissive cells. The 
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cytolytic nature of these adenoviruses, makes them unsuitable for in vivo. and 
clinical applications (Yeh and Perricaudet, 1997). 
Strategies to circumvent unwanted RCA generation, deal with designing new 
permissive cell lines and remodelling the viral backbone genome (Gorziglia et 
al. J 1996; Hehir et al. J 1996; Imler et al. J 1996). The other option of modifying 
the vector backbone, is being used to develop adenovirus genomes which 
produce lethal RCAs when propagated in 293 cells. 
6.6.3. Delivery Systems Available for Administration of Adenoviral 
Vectors to Myocardium 
Gene therapy is unlikely to become a clinically important treatment option, if it 
cannot be administered to patients in routine clinical surroundings. This issue 
is being addressed for adenoviral gene transfer into myocardium to obtain 
targeted delivery and expression of the therapeutic gene, using non-invasive 
methods. Following delivery, a homogenous infection and expression in 
significant regions of the left ventricle, by the adenoviral vector, is also 
essential for the transferred gene to manifest therapeutic effects (French, 
1997). A number of delivery methods have been used for transferring the 
adenoviral vectors into the myocardium successfully with varying degrees of 
expression patterns. These include direct intramuscular injection, 
intracoronary infusion or catheter-mediated infusion of adenovirus vector. 
Intracoronary infusion of adenovirus vector is considered a less invasive 
method compared to Intramyocardial injection which involves thorotocomy to 
expose the heart for injecting the virus. With the advances in catheterization 
technology, intracoronary infusions also have direct clinical relevance. 
However, direct intramuscular injection of virus resulted in a localized and 
more efficient expression of virus in the myocardium (Magovern et al. J 1996; 
Muhlhauser et al. J 1996). The infusion method on the other hand results in 
transduction of coronary vasculature and non-myocyte connective tissue, 
scattered throughout the region supplied by the injected coronary artery (Barr 
et al. J 1994; Muhlhauser et al. J 1996). Transgene expression has also been 
observed in non-heart tissue such as lung, thymus and liver, following direct 
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injection of adenoviral vector in the heart (Guzman et al., 1993; Kass-Eisler et 
al., 1993). This issue of non-specific transduction by adenoviral vector needs 
to be addressed for safety concerns. 
6.6.4. Targeted Delivery and Expression of Transgene 
Therapeutic genes targeted to myocardium are required to express widely 
within the target organ only. This important safety issue is being addressed by 
using cardiac-specific promoters to obtain ectopic expression of reporter and 
therapeutic genes. Muscle gene promoters such as Human Cardiac Actin 
(HCA), (Minty and Kedes, 1986), Skeletal a-actin (Sk-Act) (Karns et al., 
1995), alpha-Myosin Heavy Chain (a-MHC) (Katz and Steinhelper, 1992), and 
Myosin Light Chain-2 (MLC-2v) (Lee, 1992; Franz, 1993), have been 
characterized and cloned. Specific consensus sequences within these 
promoters regulate associated genes, in response to binding by muscle 
specific transcriptional factors. 
Human cardiac (alpha) actin gene is regulated developmentally, encoding the 
major actin species in the adult heart, and high level expression in foetal and 
embryonic skeletal muscle (Mayer et al., 1984; Mohun et al., 1984). A 485 bp, 
upstream region is known to modulate expression of this gene in muscle cells, 
but not in mouse fibroblast cells (Minty and Kedes, 1986). The skeletal a-actin 
gene is expressed in adult skeletal muscle under the transcriptional control of 
a 2000 bp promoter region. The skeletal actin promoter is found to be 
positively regulated by the c-fos and c-jun proto-oncogene transcriptional 
regulators which are induced as a hypertrophic response in the myocardium 
(Bishopric et al., 1992). The a-MHC promoter is 685 bp upstream region of 
the alpha-Myosin heavy chain gene which is expressed in adult cardiac 
muscle and is known to be positively regulated by thyroid hormone (Kitsis et 
al., 1991). 
Recently, promoters have been subjected to extensive analysis for use in 
cardiac-specific gene expression. Direct DNA injection of reporter genes 
under the transcriptional control of a-MHC promoter have shown expression 
in heart but not in muscle (Buttrick et al., 1992; Li et al., 1997). Transgene 
Discussion 198 
Chapter 6 
expression driven by Myosin Light Chain-2 (MLC-2v) promoter, has been 
shown to be ventricle-specific in transgenic animals (Lee, 1992; Franz, 1993). 
Injection of adenoviral vector expressing luciferase reporter gene transcribed 
by MLC-2v promoter, into neonatal rat cardiac cavity, showed expression in 
heart but not in skeletal muscle tissue or other tissues tested (Rothmann et 
a/., 1996). 
New methods of gene regulation are being devised to regulate the expression 
of putative therapeutic/cardioprotective genes directly in response to 
ischemia-associated signals. Recently, a combination of gene regulatory 
components that can be used to target a product to the myocardium and limit 
the expression of the gene to periods of ischemia activity, has been created 
(Prentice et a/., 1997). A single set of four tandemly repeated hypoxia 
response element (HRE) from human erythropoietin gene, placed immediately 
upstream (-86 bp), of a minimal muscle-specific a-MHC promoter, conferred 
potent positive regulation of this promoter by hypoxia in vitro, and by ischemia 
in vivo. The induction by ischemia persisted for at least 4 hours, returning to 
baseline level within 8 hours. Such an assembly of enhancer and promoter 
elements allows controlled expression of a therapeutic gene in ischemic 
myocardium. 
Use of tissue-specific promoters has been shown as a promising tool for 
modulating the promiscuous tissue tropism of the otherwise efficient 
adenoviral vectors, for gene therapy targeted to the myocardium. With 
development of promoters and identification of enhancer elements like the 
HRE, a regulatory internal "sensor" can be assembled to trigger expression of 
therapeutic genes in heart at the onset of ischemia. 
6.7. Current Status and Future Directions of Gene Therapy for the 
Myocardium 
Current clinical practice for treatment of heart disease normally involves drug 
therapy, and often surgery in severe cases. Both these interventions have 
limited efficacy and associated adverse effects. Moreover, these therapies are 
aimed at treating the consequences of a heart condition (such as ischemia), 
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rather than the cause (e.g. atherosclerosis). Novel therapeutic approaches for 
treatment of disease have become available due to recent advances in gene 
transfer technologies. Gene therapy is emerging as an acceptable clinical 
practice for treating acquired and genetic diseases. 
6.7.1. Improved Adenoviral Vectors 
Adenoviruses are continuously being developed for high efficiency gene 
transfer and long-term expression (Wang and Finer, 1996). New vectors have 
emerged which address the problems of cytotoxicity and immune response, 
by making additional mutations and deletions, exhausting the ability of the 
virus to replicate in the non-permissive host. 
6.7.1.1. Second Generation Adenoviruses 
An approach adopted for second-generation recombinant adenoviruses 
comprises development of temperature sensitive lethal mutants. Engelhardt et 
a/. designed a vector harboring a ~-galactosidase-expressing transgene, in 
which a temperature-sensitive mutation is introduced into the E2A gene, of an 
E1-deleted recombinant. At non permissive temperature, this virus fails to 
express late gene products, even when E1 is expressed in trans. In vivo. 
studies show that animals receiving the second-generation virus expressed ~­
gal for up to 70 days, compared to 14 days with first-generation viruses 
(Engelhardt et a/., 1994). Stable expression of human CF transmembrane 
conductance regulator gene has also been achieved in lungs of CF mice 
instilled with a second generation virus (Yang et a/., 1994). 
Viral vectors having E 1 IE4 double deletions have also been constructed 
(Wang et a/., 1997), with parallel development of cell lines to 
transcomplement the functions absent in the viral backbone (Wang et a/., 
1995). A cell line that transcomplements the E1, as well as the E4 gene 
functions of human adenovirus 5, has been established by introduction of the 
full-length Ad5 E4 region into 293 cells. The viral genome is designed with the 
E1 region deleted and replaced by a foreign gene, and an additional lethal E4 
region deletion. This system has been used to generate several E1/E4-
deleted adenovirus vectors containing a reporter gene in the E1 region (Wang 
Discussion 200 
Chapter 6 
et a/' J 1995; Gao et a/' J 1996; Dedieu et a/' J 1997; Wang et a/' J 1997}. The titer 
and the lacZ gene expression of E 1 IE4-deleted adenovirus vector were 
comparable to those of E1-deleted vectors. The doubly-deleted vector was 
substantially more stable in mouse liver than was the E 1-deleted construct 
(Gao et a/' J 1996). 
6.7.1.2. "Gutless" Adenoviral Vectors 
Induction of viral genes in non-permissive host cells and immune response 
problems have necessitated the development of adenoviral vectors which are 
devoid of all viral transcriptional units (Kochanek et a/' J 1996; Parks et a/' J 
1996; Yeh and Perricaudet, 1997). Such viral vectors are also known as 
"gut-less vectors" and have all the adenoviral genome removed from the 
vector, with the exception of the indispensable cis-acting elements required 
for packaging of the genome into the capsids. These vectors can 
accommodate foreign DNA inserts of a much larger size, limited only by the 
packaging constraints of the adenovirus capsid (Ali et a/' J 1994; Yeh and 
Perricaudet, 1997). The major impediment for producing these vectors is 
providing high enough levels of Late Transcriptional Unit (L TU) function in 
trans to synthesize the viral structural proteins. Ideally, this could be done by 
designing a cell line with the viral L TR integrated into its genome, but can be 
achieved with a "helper" adenovirus (Kochanek et a/' J 1996; Parks et a/' J 
1996). 
Caskey's group have developed a new adenoviral vector with no viral coding 
sequences and having a capacity for an insert up to 28 kb. Successful gene 
transfer and expression has been demonstrated using this vector which 
carried a 13.8 kb full-length dystrophin cDNA under transcriptional control of a 
6.5 kb muscle creatine kinase promoter, in addition to the E.coli lacZ gene 
reporter gene (Kochanek et a/' J 1996). The vector was designed with the 
28 kb insert flanked on either side by the Ad5 left terminal repeat and the 
complete packaging signal ( lJI). 
Interest has also been generated in exploiting the ere-lox mechanism adopted 
from bacteriophage P1 for making gutless vectors. The E1-deleted 
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recombinant virus backbone has been modified by inserting direct repeats of 
10xP sites "framing" a 25 kb viral region comprising most of the L TR, protein IX 
gene and E2. A precise excision of the 25 kb fragment occurs when this 
modified virus is infected into 293 cells expressing the cre recombinase in 
trans,. This event leaves behind a mini virus with only the L5 virion protein 
gene, the E4 region and the essential cis-acting elements required for 
packaging (Lieber et a/., 1996). However, this method is useful only for 
removing the viral genome from already available E 1-deleted recombinants. 
Similar mechanisms were involved in generating "gut-less" vectors where the 
helper virus was modified to expel the packaging signal (Parks et a/., 1996). 
The helper viruses were constructed with packaging signals flanked by 10xP 
sites so that in 293 cells that stably express the Cre recombinase (293Cre), 
the packaging signal ('P) was efficiently excised, rendering the helper virus 
genome unpackageable. The mini virus was separated from any traces of 
helper virus by CsCI density gradient purification. A titer of approximately 
9x109 pfu/ml was obtained with less than 0.01 % helper virus contamination. 
6.7.2. New Therapeutic Strategies for the Heart Failure 
A variety of methods are under development for therapies involving gene 
transfer to myocardium. Although adenovirus-mediated gene transfer is the 
most widely used, other viral and non-viral vectors are also being investigated 
to make gene transfer more clinically feasible. 
Adeno-associated virus (AA V) is a gene transfer vehicle which has gained 
recognition for its ability to transfer genes in vivo., without causing any 
apparent toxicity or inflammation in the host. Intramuscular injection of AAV 
virus encoding a reporter gene expressing into rat heart yielded no apparent 
inflammation, with the expression lasting at least two months. Similarly, 
infusion of a recombinant AAV vector into porcine coronary artery showed 
expression in cardiac myocytes, without any evidence of immune response or 
other toxicity, with the expression detectable for up to six months (Kaplitt et 
a/., 1996). 
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Due to the absence of regenerative capacity in cardiocytes, the myocytes lost 
through myocardial necrosis are irreplaceable. Cell grafting of stem cells or 
genetically modified cells has been attempted in normal and ischemia-injured 
myocardium. These methods have parallels with the surgical technique of 
cardiomyoplasty, where skeletal muscle is grafted into the infarcted 
myocardium to compensate for the reduced contractility. Skeletal myogenic 
cells transplanted into an infarcted canine myocardium showed development 
of new striated muscle showing a cardiac phenotype and were able to 
express the reporter gene (Chiu et al., 1995). In a separate study, infarcted rat 
heart grafted with labeled and genetically modified cells displayed survival of 
implanted cells in the non-infarcted region only (Aoki et al., 1996). Foreign 
expression of the myogenic determination factor MyoD in cardiac fibroblast of 
healing heart lesions, has elicited differentiation into muscle cells (Murry et al., 
1996), indicating a possible method of contractile tissue repair in myocardial 
infarcts. 
6.8. Novel Target Therapeutic Genes 
Investigations into gene expression during ischemia, progressively contribute 
to the understanding of molecular processes involved in pathophysiology of 
ischemia and heart failure. Moreover, such studies have shown changes in 
gene activity of proteins critical for physiology of the myocyte. Several gene 
expression analyses carried out in failing heart and ischemia models, have 
also revealed the presence of proteins expressed during ischemia, which 
exhibit a cardioprotective effect on the injured myocardium. 
6.8.1. Variations in Gene Expression During Ischemia 
Ischemia and reperfusion lead to induction of proto-oncogenes in heart and 
subsequent induction of genes with cardioprotective function (Knight and 
Buxton, 1996). Expression of stress proteins such as heat shock proteins and 
genes for antioxidants like Manganese superoxide dismutase (Mn-SOD) and 
catalase are induced in ischemia following reperfusion (Das et al., 1993). 
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6.8.1.1. Adaptive Response 
Expression of Glucose transporters GLUT1, is found to be increased in 
ischemia, as a mode of adapting to increased requirements of glucose uptake 
in persisting ischemia (Brosius, FC et a/., 1997). Proto-oncogenes and growth 
factors are operative in cellular repair processes and angiogenesis (Brand et 
a/., 1992). Fibroblast Growth Factor (FGF) and Transforming Growth Factor 
(TGF), are polypeptides involved in cardiac morphogenesis, which are in 
induced by myocardial ischemia and can re-express the fetal program of 
cardiac specific genes (Parker et a/., 1990). Such expression leads to 
hypertrophy and remodelling of the ventricle to adapt to the diseased 
condition (Parker and Schneider, 1991). These factors can supply a range of 
possible molecular targets for ameliorating heart injury. 
Myocyte cell death in ischemia is also postulated to be due to an activation of 
an apoptotic program, induced in the cardiocytes by oxidative-stress. The final 
result of apoptosis is fragmentation of nuclear DNA, but without change in 
functionality of cell membrane and other subcellular organelles. In ischemic 
myocardium, this process is seen as an adaptive response by the heart, to 
sacrifice some injured myocytes to regulated apoptosis, which may contribute 
less to arrhythmogenesis, than formation of a necrotic scar with cells devoid 
of membrane function (Bromme and Holtz, 1996). Identification of apoptotic 
signals in heart can be helpful in designing a strategy to modulate cell death 
during ischemia 
6.8.1.2. Transcriptional Alterations in Ischemia 
Gene expression of some myogenic proteins such as ion channels, may be 
altered in failing hearts, having direct impact on the overall physiology of the 
myocyte. The sarcoplasmic reticulum channel responsible for re-uptake of 
cytosolic Ca++, the SERCA Ca++-ATPase is shows lower levels of mRNA (Arai 
et a/., 1993) and reduced protein levels (Hasenfuss et a/., 1995; Hasenfuss et 
a/., 1997), in failing myocardium. The Na + -Ca ++ exchanger transmembrane 
protein, which is responsible for calcium extrusion across the sarcolemma, is 
increased in failing hearts (Hasenfuss et a/., 1997). Overexpression of 
SERCA Ca ++ ATPase in transgenic mice in vivo. has shown enhanced 
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contractility and relaxation in normal hearts (He et al., 1997), implying a role 
for this protein in failing heart, where it is reduced. Other, proteins involved in 
Ca ++ -handling such as phospholamban (Hajjar et al., 1997) have also gained 
attention. Ca ++ -handling in progressive heart failure is known to be altered and 
thus the associated proteins are considered as possible targets for gene 
therapy. 
6.8.1.3. Cardioprotective Genes 
Potentially cardioprotective genes and genes showing altered regulation 
during ischemia/reperfusion indicate the possible molecular processes 
underlying ischemic events. Dissection of these molecular process can 
provide insight into using these as therapeutic agents for treatment of 
myocardial ischemia. For example, heat shock protein HSP-70 
overexpression in transgenic mice (Marber et al., 1995) and using adenoviral 
gene transfer vectors (Mestril et al., 1996), render ischemic myocytes more 
tolerant to ischemic injury by providing a protective effect. Genes such as 
antioxidants are induced to nullify the effects of toxic products of 
ischemia/reperfusion. HSP-70 and SOD are now being seen as possible 
cardioprotective molecules which can be overexpressed during ischemia to 
protect the heart from acute injury. 
6.9. Summary 
In summary the project has involved subcloning of skeletal Troponin C coding 
DNA into the adenoviral shuttle vectors, the generation of adenoviral 
recombinants using plasmids constructed in the process of the project and 
analysis of the adenoviral recombinants for gene expression. 
The plasmid subcloning has resulted in construction of a range of plasm ids 
containing the sTnC cDNA in combination with constitutive and tissue-specific 
promoters. The sTnC coding sequence has been altered to incorporate an 
epitope tag for production of a skeletal Troponin C protein, with carboxyl-
terminal HA and T-antigen epitope tags. In the course of subcloning of the 
sTnC cDNA, a range of useful adenoviral shuttle vectors with tissue-specific 
promoters for wider applications, have also been generated. 
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Adenoviral recombinants with Wild-type skeletal Troponin C gene under 
control of constitutive and tissue-specific promoters have been generated. 
Adenoviral recombinants expressing the HA tagged skeletal Troponin C gene 
with constitutive and tissue-specific promoters, have also been constructed for 
intracellular localization studies. Modifications of the adenovirus construction 
protocols, were carried out in order to obtain higher yield of recombinants. 
Some of the adenoviral recombinants made have been analyzed for 
expression at the mRNA and protein level and have shown the desired 
pattern of constitutive and tissue-specific transgene expression, in vitro. 
Western blot and Immunocytochemistry protocols have been optimized for the 
detection of HA tag epitope expression in vitro. The Ad5/CMV-IE/sTnC~9-HA 
construct has demonstrated ubiquitous expression in mouse fibroblasts, 
cardiac fibroblast and cardiomyocytes, whereas the Ad5/HCA(-485)/sTnC~9-
HA recombinant shows a myocyte-specific pattern, showing expression in 
cardiomyocytes but not in cardiac fibroblasts. The tagged constructs are 
currently being applied for in vivo. studies by other members of the group. 
Future analyses employing these viruses include functional studies on 
infected cells, using in vitro. systems, such as single cardiocyte 
measurements for contractility, and force measurement analysis using 
ventricular muscle fibres isolated from in vivo. infected hearts of animals. 
Ultimate application of these sTnC-encoding adenoviruses will incorporate 
clinically relevant gene transfer protocols, including catheter-mediated 
delivery through the coronary artery, in animal models of heart disease. 
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